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Computer generated structural
model of a typical virus in the
taxonomic family Retroviridae .
HIV-1, the virus which causes
AIDS, belongs to the Lentivirus
group. The lentiviruses are
exogenous,
nononcogenic
retroviruses causing persistent
(chronic active) infections leading
to diseases with long incubation
periods. These viruses usually
infect cells of the immune system
(macrophages, T-cells) and cause
cytopathic effects in permissive
cells, such as syncytia, and cell
death. Lentiviral infections are not
cleared by the immune system,
leading to accumulated damage
over a period of many years. This
important characteristic is reflected
in the name of the subfamily (lentifor slow) .
The virion is pleomorphic in
shape, spheroidal, enveloped, and
80-lOOnm in diameter. Small
surface projections give the
envelope a rough appearance;
spikes are dispersed evenly over
the surface.
The genome is linear, single
stranded, RNA. The total genome
of one monomer is 9200 nucleotides
long.
Special Thanks to David Mai of
Meds 98 for his artistic
contribution.

•••••••••••••••••••••••••••••••••••••••••••••
67 (1) 19 9 8 - - - - - - - - - - - - - - - - - - - - - - - - U. W .O. Medical Journal

GUIDELINES

FOR

AUTHORS

The UWO Medical Journal is an interdisciplinary medical publication, established in 1930. The Journal is
published twice each academic year: Fall and Spring.
© All material published by the UWO Medical Journal is copyright protected-no section of the UWO Medical
Journal may be reproduced without the expressed written permission of the Editor.
SUBMISSIONS WHICH DO NOT FOLLOW THESE GUIDELINES WILL NOT BE ACCEPTED FOR PUBLICATION.

All inquiries should be directed to the Editorial Board.
Please do not contact the editorial staff at home.
Office:
e-mail:
Phone & Fax:
WebSite:

MS-175, Health Sciences Building
joumal@julian. uwo.ca
(519) 661-4238
www.med.uwo.ca / medjrnl/

NATURE OF THE JO URNAL

The purpose of the UWO Medical Journa l is to
provide a single forum for original articles based on
research or clinical medicine of topical or historical
interest. Since readership of the Journal is
interdisciplinary, articles published will attempt to reflect
a wide range of medical interests . In this regard,
submissions should be directed towards the general
medical reader. Articles which do not pertain to the
feature topic will be given lower priority as will those
with excessive technical jargon. Please restrict submissions
to under 2,000 words.
Informal peer review is required, i.e., non-specialist
authors are encouraged to collaborate with, or at
minimum, have their work reviewed for content by a
specialist in the field. This individual, if not a co-author, is
to be acknowledged at the end of the paper. In addition, it
is recommended that all submissions be proof read for
significant stylistic or grammatical errors. The editor will
not assume responsibility for corrections of this nature
and articles requiring such revisions will be returned to
the author.
Submissions and disks become the property of the
Journal. The Journal reserves the right to correct errors of
punctuation or spelling. Affiliation with UWO is not a
prerequisite for authorship.
References are indicated numerically in the texf and
listed as endnotes in order of appearance.2 Do not use the
'endnote' feature of your word processing program; list
references as part of the text on a separate page
immediately following the body of the document.
Punctuation comes before reference numbers and
sentences are separated by one space only. Examples of
Journal reference format follow below:
1. Douglas NJ, Thomas S, Jan MA . Clinical value of
polysomnography. Lancet 1992; 339(2):347-50.
2. Dement WC, Carskadon MA, Richardson G. Excessive
daytime sleepiness in the sleep apnea syndrome. In:
Guilleminault C, Qement WC, eds . Sleep Apnea
Syndromes. New York: Alan R Liss, 1978:23-46.

2

SUBMISSIO NS

Please direct submissions, including return address,
phone and fax numbers, to: UWO Medical Journal, Health
Sciences Building, Room MS-175, University of Western
Ontario, London, Ontario, N6A SCI.
Submissions are to include a cover letter, two doublespaced paper copies, and the full text on a 3.5" IBM
compatible floppy diskette in Microsoft Word or
WordPerfect format. The cover letter should be signed by
all authors and indicate that the manuscript has not been
published previously.
Short biographical notes on the authors are to be
included at the beginning of each paper, on a separate
page.
Figures s hould be professionally drawn;
photocopying of illustrations from texts, without the
permission of the publisher, is copyright infringement.
Each figure, table, or illustration should be submitted on a
separate page. Any illustration with a grey-scale should be
in the form of a photograph. Two copies of each figure,
table, or illustration should be included; each should have
its number written on the back, as well as the name of the
first author. Legends, which are to be included at the end
of the text, should start on a separate page with Arabic
numerals corresponding to the figures and tables.
ELECTRO NIC SUBMISSION

Articles and letters to the Editor may be submitted via
our e-mail link on our site on the world wide web at our
URL : www.med.uwo.ca/medjrnl/. Any documents
intended for publication should be sent as attached files,
and not as e-mail messages . Acceptable formats for
attached files are document files of any version of
Microsoft Word, or WordPerfect; other file formats will
not be accepted. All elements of the submission, including
biographical notes on the authors, body of the article,
captions for tables and figures, and references should be
included as described above. A statement indicating that
the manuscript is original and has not been published
previously should be included as a separate page at the
beginning of the document file . Illustrations and
photographs cannot be submitted electronically at present,
and must be delivered or mailed to the Journal office.

Submit To Us!!

- - - - - - - -- - - -- - - - - - - - - - - - U.W.O. Medica/Joumal 67 (1 ) 1998

CONTENTS
DEPARTMENTS

Interuiew with Dr. Michael]. Rieder, Recipient
of the 1997 Do11glas Bocking Award
(P. 25)

ETHICS
1.
A PRACTICAL METHOD FOR APPROACHING BIOETHJCAL ISSUES
By Fady Balaa and Asif Doja ............................................................................................................ ..7
2.
IXXTOR'S CALL
By Dr. Jeff Nisker ............................................................................ .................................................... 10
HUMO UR
1.
NUCLEAR MEDICINE - BEYO ND MERCK
By Ian Mcllraith ............................................. ........................................... ..... ..................................... 15
MEDICA L MYTHS
1.
HEALTH FACT OR FICTIO
By Matthew C rystal ............. ........... ............................ .......................... ...... ............... ........ ................16
MEDICINE O N THE INTERNET
1.
REVIEW OF MULTIMEDIA SOFTWARE: Urinary Tract Infection In Wom en
By Mona Orady and Anand Pand ya .............. ...... ...................... .. ................................................... 18
2. MEDICINE 0 THE INTERNET
By Richard Cleve and Anand Pand ya .................. .................................................... .......................19
MEDICINE AND THE LAW
1.
VICARIOUS LIABILITY OF HOSPITALS AND THEIR PHYSICIANS
By Mark Redinger ............................ ..................................................................................................21
PROFI LES
1.
INTERVIEW WITH DR. MICHAEL J. RIEDER, RECIPIENT O F THE 1997 DOUGLAS
SOCKING AWARD
By Helen Lewandowski ..................... ................. .......................... .................... ................................ 25
PROMOT ION AND PREVENTION
1.
CHANGING AIDS-RISK BEHAVIOUR: A Strategy Based On Underlying Psychological
Processes
By Dan Mendonca .............. ................................ ................................................................................ 28
T H INKING O N YO UR FEET
1.
A CASE OF AIDS
By Romy Saibil ............................................................................................. ....................................... 31
VOCA BULARY
1.
MEDICAL VOCABULARY
By Zakir Esufali ............... ............ ....................................................................................................... 33

F EA TUR E AR Tl C L E S

A Glimpseofth e Face ofAIDSin Tanzania
(P.48)

1.
2.
3.
4.

5.

6.
7.

8.
9.

Orular Man if estations of AIDS
(P.62)

10.
11.

A REVIEW OF THE TRANSMISSffiiLITY OF THE HUMAN IMMUNODEFICIENCY VIRUS
By Bijan Motamedi .............................................. .............................................................................. 35
VIRUSES AND THE IMMUNE SYSTEM: Lessons from HIV
By Dr. Grant McFadden ....................................................................................................................39
THE EFFECT OF HIV INFECTIO 0 TUBERCULOSIS
By Jan MacDonald ............................. ............................................................................. .................... 41
CHALLE GES OF HIV DRUG COMBINATIO THERAPY:
Psychosocial and Practical Impact Reviewed
By J. Scott Turton ............................................................................ .................................................... 44
HIV I AIDS: Epidemiology, Ad vances in Therapy, Prevention
By Dr. Janet Gilmo u r ................................................................. ........... ...... ....................................... 46
A GLIMPSE OF THE FACE OF AIDS IN TANZANIA
By Jennifer Hankins and Shane Longman ........................ .............. .. .... ......................................... 48
THE GEOGRAPHY OF AIDS: Spatial Diffusion and the Canadian Experience
By John Ho ........ ........... ,.................................. ....................................................................................50
HIV I AIDS IN THE SPORTS SETTING
By Matthew Menon ........................................................................................ ,..................................54
INFECTIOUS SKIN MANIFESTATIO NS OF HIV AND AIDS
By oreen Ahmad ....... ,.. ............... ................................................ ..................... ...............................57
UNO ERSTANDING THE ROLE O F CHEMO KINE RECEPTORS IN HIV INFECTIO
By Walter Mak ............ ................................................. ............ .............. ...................................... .......59
OCULARMANIFESTATIO SOFAIDS
By Harpinder Paul Johar and Marc Raymond ............................................................................... 62

U. W.O. Medical Journal 67 (1)1 9 9 8 - - - - - - - - - - - - - - - - - - - - - - - - -

3

ABOUT THE

EDITORIAL BOARD

EDITOR-IN-CHIEF

SENIOR ASSOCIATE EDITOR

Jordan B. Solmon is a fourth year
medical student with a Bachelor of
Science degree from the University of
Toronto . He will be purs uing
residency training in General Surgery
at the University of Toronto.

Carla Garcia is a second year
medical s tudent at UWO . She
earned her Honours B. Sc . In
Zoology, with a special interest in
Molecular Genetics, from the
University of Western Ontario.
Ms. Garcia is interested in medical
education in the media.

JUNIOR ASSOCIATE EDITOR

SENIOR ASSOCIATE EDITOR
Aaron Glickman is a second year
medical s tudent at UWO . He
completed his B.A . at UWO, and
subsequently received hi s M . Sc.
From the University of Toronto.

Daniel Hackam is a second
year medical student at UWO.

The Medical Journal ha s undergone some major
restructuring in the last year. This year, we have e tablished
regular departments, and staffed each with a Departmental
Editor. We hope that these recurring sections will broaden
the scope of the Journal and keep things interesting . An
enthusiastic staff of 14 has settled into our new office,
located in MS-175, Medical Sciences Building, and we have
undertaken a campaign to increase both the visibility and
the quality if the Journal. We have launched a new web site
which can be visited at www.med.uwo.ca / medjrnl / . For
this issue, we received more than four times the average
number of submissions that we typically get, and all of them
were focused on our Feature Topic. We hope this marks the
beginning of a new 'era', in which the Journal is eagerly
anticipated, and the content is as informative and timely as
it is diverse and interesting.
Jordan B. Solmon
Editor-In Chief
Meds 1998

CONTRIBUTORS TO THE FALL 1997 ISSUE

Other (Law, ACOL)
6%

MEDS 1998

36%

11 %

MEDSl
11 %

MEDS2001
28%

In the past, the Journal has had a subscription fee of $17.00. For everal years now, this fee has not been collected,
and there are not any plans to re-institute the fee . In lieu of this expense, we invite anyone who is interested, to make a
charitable donation to the John Gordon Home. Thi is a hospice and supportive living facility for those afflicted with
HIV I AIDS. All cheques should be made payable to the John Gordon Home, and sent to the University of Western
Ontario Medical Journal office. Receipts will be provided. Thank you for your support of this worthwhile community
resource.

4

- - - - - - - - - - - - - - - - - - - - - - - - U. W .O. Medica/Journal 67 (1)1998

EDITORIALS
HIV/AIDS

and

Cultural

riedrich Nietzche professed that illness was vital for
cultural development. When one evaluates the
history of catastrophic afflictions which have beset
humankind, the veracity of this notion is obvious. The
Greeks had blindness, Medieval Europeans had the
Bubonic Plague, and 19th century Europe had
tuberculosis. 1 Presently, the truism is manifest as the
scourge of HIV I AIDS. Culture is an inclusive term which
encompasses a society's art, science, spirituality,
commerce, and patterns of interaction; it denotes a
group's Worldview. In the Western world, every facet of
the population has been given voice by the AIDS
pandemic.
Explanations for the origins of HIV are numerous.
Theories range from accidents in U.S . and Soviet
laboratories involved in biological warfare, to green
monkeys that harbored the disease and propagated it to
Man in Africa 2, to Patient Zero, allegedly a promiscuous
Canadian male homosexual airline steward, who
recklessly spread his own rare illness.
Demagogues, in some cases, revel in self-satisfied
assuredness as their preaching seems validated: just as the
biblical cities of Sodom and Gomorrah were destroyed for
licentious behavior, Cardinal Ratzinger of the Roman
Catholic church cited HIV I AIDS as God's wrath against a
permissive society and the abomination of
homosexuality.2
The artistic community has exploited its pulpit in the
media, and has been a visible, if not venerable
philanthropic force. The AIDS Awareness Ribbon was
inspired by the yellow ribbons worn on jacket lapels,
during the Persian Gulf War, to honour American
soldiers. Conceived by Visual AIDS, a New York based
charity group of professional artists, they chose the colour
red because of its connection to blood, and its symbolic
association with emotions such as anger and passion. 3•4
Worn by host Jeremy Irons at the 1991 Tony Awards, the
AIDS Ribbon made its public debut.
A militant faction of skeptics exists, and alleges that in
14 years, the "HIV hypothesis" has been unproductive,
and non-predictive, due to the fact that AIDS is neither an
infectious epidemic, nor is it caused by HIV. 5 Activist
groups, such as Continuum, seem to be belligerent in their
denial of the HIV I AIDS crisis. Expounding their premise
that HIV does not exist as a unique exogenous lentivirus,
they argue that the global promotion of anti-viral drugs is
responsible for the spread of AIDS-like symptoms. They
have crafted a hypothesis which states that the condition
is the iatrogenic consequence of a despotic medical and
pharmaceutical conspiracy.
Championing the war against HIV I AI DS, medical
professionals and community based agencies have indeed
experienced their share of triumphs and disappointments.

F

Evolution

Retroviruses were first postulated, and then discovered, in
the early 1970's. 6 By 1982, HTLV-1, the firs t human
retrovirus had been isolated and characterized. 5 In 1980,
the first scientific report on the subject was published . It
concerned homosexual males, from the Los Angeles area,
who had presented with unusual skin in fections and
cancers.2 An early bias, which is perpetuated even today
by ignorance and hatred, was established in 1981: based
solely on the demographics of the earliest, isolated cases,
the disease was named Gay Compromise Syndrome.7 This
term, with its negative connota tions, was eventually
replaced by the acronym AIDS. The virus responsible for
AIDS was isolated in 1983 by researchers at the Pasteur
Institute in France, and they called it Lymphadenopathyassociated Virus (LAV). The International Committee on
the Taxonomy of Viruses recommended the use of the
term Human Immunodeficiency Virus (HIV) in 1986. 2
1997 has been deemed a pivotal year in the ongoing
battle against HIV I AIDS. Combination therapies, known
as "drug cocktails" are widely prescribed, and declines in
the rate of death from AIDS in developed countries have
been reported. Plasma HIV-1 RNA determin ants have
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Editor1a
usurped CD4 cell counts as the most important marker of
HIV progression and prognosis. Nonetheless, a daunting
reality remains. It is stated in a recent commentary in the
CMAJ that drug resi s tance and inaccessibility of
therapeutic agents, as well as a resurgence of new
infections in key populations, pose continuing challenges. 8
Community health units and educators fear that an
attitude of complacency has resurfaced amidst the
optimism of promising recent developments.
Services available to those whose lives have been
affected by HIV I AIDS are as diverse as the patient
population itself. From the throes of suffering has
emerged a climate of medical urgenc y and s ocial
awareness and tolerance.
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The University of Western Ontario M edical Jou rnal has
devoted this issue to the topic of HIV I AIDS because it is
relevant to medical practitioners at all levels, and in all
fields. We hope that this issue will serve to educate our
readers, and to supplement the information regarding
HIV I AIDS that is currently presented in the m edical
curriculum at Western.
Q
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ETHICS
EDITOR: D AVID SATIN

A Practical Method for
Approaching Bioethical Issues
By Fady Balaa and Asif Doja, MEDS 2000

ndividuals entering the field of medicine come from
v aried and diverse backgrounds; as a result, some
people have had little or no experience in the study of
biomedical ethics, whereas others have multiple degrees
in the field. Nonetheless, every medical student will come
to a point in his training where he will encounter a
situation that will demand ethical analysis. More to the
point, he will be forced to make decisions that he will have
to justify to his supervisors, colleagues and patients. The
purpose of this article is to introduce a practical method of
analysis that students can adopt and improve upon as
their careers progress.
Presented here is an approach for examining ethical
dilemmas which was developed by Dr. Keith Arnold from
the Department of Philosophy at the University of Ottawa.
This approach is a very practical one for medical students
since it is straight forward, case-specific, and allows for all
aspec t s and vi ewpoints of a particular issue to be
presented. This is neither the only method for examining
moral problems, nor is it necessarily the best -- it is simply
one particular procedure which students can use, modify
or even discard, as they deem appropriate.

I

INTRODUCTIO N
Before methods for examining ethical issues can be
discussed, it is important to form ulate agreed upon
definitions of certain terms. The most important of these
concepts would have to be that of an ethical dilemma. An
e thical dilemma can be seen as a conflict which arises
when two or more parties disagree; to do good for one
party may be to do harm to another. Essentially, it is a
situation wherein one is not simultaneously able to satisfy
everyone's wants, needs and rights. From this definition, it
follows that a blanket term such as "abortion" does not in
itself constitute an ethical dilemma. Instead, this concept
has to be applied to a specific situation. For example, we
could have a situation in which a couple disagrees, as the
woman desires an abortion and the male wishes to
prevent the abortion (i.e. the 1989 Jean-Guy Trembley v.
Chantal Daigle case). Essentially, the example
demonstrates that an ethical dilemma by definition arises
only when we have two opposing viewpoints.

ABOUT THE AUTHORS

Fady Balaa and Asif Doja both completed their
undergraduate degrees at the University of Ottawa and are
presently in their second year of Medicine at the University
of Western Ontario.

PRINCIPALISM VS. PROCED URALISM
In the field of Biomedical ethics, there are two general
approaches for examining moral problems. Principalism, or
'the engineering model', involves applying a set of rigid
principles to a case. Proceduralism involves the evaluation
of each case based upon the specific data presented. It is
this latter approach that will be focussed on.
Principalism is also called the 'top-down approach' as it
implies that the process of ethical problem solving is
deductive, rather than inductive. The principles used are
insensitive to the facts of different cases, and there is an
implied certainty to the answer that results . The four
principles are:
1. Principle of Respect for Persons (Autonomy): states that
one should respect all those involved in a dilemma as
persons, with dignity, freedom and the capacity for selfdetermination. A person should never be used as a
means to an end.
2. Principle of Non-maleficence: one should attempt to inflict
no harm. If one cannot do good without doing harm, then
one should forego that course of action.
3. Principle of Beneficence: one should attempt to maximize
benefits and decrease harm.
4. Principle of Justice: one should treat equals equally and
unequals unequally. The goal is to appreciate the
difference between the encumbered and the
unencumbered. For example, it is obvious that a person
in a wheelchair differs in some respects from an ablebodied person, thus in the spirit of leveling the playing
field, the individual in the wheelchair may be entitled to
certain privileges the able-bodied person does not have.
Recently, there has been a shift away from Principalism
to Proceduralism, or the 'data driven method'. This method
of ethical analysis involves the examination of each dilemma
on a case by case basis. In this approach, there are no set
standards with which to evaluate a case. Instead, each case
is seen as unique, and we see a bottom-up methodology.
The reasoning inv olved is inductive. It is vital to
acknowledge the many points of view of all those involved
in order to appreciate the perspectives from which the case
can be viewed. To this end, the procedural approach uses
strategies for examining different viewpoints. The goal is to
utilize the different strategies and then to see if one still
arrives at the same conclusion. An advantage of the specific
procedural approach presented here is that one's own
personal beliefs are incorporated, as are the aforementioned
principles, as well as pertinent laws, codes and medical
facts.
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THE PROCED URAL APPROACH
I. CASE SPECIFICATIO NS

This initial step is perhaps the most crucial link in
the chain of steps implemented in the procedural
approach. The center of the entire procedural approach
stems from the consideration of the specifics of each
case. By developing a micro-his tory of the case, the
uniqueness of situation is recognized.

II. ID ENTIFY STAKEHOLDERS

Hospitals
lbgether

Ethical dilemmas encountered in the health care
profession are often not limited to one or two
individuals, but instead involve a multitude of people
who will eventually be influenced by the issue. As such,
a stakeholder is defined as any individual who has an
interest in, and will be affected by, the decision being
made. There are three kinds of stakeholders:
First Party: The individual who is directly affected
by the decision being made. Most often the patient is the
primary stakeholder.
Second Party: Any individual who is involved in the
decision making process, which will ultimatel y
influence the first party. This includes the physician,
and nurses.
Third Party: Any other individual who is indirectly
affected by the decision being made . This includes
family, friends, and others.

III. ID ENTIFY M ORAL DILEMMA

Joint
Committee
Continuing the questjor innovative and
qffordable health servicesfor the peopleif
London and Southwestern Ontario.

· --·-·-----8

An y attempt to reach common ground in such
situations requires that all parties involved recognize
the same basic ethical dilemma. The following is an
example of a specific ethical dilemma: A physician's
right to breach patient confidentiality in order to protect
the health of other individuals vs. a patient's wish that
confidentiality be upheld at all costs.

IV. ID ENTIFY COMMUNITY STAN DARDS
Society and the perspective of the community at
large will tend to influence the outcome of an ethical
dilemma. The opinion of the community at large can
follow one of two patterns:
ull H y pothesis : The community at large is in
agreement regarding the issue, and thus the greater
percentage of people lie on one side of the argument.
2. Moral Equipoise: The community is divided equally
in terms of percen tage for and against a specific
argument. As such, no community standard exists.
1.

V. CON SIDER PERSON AL VA LUES
At this stage of the ethical analysis, it is suggested
that one should introduce his own personal values and
beliefs. These personal opinions are not meant to be the
ultimate factor in reaching a decision, but instead play a
role of guidance. By doing this, the examiner brings
himseli closer to the case and thus ensures that the final
decision reached will be as humanistic as possible.
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VI. CO NSID ER PERSPECTIVES OF
STAKEHO LD ERS
The perspective of all the stakeholders who will be
influenced by the decision being reached must play a role
in the decision making process. This is yet another link, in
the chain, which emphasizes and allows for the
recognition of the uniqueness of each case. Certainly,
identical ethical dilemmas will appear time and time
again, however the individuals involved in the dilemma
will differ from situation to situation. As such, this step
will ensure that the needs , rights, and wants of any
indiv idual are not overlooked due to generalizations
which might stem from previous experiences.

VII. EXAMINE CASE IN DEPENDENT VARIABLES
Despite the emphasis placed on examining the
uniqueness of each situation, there are stages when the
examiner must consider factors that are consistent from
ca se to case. It is important to recognize that the se
parameters should not pla y the role of an ultimate
authority in the decision, but instead should offer some
guidance in the decision making process. The following
are some example of case-independent variables:
1. The four pillars of the procedural approach: Principles
of autonomy, non-maleficence, beneficence, and justice
(discussed earlier)

2. Codes of ethics : There are v arious codes that are
expected to regulate the conduct of physicians, nurses,
and other members of the health care team, and thus
offer protection to those who will be influenced by the
decision. These codes include the Canadian Charter of
Rights and Freedoms, Ontario Human Rights Act,
Canada Health Act, and Canadian Medical Association
Code of Ethics.
3. Pertinent laws: The Criminal Code of Canada, and
several other bills provide guidance to physicians and
health care workers when making decisions regarding
ethical dilemmas.
onetheless, there are continually
new situations arising which the law has not been
exposed to, and thus can not regulate.
4. Medical facts : The medical background of the case
being considered, and the success rates of the various
options should be considered.

make it more difficult. In this instance the examiner
considers the viewpoints of family members and other
stakeholders, by placing people who are close to him in
the position of the first party. Analysis of this new and
more complicated case facilitates the analysis of the
original one.
3. Maxi-Mini / Mini-Max: The examiner should follow a
course of action which will maximize the benefits and
m inimize the harms . The worse outcome should be
avoided at all costs.
4. Universal consequences: The examiner should consider
the consequences if all other identical cases were
handled in the same manner. What would happen if all
others did what he is about to do?

IX. COME TO A D ECISION
The end result of every ethical dilemma is that a
decision has to made. After all the information has been
gathered and the perspective of all those involved has
been considered, the examiner can reach a conclusion
regarding the best possible plan of action. In doing so the
examiner will consider the arguments for and against each
side of the dilemma. It is important to note that certain
arguments will be more influential than others. Regardless
of the conclusion reached, the examiner must strive to
ens ure that the final outcome is fair (or at least is not
unfair) to all the stakeholders.
The control over life and death associated with the
medical profession, today more than ever, implies that
future physicians can expect to repeatedly encounter new
and unanticipated ethical dilemmas, many of which will
have no laws or precedents to refer to for guidance. It is
hoped that the material presented here will be of use to
medical students in formulating their own strategies to
deal with ethical issues.
Q
REFERENCES
1. This report is based on a series of lectures present by Dr. Keith Arnold in the
course Bio-Ethics PHI 2396 offered by the department of philosophy at the
University of Ottawa, Sept. -Dec. 95'.

VIII. APPLY PROCEDURAL STRATEG IES
The procedural approach offers strategies that the
examiner can apply in order to facilitate the case analysis.
This stage is particularly useful, because it ensures that
experiences from previous cases are not transferred into
the analysis. The four strategies are:
1. Role/ Reversal: The examiner considers the situation as
if he was in place of the first party. As such he will
ensure that none of the actions taken will treat the first
party unfairly.

2. Hard I

ew cases: The examiner changes the case to
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DOCTOR'S
he set is a mirror image framed by two small tables
holding telephones with answering machines. Within the
tables' boundaries stand Toni, stage right, and Tony,
stage left. Toni is a 40 year old woman _in moderate make ~p,
business suit (reasonnbly casual) over a lzght sweater. Tony zs a
40 year old man wearing sport jacket, open shirt and casual
trousers. They stand back to back in freeze, centre stage. They
then take one step lateral and one forward, and freeze. After 5
seconds tandem monologue begins.

T

TONI & TONY (in unison): My parents christened me
TONI: Antoinette

CALL

By Dr. JeffNisker, LHSC-UC

TONI & TONY (in unison): But not tonight.
TONY (serious): Her tone bore hollowness to my core. You see
a few days ago I went to Norma's office (pause) for an
HIV test.
TONI: As my relationship with Bob was stable, (pensively)
what am I saying stable? I'm su re he's the soulmate
I've sought ... for so many years, and since I started the
pill four months ago, I felt it was time we could "decondomize" our relationship. I know Bob wants to "decondomize", really wants to "de-condomize". Even
though I was not "at risk" for HIV, responsibility
dictated I first have an HIV test.

TONY: Anthony
TONI & TONY (in unison): My friends call me Toni(y).
TONI: I came home from the ritual post-work physical
ablution that grants my home serenity.
TONY: My answering machine glance (they indicate respective
answering machines) was met by the usual red staccato
response.
TONI: This message lay waiting one hour ago.
DOCTOR'S VOICE (tape reveals a fatigued, worried female
voice): Hi Toni(y), it's Norma Evans. Cou ld you
please call me when you get home . . . um . .. It 's kind
of important . .. sigh . .. please call me. (click, tone)
TONI (points to answering 1n11chine): My family doc~or, No~a
Evans, requesting return of her call ... tonzght . .. zn
such despairing voice.
TONY: The despair in her voice chilled me... Nor1n11 is one of
the most upbeat people I know. (brightens) We went to
medical school together.
TONI: Everyone responds upbeat to my tape's effervescent a
capella invitation. Though more my tr~sted doc.tor
than friend, Norma usually responds zn matchzng
accent and musical motif (countenance darkens; gazes
ahead sadly).

TONY: I was to see Susan on the weekend and obviously
wanted the all-clear as soon as possible.
TONI: But Norma explained that though the blood is
couriered to the lab, it usually takes two weeks before
the results are 1n11il-returned.
TONY: Considering our mail system, I resigned to three weeks;
but the fact that Norma was calling me in just three
days ... in such sadness ... must mean that she was called
by the public health lab to contact the HIV "carrier"
(pause, points to self) immediately to ensure no further
spread of the virus.
TONI: As I replayed the tape, my doctor's voice inflected no
chromatic quality to contrary convince.
TONY: My immediate phone to my physician's home heard
babysitter words apologize "Dr. Evans is working late
in her office; she'll be home in about an hour."
TONI: Controlled fingers purposefully pressed each offered
number... only to receive a receptionist's cheery taped
message, (mimic) "''m sorry, the doctor's office is
closed and will reopen at 9:00 a.m. tomorrow. In case
of emergency page the doctor on call." (pause) Before
my whispered "please 1n11y my doctor be on call", her
associate's name pierced my prayer.
TONY: I could not reach my doctor to certify my sentence.

ABOUI' THE AUTHOR
Jeff Nisker is a Professor of Obstetrics and Gymrecology at
the University of Western Ontario and Coordinatore of the
Yellow Brick Road Narrative Bioethics Programme.
"Doctor's Call" was performed in 1997 for AIDS
Vancouver during AIDS Awareness Week, and has also
been performed this fall for the Canadian Bioethics Society
and Dartmouth University.
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TONI: To commute my condemnation.
TONY: The babysitter's approximation of Norma 's ETA to
confirm my already accepted sentence, afforded an hour
to reflect my source of HIV and how to tell my loved
ones.
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TO I: I've been in two prior relationships. Oral
contraceptives protected me from pregnancy, but
obviously not from HIV. At that time, I perceived no
need for condom precaution. I'm sure my partners
were strictly heterosexual. And I don't think they were
unfaithful to me.
TONY: My previous partner is also a physician. I don't think
she ever submitted for an HIV test. Could she have
picked up HIV in the office, the ER? I know that's
impossible . . . what am I saying (can 't believe self
shaking head)--l'm a physician!
TONI: I know you need a significant inoculation of the virus,
more than you can get from looking down a patient's
throat or being coughed upon. Oh my god, I can't
believe what I'm saying! I'm a physician!
TONY: I'm sounding like the fearful uninformed, afraid to
come close to, or administer care to, people with HIV.
I'm a physician ... I should be enlightened ... I should be
sympathetic.
TONI: Was my previous partner always faithful to me? I
never questioned his faithfulness before. But there were
times, especially toward the end of our relationship,
when things were quite bad between us. I didn't even
want to be near him. I'm sure he knew it.
TONY: Until this minute, I never perceived my previous
partner could have been unfaithful. My Pollyanna
ethos assumes everyone as loyal as I... but the
possibility exists. I never felt with anyone the emotional
unity sewn so completely with Susan. I didn't know it
could exist until Susan. Perhaps my former partner
felt my disconnection and sought intimacy elsewhere.
TONI: Could Jim have picked up HIV from some woman and
pa ssed it to me? Some woman who gave him the
comfort I couldn't. Woman? ... Oh ... Could it have been
a man? Could Jim be bisexual? I don 't think so. But
how would I know?
TONY: How could I be so stupid? To succumb my sons to
their father 's slide through Hell, to being fatherless at
the age they need me the most. (pause) I broke faith
with my sons when I trusted the faithfulness of others.
TONI: How could I be tempted by trust?

TONY: I clearly remember my run to employee health right
after surgery for blood tests, to see if I needed a
hepatitis shot. I had not thought about that man in
years.
TONI: But I remember his face so clearly now. I see his eyes
when, just as he was ready to leave hospital, I asked
him to be tested for HIV.
TONY: I really did ask him. Physically holding back coercive
consonants in the name of respect for his freedom to
choose, to choose whether or not to be tested.
TONI: But I did compassionately encourage him to be tested.
TONY: I remember how relieved I was when he consented to
the HIV test.
TONI: Although his HIV test was negative then, he could still
have had HIV. What if he picked it up within the
previous 6 months? His blood may not yet have
converted to HIV positive.
TONY:

If he eventually became HIV positive, you would think
that he would have called the hospital to warn us, but
how would he know unless he was re-tested? Or
developed symptoms of AIDS?

TONI: Symptoms could take years to surface.
TONY: But he wasn't gay. At least, I don't think he was gay.
But that's not something we asked about in those days.
TONI: And though sexual orientation is part of one's social
history, I'm not sure we ask about it today.
TONY: I'm not sure we should ask about it today.
TONI: Will I ask my patients about sexual orientation from
now on? (freaking) What am I talking about? There is
no "from now on"! What patient in their right mind
would want me for their doctor?
TONY: Will I have to inform each patient of my HIV status
before I accept them into my practice (pause) or touch
them? Is that what those doctors with HIV do?
TONI: (exacerbated) Is it fair to ask a patient to remain in my
care or consent to physical exam?

TONY: I can't believe I hear my voice condemning others for
what is clearly my responsibility. Have I descended to
seek share of responsibility? It's my fault for my
misfortune, full stop! Not misfortune... foolishness .

TONY: Some may say yes to please me, but I know how great is
the fear of AIDS. I feared it myself

TONI: There was a patient during whose surgery a largegauge needle went through my glove, (looking at
fingers) Jar into my finger's flesh .

TONI: (exhausted) I see myself leperized: patients not shaking
hands, making sure I don 't come too close, backing out
of my examining room.
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TONY: I see them looking for a sink

TONI (defensive): Not that three days ago I was the slightest bit
worried it would be HIV positive.

TONI: To wash their hands,
TONY: To cleanse each pore of possibility,

TONY: I just didn't want people to think I was worried about
being HIV positive.

TONI: Before they get in their cars,

TONI: Think I was promiscuous.

TONY: Carry contagion (pause)

TONY: Think I was gay.

TONI: To their partners (pause)

TONI & TONY (in unison): Think less of me.

TONY: To their kids.

TONY: I reaped reassurance from the requisition's check-box
inquire of the reason for the HIV test.

TONI & TONY (in unison): Do I change my practice?
TONI: Restrict my care to others same virus infected?
TONY: Rather than worrying my patients?
TONI: Rather than worrying about my patients? (pause)
TONY: When I asked my doctor for an HIV test, she asked if I
wanted to "number-code-conceal" my name. (slowly
nodding) I eagerly embraced anonymity.

STRATFORD GENERAL HOSPITAL

TONI: Sex with women?
TONY: Sex with men?
TONI: Blood transfusion? (confused)
TONY: My eyes riveted the requisition, refusing their leave
until I saw the "sex with women" box secured.
TONI: I have been unwell of late. (questioning, thinking) A
series of minor maladies, that I merely shrugged off as
bad luck.
TONY: But I had been always so healthy before, (slowly) and
now viewing through my acutely focus ed
retrospectoscope, I recognize these were symptoms of
early AIDS.
TONI: Upper respiratory tract infections, fatigue , brittle
fingernails, (pause) skin eruptions that were most
certainly herpes zoster.

Stratford General Hospital is a 134 bed hospital located in the
Festival City of Stratford. The hospital has been designed as the
district referral centre, and serves a population of approximately
62,000, including the City of Stratford, Huron and Perth counties,
as well the bordering counties.
Within an environment committed to health promotion and
disease prevention, we provide selected outpatient and inpatient
programs in medical, surgical, maternal/child, long-term care,
rehabilitation, palliative and mental health services. Supporting
these services are specialized diagnostic and therapeutic
programs.

Stratford General Hospital is dedicated to quality,
respect, compassion and leadership.
Stratford General Hospital
46 General Hospital Drive
Stratford, Ontario
N5A 2Y6

"Exceptional Care, Exceptional People "
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TONY: What am I saying? That my body is already depleted
of its immune defenses? That I already have fulminant
AIDS? Oh, I wish Norma Evans would call.
TONI: Oh how I wish she'd call.
TONY (pause quietly): I've heard so many times (quoting)
"HIV will touch us all."
TONI (still quiet, but getting louder): "We will all suffer its
existence."
TONY (getting louder): "We will all have a friend or a loved
one who AIDS will torment."
TONI (getting louder): "Will kill."
TONY: But I never thought it would be me.
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TONI (stop; look up): Five years ago HIV killed a friend of
mine.

TONI: How do I tell my children?
TONY: Two teenage boys ...

TONY (pause, reflective, voice lower): Stuart was a physician ... a
kind person ... a man with whom I swam many pool laps,
shared dechlorination, cerebrated solutions to our medical
system's frustrations.
TONI: His death, the waste of the second half of his life, spoke to
me in decibels beyond the cadavers of celebrities in
Hollywood or New York.
TONY (pause): I'm not sure if Stuart was gay. I never considered
that he might be gay until AIDS pummeled his person. It
wasn't important then. (pause) It's important now.

TONI: I see their disbelief ..
TONY: I feel their pain ...
TONI: I refute their refusal to accept my diagnosis. I provide
optimistic but reasonable prognosis ... as I explain what
has happened, (pause) what will happen.

TONY: I saw how they shared my sister's suffering. I know how
deeply they will share mine, long before I suffer.

TONY: Previewing that conversation, I admonish words
adamantly assuring my HET-er-o-sexuality
(defensively), insistif!g my innocence. (amazed, angry at
selj) I thought myselj enlightened enough not to fei!l this
need, foster this prejudice. I cri~e the clarity in my_ voice
emphasizing I contracted HW om a woman or from a
patient. I hate myself for this eclaration. It diminishes
gay men. (pause amf quieter) It diminishes me. It's like a
;oke I heard and hated ten years ago, in which a man after
learning he has AIDS tries to convince his parents he's
Haitian. I encourage m}lself that this heterosexual
assurance is for my kids well-being ... not that they'd
think less of me... we have always had an open loving
relationship, but heterosexual assurance might obviate
schoolyard smiles and knowing nods ... Why must a
heterosexual ribbon adorn death' s victory?

TONI: I know they will deny my diagnosis.

TONI: What about my partner...

TONY: Deny it to me.

TONI & TONY (in unison):My life's love?

TONI: How do I tell my parents?
TONY: I saw how they aged rapidly during my sister's recent
illness.
TONI: And although my sister is now well, my parents have not
recovered.

TONI & TONY (in unison): Deny it to themselves.
TONI: They will demand exceptional therapy. They will insist
insight of the best AIDS physicians in the world, for
second, third, thirteenth opinions.
TONY: As many as it takes.
TO I: To be treated.

TONI: Bob.
TONY: Susan. (pause) We hold each other in a magnetic field
of oneness.
TONI: Although Bob 's been using condoms, could I have
given hzm HW through my secretions? Could licking
or even kissing pass on the virus if you did enough of
it? What am f saying? I'm a physiczan, I should know
better!

TONI (relieved): I know my sister will be okay. She 'll be
wonderfully supportive. My friends will be supportive too.

TONY: How do I tell Susan? I mean, we've only been together
for six months, but I feel the sun follow her face,
wrapping me in rainbow of her warmth. I carry her
with me everywhere... Is there any chance I could have
infected her? ... We've been using condoms, and they
never broke... but I wasn't really super careful. The
sheets sometimes are secretion soaked. Could I have
infected her? (starts agitated walking) It 's unthinkable
(negatively shaking head) ... it's just unthinkable... I
don't care about me having HW, (pleading) but please,
please not Susan.

TONY: Though some will twinkle prescience of "wayward
encounter", they will stand by me, help when the time
comes. Oh, how I wish that phone would ring.

TONI (cold):
I will sever all ties with Bob ... with love ... with
the future. Once the doctor's call (pause) confirms the
condemnation I already know.

TONY: To be cured.
TO I: They will want to take my HW from me, (gesturing with
hands) give it to themselves.
TONY (pause): My distant death will be their proximate death.

U.W.O. Medical Journal 67 ( 1 ) 1 9 9 8 - - - - - - - - - - - - - - - - - - - - - - - -

13

Ethics
TONY: Somewhere in the next 24 hours, I will tell Susan that
though I love her beyond what I believed love was
possible, my HIV means our dream of together must
dissolve.
TONI: Bob will tell me that it doesn't matter. .. and you know,
he'll actually mean it. He'll say that he wants to see
this through with me... he'll mean that too.. . But I
can't do that to him. It's over. I'll face the future alone.
TONY: Susan can easily find a better partner, much better
than me, better than I ever was, ever could be. That's a
certainty. She's so bright ... beautiful to her soul. I will
miss Susan. I will miss her touch, her eyes, her smell,
her mind... I miss her already.
TONI

(crying; thinks): You know, losing Bob is what hurts
most. (hesitates) How do I retreat from his rightness,
his rightness for me?

TONY: I am already empty. Empty not feeling Susan's future
entwined with mine.
TONI: Somehow we must tune a new attitude, a new
permission to admit vulnerability in relationship,

TONY: A new responsibility to protect our partners,
TONI: To protect ourselves,
TONY: A new acceptance that any of us who have ever had sex
unprotected by condoms could be carrying HIV.
TONI

(pause): Why have I so calmly acquiesced a curtain that
an hour ago I would have railed against, protested its
possibility?

TONY: Is this calm a shroud, or peace allowed when battle
beckons?
TONI: Is this calm carved by my training that emotion lessens
objectivity, lessens us?
TONY: Is this calm a fa~ade, or a blanket quenching the
immutable verdict's venom?
TONI: This calm is a gift, a gift to sift skill from sentiment, to
claim competence required to help loved ones through
their imminent anguish.
TONY: This calm will remain till the call,

London RegionDI Cancer Ctnlrt
Centre RigionDI dt Cancirologit de London
790 Commissiontn Rood &st
London, Ontario N6A 4L6
Ttl: (519) 685-8615
Fax: (519) 685-8611

TONI: Through the call,
TONY: To explain the call
TONI & TONY (in unison): To those /love.

The UNIVERSITY of WESTERN ONTARIO
Faculty of Medicine • Department of Oncology
790 Commissioners Road East,
London' Ontario N6A 4L6
(519} 685-8600

Dr. Leslie Levin, MD, FRCP (C)
Chief Executive Officer
London Regional Cancer Centre
Professor and Chair, Department of Oncology

TONI: This calm will remain till the ...
Phone rings; Toni and Tony stare at respective phones. It rings
a second time. They remain transfixed by the tone,
then slowly they symmetrically lift the receivers to
their stage lateral ears. Their eyes move up and
slightly stage center as they answer.
TONY & TONI: Hello?

The London Regional Cancer Centre is a modern,
well-equ ipped, ambulatory treatment facil ity.

The tape comes on. They stare motionless while the doctor's
voice is heard.

The opportunity exists to participate in clinical
and basic research programs.
The Department of Oncology offers postgraduate
training in Medical and Radiation Oncology.
For details, contact:

Dr. Walter Kocha, MD, FRCPC
Residency Program Director
Department of Medical Oncology
(519) 685-8638
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DOCTOR'S VOICE (fatigue and sadness strung): Hi Tony, so
glad you got my message. I have something
unfortunate to tell you ... your HIV test ... it needs to be
repeated ... They wrote the number code on the
requisition and your name on the blood tube, so they
automatically discard the sample. You can have it
repeated tomorrow (lights out).

Dr. Barbara Fisher, MD , FRCPC
Residency Program Director
Department of Radiation Oncology
(519) 865-8650
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Nuclear

Medicine

Beyond

Merck

By Ian Mcllraith, MEDS 2000

his past summer I turned down a tremendously
unprofitable minimum wage job for the
tremendously keen undertaking of electives.
Armed with a full year of medical education (what more
do yo u need to know?), I felt ready to tackle real
medicine in a clinical setting. So, I grabbed the Alumni
Binder to find a doctor who would show me the way.
One of the listings in my hometown was in Nuclear
Medicine. That sounded vag uely interesting, even
though I knew absolutely nothing about the field . I
promptly consulted the Merck Manual (every PBL
tutor's worst nightmare and every student's most
val uable, and perhaps only, resource), to find out
exactly what this "nuclear medicine" was all about. I
found out that it was "the medical application of
unsealed radioactive materials for diagnosis and
therapy".1 Great! I was as ready for this as for any PBL
session, so off I went.
The little child in me was excited upon entering the
uclear Medicine department for the first time: "Look at
a_ll the neat toys to play with! " I was disappointed to
find out that the doctors do not actually get to play with
all the equipment--there are technicians that do all that
for them. This initial letdown was quickly displaced by
panic as the doctor put up a can and asked me what I
thought. For anyone who has never seen the pictures
generated in Nuclear Medicine, they are fondly referred
~o ~s. "fuzzograms" because the y are remarkabl y
mdtshnct to the untrained eye, which is the category I fit
into. Not only did I not know how to interpret this
result, I ~id not even know what part of the anatomy I
was lookmg at. Once we had sorted out that it was a
lung scan, my mind frantically raced back to the
respiratory physiology lecture s while the doctor
exp~ained the subtleties of this diagnostic modality. The
patient had a V / Q mismatch, which was actually
observable without reliance upon the eye of faith, and
suddenly uclear Medicine seemed really interesting!
I spent a fair amount of time with this doctor, and I
definitely know a lot more about this field. I also have a
deeper respect for it. A few important points to m y
fellow students, so that you have not totally wasted
your time reading this article, and also so that you know
more about Nuclear Medicine than the first line of
Merck:

T

Nuclear Medicine uses radiopharmaceuticals which
are introduced into the patient, so that unlike
ra~iology, the patient is the source of radioactivity.
This allows many "fuzzograms" per exposure.
2. While x-rays displa y anatomy, Nuclear Medicine
images display physiology. This is an important
distinction, and it hints at the unique uses of this
modality; it would be difficult to see a V / Q
mismatch on an x-ray.
1.

uclear Medicine is typically lumped together with
radiology and pathology as a "lifestyle" choice, and
indeed it has all the benefits associated with such a
specialty. However, there is also the potential for more
extensive patient contact (whole, live, conscious
patients!) than these other fields. Nuclear Medicine
o~erlaps with Internal Medicine in that thyroid
dtsorders are generally treated by Nuclear Medicine
specialists. These doctors are qualified to administer the
radioio_dine u~ed to ablate hyperactive thyroid glands,
and this provtdes the opportunity for counseling and
educating patients.
Perhaps the most important thing that I learned is
that Nuclear Medicine is extremely interesting. As
Henry . Wagner wrote, "the excitement of nuclear
medicine remains the best kept secret in medicine."2 You
will not find that in Merck.
For those of you who are interested, here are some
Internet resources related to Nuclear Medicine:
1. UWO Nu_clear Medicine Residency Program page:

HTTP: I I JOhns.largnet. uwo.ca I nucrad I nucres.html
2. A couple good information pages:
HTTP: I I www .mallinckrod t.nl/ nucmed / no frames I
general/ nucmed.htm
HTTP: I I www .louisville.edu / sahs/ nmt/ whatisnmt.htm
3. For those who want to view a few nuclear medicine
scans:
HTTP:/ /www.radiology.arizona.edu/ -nucmed/title.htm
HTTP:/ /www.aloha.net/ -peters/ organ.html
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Statement: Sexually Transmitted Diseases (STDs) are
more common in the Middlesex- London
region.
True:
STDs are 29% more common in the
Middlesex-London region than in the rest of
Ontario . Of all the infectious diseases,
reported cases of Chlamydia accounted for
84% of the total.1 Chlamydia is transmitted
throu gh unprotec ted sex wi th an infected
partner . In order to effec tively explain the
higher incidence in the Middlesex-London
region, more research into the specific
demographics and diagnostic practices will be
necessary. When comparing all of the regions
in Southwestern Ontario there is no apparent
reason for the rates to be exaggerated in
Middlesex.
Statement: Death rates from AIDS have increased almost
300% between the years 1987 and 1992 in both
men and women.
Mortality rates for women were unchanged
False:
from 1987 to 1992. Men, however, have seen
an increase in mortality rates approaching
300% for the same time period .2 Does this
statistic imply that women need not be
concerned? No, women should be quite
concerned because the demographics of the
disease are changing drastically as AIDS
continues to infiltrate the heterosexual
population in o u r socie ty . The Human
Immunod eficiency Virus (HIV) does not
target men specifically, bu t the spread of the
disease initially through the gay population
erroneously led to the belief that AIDS was a
disease of homosexual males.
A demographic analysis of Southwe tern
Ontario showed that AIDS mortality had the
highest incidence in the Middlesex and Essex
regions.
Statement: !h~ Southwestern Ontario region has a higher
mc1d ence of STDs when compared with the
rest of Ontario.
Chlamydia has been the most prevalent
False:
communicable disease reported in the
Southwestern Ontario region, but the
ABOUI' THE AUI'HOR
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incidence rates in this region are still below
those for the rest of Ontario. The incidence of
chlamydia being reported was 120 per 100,000
which is below the On tario incidence of
approximately 135 per 100,000. The incidence
of gonorrhea and AIDS were considerably
below the levels for the rest of Ontario .
Gonorrhea showed an incidence of 15 per
100,000 and the incidence of AIDS was 3 per
100,000 in the Southwestern On tario region,
well below the Ontario rates of 45 per 100,000
for gonorrhea and 5 per 100,000 for AIDS.
Looking at the big picture, STDs were
reported 144 times per 100,000 in
Southwestern Ontario which is significantly
lower than the 190 reported cases per 100,000
in the whole of Ontario. 2
Statement: Teenagers and young adults are at the highest
risk of acquiring a sexually transmitted
disease.
True:
The highest rates of chlamydia infections, for
example, are in the 15 -24 age group. In 199192 there were over 1300 reported cases among
Southwestern Ontario 15-19 year olds. 1 When
comparing the rates of incidence by age in
Ontario and Southwestern Ontario, the
distributions are very similar, albeit with
lower incidences in the Southwestern Ontario
region. What causes the rates to be so high
within this group? The practice of unsafe sex
among this age group is extremely prevalent,
accounting for the inflated incidences.
Statement: London residents are well aware of their
community's health status.
False:
A random telephone survey asking London
residents about their knowledge of their own
community showed that Londoners
underestimated their community's lifestyle
and health problems.3 If knowledge is a key
weapon in conquering health and lifestyle
issues, then what can be done to prepare
Londoners and other Southwestern Ontario
residen ts to become integral components of
active health promotion? Public health units
have taken the s tance that, "Th e effective
control of infectious diseases requires multiple
strategies to prevent the occurrence of disease
in suscep tible populations, interrupt the
transmission of infectious agents from one
person to another, and treat infected
individuals and their contacts." 2
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Education is the key to slowing the spread of
infectious agents. Resources include Internet
searches, library visits and trips to the local
health unit. Public Health Units are
instrumental in creating ways of
disseminating information to the public as a
whole, but it is the responsibility of each and
every public health official to promote proper
lifestyle choices for their own community and
all the patients they specifically interact with.
Understanding the socioeconomic conditions
of patients is a vital first step toward ensuring
that patients consider the options and
treatments that are available. The role of the
physician is to aid in the prevention of disease
transmission and to promote healthy lifestyle
choices, while recognizing the limitations of
the patient's resources. We must remember
that words of encouragement or
discouragement by a physician hold a great
deal of weight; this responsibility cannot be
ignored.
REFERENCES
1. Mai V, Alder R, Lueske B. Did you know ... The Community Health
Reporter 1(1):1
2. Mai V . Major Notifiable Diseases. ln: Alder R, Vingilis E, Mai V, eds .
Community Health and Well-Being in Southwestern Ontario 1996: 159-71.
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he pain and discomfort of urinary tract infection is
well known to women. For some, urinary tract
infection may be an ongoing problem, often leading
to extensive and costly treatment as well as feelings of
frustration.
Therefore, Axia knowledge products introduces a first
in health education - a powerful and user-friendly CD
ROM software package for women to learn more about
the causes, treatments and prevention of urinary tract
infection. The goal is to provide an innovative learning
environment to uncover the fundamental knowledge and
skills needed for people to be proactive in their own health
care.
The program is divided into four sections. The Guided
Tour is a great place to start to get the most out of the
program. It shows you how information is organized and
how to navigate through the program. Next, the Overview
summarizes key information on urinary tract infection cause, treatment and prevention. The Learn UTI (urinary
tract infection) section integrates multimedia, sound, and
graphics to permit the user to develop an understanding
of the subject. Finally, the Test Yourself section lets you
assess your learning and allows you to move at your own
pace.
There are two main themes that make this a
blockbuster program. First, it is patient focussed and deals
with a sensitive subject matter in a candid,
straightforward manner. The program is very
comprehensive. The informative presentation is v ery
human because it uses patient-doctor conversations to
bring out important points. You feel as if you are in a
doctor's office getting your questions and concerns
addressed and resolved . Thus, this program has an
outstanding potential in health care at an entry level
because it could serve as an excellent teaching tool in
doctors' waiting rooms and clinics.

T
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Creative use of multimedia technology to present
medical information is the second theme that makes this
program impressive. Throughout the program there are
audio and video clips that entertain as well as reinforce
the information. For instance, one video clip shows an
excerpt from a patient doctor interview that mentions the
signs and symptoms of bladder infection. Medical
specialists in the field of microbiology, urology, and
nearly thirty women have contributed their experiences
towards the development of these clips. Furthermore, the
use of diagrams and animation gives this program an
attractive design that captures the audience's attention.
The traditional method of presenting this information
would be either in the form of a pamphlet or a
videocassette. This CD ROM is revolutionary because it
begins a new era in interactive learning through novel and
meaningful application of computer technology.
This program has much strength that makes it a top
quality product. Its only weakness is a temporary one;
there is an "online" button that links directly to the
Urinary Tract Infection in Women Internet site. This site is
not yet developed, but will evolve over time to include
chat sessions, bulletin boards, and news on urinary tract
infection, treatment and prevention.
In conclusion, Urinary Tract Infection in Women CD
ROM receives our highest commendations for being a
pioneer in educating both doctors and patients using
computers. There is tremendous potential here to develop
other educational CD ROMs in areas like Heart Disease,
Cancer and Diabetes.
Evaluation: Two Thumbs Up
Rating: General Audience
Axia Multimedia Corporation
600-1040 7th Avenue SW
Calgary, Alberta, Canada, T2P 3G9
Tel: (403) 231-1709
Internet: www.axia.com
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he world-wide web has generated much publicity
despite having been formed only seven years ago.
The promise of the web continues to be the ability
to access the information of the world when you want
it. The reality, after all these years, is still inconsistent
quality and fragmented information, or incomplete
sites. With access to traditional information sources,
the health care professional may well ask "why bother
with the Internet?" At least part of the answer has
come from recent developments as covered by both the
popular and scientific press. On the one ha~d, m~ny
people with rare diseases have found the tdenhty,
treatments, and support groups that their local health
authorities were unable to provide them with. On the
other hand, the darker side of the web has been seen
with the spreading of illegal, antiquated conco~tions,
and biased, inaccurate information. It is almost wtthout
question that world-wide web users will surf
themselves to both good and bad health, increasingly.
Therefore, most of the information from the web must
be viewed critically by checking (1) What is the
authority of the information? (2) Does the information
serve the sponsor's interest? (3) Is it fact or opinion?
The goal of this article is increase medical
awareness by presenting reputed web-sites.

T

NEWS

The health care professional should be prepared for
patients' questions about late-breaking news, often as
een in the newspaper or more recently cable and
web-based sources such as C
. A number of websites carry feeds from various news-wires. Most
notable in the area of health-care are (of newspaper
fame) HTTP:/ /www.reu tershealth.com, and CNN (of
cable television fame) HTTP:/ /www.cnn.com/HEALTH.
Rather than the large general news sites, many will
find the more specific speciality news sites more
useful. Sites such as the Doctor's Guide to the Web at
HTTP:/ / www.pslgroup.com / docguide.htm, contain
news from conferences and the net in many disease
areas. Even more specific, and dealing with this
journal's theme, is the Canadian AIDS News site at
HTTP :/ / www.cpha .ca/CPHA/canews
which
specialises in the latest developments in AIDS research
and treatment.
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Because of the rising costs of publications, and the
rapid pace of breaking news, many journals n~w make
availa ble online full articles, search engmes, or
supplemental material to their paper journals. Links to
most of the major medical journals can be found at one
of two sites: HTTP:/ /www.we bmedlit.com and
HTTP:/ /www.medscape.com. The CMA's journal can
be found at HTTP:/ /www.cma.ca/journals /cmaj /.
After coming to the realisation that many people
who needed access to Medline did not have access, the
ational
Library
of
Medicine
(US),
HTTP:/ /www.nlm.nih.gov, made Medline searches
freely available to all. This free implementation ~f
Medline contains the complete database; however, 1t
lacks the sophistication of the commercial
implementations of Medline.
PHARMACEUTICALS

Arguably one of the fastest cha.ngin~ areas. in
medicine is the field of pharmaceuticals, mcludmg
recommendations and alternative therapies. The worldwide web is ideally suited for presenting this kind of
material. However, one should be especially cautious
here; the use of information from the web requires
extreme discretion since many of the sites are either

ALEXANDRIA HOSPITAL
INGERSOLL, ONTARIO
Located in Southwestern Ontario, a community
hospital with a large catchment area is searching for
family physicians who wish to have the small town
atmosphere and yet be located only 20 minutes from
the lovely city of London.
Opportunities exist for solo, traditional group and
in-hospital practices. Must be willing to cover
emergency call on a rotating basis. Obstetrics,
surgical assisting and anesthesia are optional.
The hospital was the first rural hospital in Ontario
to establish an alliance with an academic centre, the
London Health Science Centre. This has aUowed us
to reduce costs, meet and exceed government
benchmarks and expand your clinical services to the
community.
If you are a physician candidate who would like to

visit our friendly community please caU or write to:
Alexandra Ho pita!
Attention: Sandy WhittaU, Site Admini trator
29 oxon Street
Ingersoll, Ontario 5C 3V6
(519) 485-1732 Ext. 231
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sponsored by a supply company, or are set up by nonmedical
authoritie s.
Medicine
et,
HTTP:/ / www.medicinenet.com, is a comprehensive site
organised by disease, clinical trials, expert-opinions, and
by medication side-effects. Featuring an encyclopaedia of
drugs, and various discus s ion groups, Pharminfo,
HTTP: / / www .pharminfo .com, provides a valuable
resource. Finally, HTTP:/ / www.pitt.edu / cbw / Internet/
offers information on alternative medical treatment and
includes information on AIDS.
RESOURCES

Essentially, the sites mentioned above are
interesting starting points for patients who want to
play an active role in their health management, and for
doctors who want to keep up-to-date in the rapidly
changing world of medicine.
REFER£ CES
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An ongoing project at the ational Libraries of
Medicine (US) is to create an online anatomical " isible
human ." Currently, they are s till colle c ting
radiographic representations of the human body. Their
ultimate aim is a completely seamless interface.
HTTP: / / www.nlm.nih / gov / research / visible / vi ible_
human.html.
The Family Doctor, HTTP: / / www .familydr.com ,
and Medscape, HTTP :/ / www.medscape.com, are
supersites because they contain reams of pra ctical
information aimed at patients, medical students, and
the practising professional. Included between the two
are medical dictionaries, "clinical pearls", frequently
asked question files, and pharmacy information.
Finally, Achoo, based on the popular search engine
Yahoo!, strives to be the best medicine search engine
available at HTTP:/ / www.achoo.com.
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VICARIOUS LIABILITY OF HOSPITALS
AND THEIR PHYSICIANS
By Mark Redinger
I. INTRODUCTION
It has been over 17 years since the Court of Appeal ruled
in Yepremian v. Scarborough General Hospital, that
hospitals were not liable for the negligent actions of their
doctors. Since that time there have been significant advances
in Canadian tort law, yet the law in many cases regarding
vicarious liability of medical institutions has not changed
that much. The recent Krever report on the blood inquiry
offers us a unique opportunity to examine liability issues for
health service workers, and the liability of those institutions
that employ them. The size and scope of medical services is
staggering by any account.
ation wide the consolidated
federal, provincial and territorial health expenditure tops
almost 47 billion dollars. Over 10% of the population in
Ontario alone is employed in health services, and the
province spends an average of $2,614 per patient. The Krever
inquiry demonstrates the potential for mishaps in the system
and the widespread effect of those mistakes on citizens.
This paper will examine the liability issues involved for
medical workers, doctors and students employed in health
services. Specifically, it will examine the concept of vicarious
liability and circumstances in which liability for medical
mishap in the course of employment can be transferred or
imputed to hospitals or health organizations such as the Red
Cross. It will argue that in many cases, liability for medical
mishap should rightly be imputed to hospitals or medical
organizations and that the present view of practitioners as
independent contractors is outdated.
Initially it is necessary to define vicarious liability as it is
legally understood. The doctrine of respondeat superior or
vicarious liability is defined as "the imposition of liability on
one person for the actionable conduct of another, based
solely on a relationship between the two persons." In an
employment context, vicarious liability deals with the degree
to which an employer can be held responsible for the acts of
his / her employee. Or more simply, whether an employer
can be held liable based solely upon the relationship between
the two parties
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II. OBJECTIVES
As Justice Blair correctly recognized in Yepremian, the
acknowledgment of a duty of care in situations invariably
involves a policy decision. When courts and legislatures
assign liability it is usually intended to accomplish two
tasks. At one level the imposition of liability is intended to
compensa te injured parties at the expense of the party
responsible. At a second level liability is designed to deter
prohibited or unwanted behavior.
For the employer, vicarious liability is usually imposed
for one of four reasons. First, the employer is likely to have
created the circumstances in which the employee acted, and
should bear responsibility for it. Second, the employer is in
the position to minimize the act by allocating certain staff to
specific duties. Third, the employer is in a position of
authori ty and is able to discipline the employee for
wrongdoing or profit from good work. Fourth, by imposing
liability, it is hoped that employers will take appropriate
measures to avoid liability situations. A more cynical view
promoted by some authors may be that vicarious liability is
imposed simply to satisfy judgments that ordinary
employees may not be able to do. This ' deep pocket'
analysis has evolved from a belief that many employees are
judgement proof and may not have the assets in order to
satisfy large law suits.
Critics of vicarious liability maintain that instead of
acting as a deterrent, employers take a distribution theory
approach to liability issues. It is argued that employers are
inclined to simply pass on the costs of insuring employees
down to the customers in the form of higher prices. It must
be noted however that such decisions take place within the
context of the market place and are based on an assessment
of the willingness of customers to shoulder those extra costs.
A vicarious liability model does not prevent employers
from suing offending employees for indemnification in
order to recover the costs of litigation.
Ill. VICARIOUS LIABILITY/RESPONDEAT SUPERIOR
Currently, there are three requirements that must be
satisfied in order to impose vicarious liability upon an
employer. First, there must be an employment relationship;
second, there must be fault in the legal sense; and third, the
act of the employee must have taken place within the scope
of employment.

Employment Relationship
The first threshold to be addressed is whether the
parties are in an employment relationship. In Armstrong v.
Mac's Milk Ltd , the High Court of Ontario consid ered
whether there could be an employment relationship in the
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absence of a written contract. The court concluded that
whether a party was in a employment relationship was
determined by examining the content of the relationship
between the parties. Specifically, Holland J. applied a
"control test" to look at whether the individual was subject
to the control and directions of the employer in resp ct to
how the job was to be completed. Justice Holland noted
however that changes in corporate structure such a the
advent of independent contractor could make that test
in v alid . In those circumstances it would be more
appropriate to apply an "organizational test" to examine
whether the individual's duties formed an integral part of
the business.
In the medical context, identifying an employment
relationship is a critical threshold to overcome and will
depend on the role that is exercised by the individual in
question. Hospitals will normally be responsible fo r the
actions of their employees; but who is a hosp ital
employee? urses are usually employees of the hospital,
as are orderlies, since they are supervised by the ho pital
and paid directl y by the institution. But what about
temporary positions, or people paid by third partie that
are brought in from the outside to perform services? The
law is not as clear in these situations, and an analysis must
proceed on a case by case basis. For example, medical
Residents have been considered employees even though
there may not be the same degree of control exercis d by
the hospital as on an orderly or nurse. In so doing, the
court has given consideration to their status within the
hospital and the agreement between the hospital and the
university.
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Hanover, Ontario
has immediate vacancies for:
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Community with young group of GP' s want to recru it new phy icians
On Call Respon ibilitie one in 14
Catchme nt Population of 15,000
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Large ew Indoor Aquatic Centre and Library
Major Recreational Facilitie
Plentiful and Affordable Hou ing
2 hours fro m Toronto, London and Hami lton.45 min. from Owen ound
Interested applicants hould make enquiries
or send a completed curriculu m vitae to:
Mrs. Katrina W ilson, Executi ve Director
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Hanover District Ho pita!
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Hanover, Ontario
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Current Canadian law does not recognize hospitals as
being liable for the actions of doctors in their professional
duties. Physicians who are accredited to practice are not
considered employees of the hospital to whom vicarious
liability applies, but instead are considered independent
practitioners. The present law that insulates hospitals from
liability for the acts of doctors is problematic as
employment law has now expanded greatly since the 1980's
and under current tests it may fail. By virtue of being the
workplace the hospital exercises a great deal of control over
the doctor in maintaining a site, granting access to facilities,
and scheduling . In Brown et al. v. YMHA Jewish
Community Centre of Winnipeg the Supreme Court of
Canada considered the definition of 'employee' under the
Payment of Wages Act, S.M . 1975, c.21 , and the
Construction Industry Wages Act R.S.M. 1970 c. C190 (am
1980-81, c. 38, s. 3) in Manitoba. The court concluded that
'employee' was a broad and inclusive term. In determining
whether an employment relationship existed it was not
necessary to prove that there was a contract, or that the
employees were paid by the employer directly. However,
the court still required that the employer control and direct
the employee to evidence employment. In addition, recent
cases ha ve also concluded that neither payment by an
employer, nor evidence of a contract is determinative if
finding an employment relationship. These factors
combined may serve to demons tra te an employment
relationship in a situation traditionally excluded from that
designation.
Fault
The second thre hold that must be overcome is whether
the employee was at fault in the matter. If there is no fault
in a negligence sense, then the courts will not impose
liability upon the employer for the employee' s acts.
Vicarious liability is "... still an action for negligence, and the
ordinary rules of negligence liability are still applied to it..."
egligence of the employee, especially a medical employee
is a question of fact that must be determined by the courts.
Much has been written about medical negligence or
malpractice and this paper will not expand upon that
wealth of information. Aside from stating that under a
vicarious liability model, the analysis of malpractice will
not change. The law does not require that doctors and
hospitals perform miracles in the care of patients. Courts
instead question whether doctors and health care workers
have e xercised a reasonable amount of care that is
commensurate with that provided by other practitioners of
the same experience and standing. In cases against hospitals
alleging vicarious liability for hospital employees, the
plaintiff has fo cused upon determining whether the
hospita l has been negligent in its care, either through
overlooking details or otherwise.
Scope of Employment
The third threshold, and the most difficult to prove, is
whether the employee's conduct was within the scope of
their employment. For sound practical reasons employers
are not ordinarily responsible for acts committed by their
employees while not under their control or supervision.
The recognition of vicarious liability for hospitals does not
create a new level of tort analysis. Thus, even if the court
recogrtizes vicarious liability in application to the doctor,
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ho pitals will still not be responsible for acts committed by
doctors, nurses or orderlies employed by a hospital that
are considered outside the scope of employment .
Understandably, determining what constitutes the scope of
employment has been the subject of much litigation.
In Jennings v . C.N.R. the British Columbia Court of
Appeal [hereinafter the B.C.C.A.] considered whether a
c_o nductor who_ a~saulted a passenger while collecting
hckets acted Within the scope of his employment. The
B.C.C.A. concluded that the collection of tickets was within
the scope of his employment. The court went on to
conclude that a carrier owed a clear duty of care to its
passengers in order to ensure their safety, and thus had a
duty to restrain the conductor's conduct where it conflicted
with that duty. In Lockhart v. Canadian Pacific Ry. Co. the
Supreme Court of Canada considered whether the
approval of the employees' method was necessary to
ren?~r an act within the scope of employment. In its
deoswn the court held that liability would extend to an
employer even though the manner in which the business
was being carried out was contrary to express instructions.
The rule in Lockhart further restricts the ability of
employers to escape liability for employee acts.
The court in Yepremian expressly rejected this
analysis. _Instead the court has responded by holding that
the hospital owes no duty of care to the patient for the
provision of medical care as practiced by a doctor. Thus,
negligent medical acts carried on by doctors in the
hospital, under the hospital's supervision, and with the
hospital's facilities are not within the scope of employment
within the hospital.
(i) Outside the Scope
ot every act of an employee will be imputed to an
employer . The following cases illustrate situations in
which the court determined that the employees acted
outside, or independent of their employment. In
Consolidated Mining v. Murdoch, the Supreme Court of
Canada (SCC) held that an employer who carried on
operations at a remote site, was not liable for the fire
started by his two employees. The court concluded that the
scope of employment was contained in the employment
contract which, in this case, specifically excluded the
situation in which the fire took place. This reasoning was
upheld by the Supreme Court of British Columbia in
Barrett v. The Ship "Arcadia" et al. In that case an assault
perpetrated by an officer steward posing as a passenger
steward was deemed not to be the responsibility of the
employer. In its reasoning the court concluded, like
Jennings, that a carrier was not absolutely liable for acts of
its employees, but was responsible to take all reasonable
steps to safeguard its passengers. Barrett did not disturb
the courts earlier position that a carrier would be liable if
the act contested had been conducted in the scope of
employment. In so doing the Supreme Court of British
Columbia has maintained a key element of vicarious
liability, namely, the requirement that the impugned act be
found to have occurred not only while the individual is
employed but within the scope of their employment.
Tests
In addition to the aforementioned criteria the court has
expanded the definition of the employee - employer
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situations through the development of several common law
tests. These tests are designed to look at the totality of the
employee-er relationship in order to determine whether an
employment relationship exists beyond terminology.
IV. ANALYSIS
From the above discussion it should be clear that courts
now look beyond mere titles in order to determine whether
an employment relationship does exist. The totality of the
working conditions combined with the perception of an
employment relationship may result in a sufficient finding
of fact in order to justify the imposition of liability. In terms
of doctors it may be argued successfully that sufficient
control elements exist to make hospitals liable for their
negligent conduct. In Yepremian, where the negligent act of
an Internist resulted in brain damage, the plaintiffs were
successful at trial on the basis that the hospital owed a "nondeleg~ble duty of care to the patient." The Court of Appeal
revers~g, held that there was no evidence of such a duty of
care bemg owed. The majority also found that the Internist
was an independent contractor by virtue of the fact that he
was not paid directly by the hospital, he billed OHIP for
servi~es, even though he was provided with space by the
hospital and was allowed to make use of hospital facilitates.
We will never know what would have happened had
Yepremian been appealed to the Supreme Court. However,
the minority decisions both made strong statements in favor
of recognizing such a duty. In particular Houlden J.A.
conc~uded that the standard of review applicable to
hospitals should be commensurate with their role in
present day society. Yet, to date Yepremian has not be
overturned successfully and has in fact been followed in
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several cases. In Papp v. orth York Branson Hospital the
court held that even in team work situations where both
doctors and nurses were working together, the ho pital
could not be responsible for the negligent acts of the
combined team. One should note that in the present
political climate of accountability, where the public is often
referred to as 'customers' and 'clients' of public services,
many if not most citizens would be surprised to learn that
upon admittance to a health care facility, the doctor and not
the hospital was liable for negligent conduct. American
authors have concluded, correctly I belie e, that more often
than not, patients view both the doctor and hospital as a
single body with the doctor acting as an agent for the
institution.
Doctors and medical institutions should not be afraid
about accepting a vicarious liability model. Such an action
would be in line with policy objectives and likely reflect the
reality of hospitals today. It is submitted that by placing the
responsibility upon the hospital, courts and legislature
would be placing the burden to avoid liability situations
upon the body best able to deal with it. Hospital are
probably in the best position to discipline doctors by
restricting hours of work, and hospitals administrator are
probably in the best position to allocate individuals in order
to minimize potential problems. Further, vicarious liability
may serve to streamline the system by providing a singular
body accountable to the patient. All these efforts combined
may in the long run serve the patient better by providing a
higher quality of guaranteed service by the institution that

most patients would likely naturally identify as bearing that
responsibility. While opponents of recognizing vicarious
liability for doctors may argue that hospitals are ill
equipped to deal with that responsibility, it must surely be
noted that hospitals are already vicariously responsible for
the acts of employee . Further, the imposition of liability
would not remove the ability for the institution to seek
indemnification from the doctor for negligent acts.
V. CONCLUSION
It is not difficult to mea ure when employers will be
held liable for the actions of their employees. Given the
range and scope of decisions, employers can "look forward"
to being held responsible unless they can satisfy the court
on a narrow band that they should not be held liable. For
hospitals and health care facilities the ability to avoid
liability is greater when it can be successfully argued that
the individual is an independent contractor.
As
demonstrated, this may not be a reflection of the reality
practiced daily in Canadian hospitals, nor what the public
would expect of them. For the plaintiff in a malpractice
situation he /she must establish more than just
employment, and fault, but also sound policy reasons as
well in order to assign liability against the institution. The
argument on behalf of the hospitals is easier to demonstrate
as currently doctors are not considered employees. Thus,
unless there is a movement towards assigning institutional
Q
liability the current system is unlikely to change.
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INTERVIEW W I TH DR. MICHAEL J.
RIEDER, RECIPIENT OF THE 1997
DOUGLAS BOCKING AWARD
By Helen Lewandowski, MEDS 2001
r. Michael J. Rieder is
a medical researcher
and pediatrician who
is also highly involved in
medical education . Aside
from his research in the area
of Pharmacology, and his work
at the Children's Hospital of
Wes tern Ontario, he is the
Chairman of the P h ase 4
(Clerkship) Committee at the
Faculty of Medicine. He is also
the father of three boys aged
14, 12 and 7 years, whom he
refers to as his "treasures". His
interests outside of work include the American Civil War,
mountain-bike riding and cooking for his family. He is also a
fan of Baroque music and enjoys the poetry of Rudyard
Kipling.
.
Recently, Dr. Rieder was awarded the Douglas ~g
Award by Western's Faculty of medicine. This _is a seruor
teaching award, given in the Faculty, at graduatior:', by the
graduating class and the Dean's office. Rece~ving this awar?
came as a surprise to Dr. Rieder: "I was surprised that I won It
because it's traditionally won b y people who do a lot of
teaching in first and second year and I don't see anyone ~ the
class until third year. So it's not an award ~t_someo~e m m y
line of teaching would normally win, which IS why It was a
big honor".
.
Dr. Rieder has also received numerous awards outside
Western. He is a distinguished researcher in the field of
Pharmacology, and his research has focused on adverse drug
reactions, with a special interest in HN. Dr. Rieder ~as
designated Young Investigator of th~ Year by the C~adian
Society for Clinical Pharmacology m 199~, and recei_v~d a
s imilar award from th e American Soctety for Chmcal
Pharmacology in 1996. He has also done work in_the area of
medical education, which was acknowledged this past year
when he was appointed Harvard Macy Scholar at _Harvar?
Medical School's Macy Institute of Medical Education. This
scholarship brings together medical educators from across the
U.S.A. and the world to focus on medical education, and Dr.
Rieder was the first Canadian academic to ever receive it.

D
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TH E PATH TO LONDON

What were the events that led up to you com ing to
W estern?
M y university career began at the Unive r si ty of
Saskatchewan in Pharmacy. However, in my secon d year,
I realized that although I wanted to do research and liked
w orking with people, I didn't like the commercial asp~ct
of Pharmac y . So I applied to me d ical sc h o ol m
Saskatchewan, was accepted, and after graduation in 1980
went to Wayne State University in Michigan to d o _my
Pediatric Residency. I then came back to Canad~ and di? a
Fellowship in Emergency Medicine a t the Hospttal for Stck
Ch ildren in Toronto. During my Residen cy, I h ad an
interest in p harmacology since my w h ole f~mil~ i~ in
Pharmacy except for me . I go t in teres ted m chmcal
pharmacology, so I did m y Ph.D. in Pharm~cology a t the
University of Toronto. After that, I was looking for a staff
job and London seemed most attractive.

Why London?
It was a combination of things. To be blunt, I liked the
size of the city. I'm from a small town of 700 people~ and
b oth my wife and I are small town people so we like a
smaller city. I like the feel of a university t~wn, w~ch
London is. I turned down a job a t the Hospttal for Stck
Children a t U ofT to come here because the research
opportunities were broader here than in Toronto. My
interes ts are immunity and immunopharmacology, and
m y research career here has done quite well.

IMMUNOPHARMACOLOGY AND ADVERSE DRUG
REACTION S

Could you describe the main research areas that you are
currently exploring?
The primary research area tha t I am involved in is
basic science research. More specifically, this includes the
study of the role of drug metabolism in the production of
adverse drug reactions, with a special interest in HN .. My
main interest right now is looking at how ~~ r~actions
occur. The current focus is on the sulfa antibiOtics and
how they produce adverse drug reactions. There are two
questions we are working on in this area. One is how HN
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infection influences sulfa metabolism and sulfa sensitivity.
A secondary interest is how some of the sulfa metabolites
interfere with, or act upon, the immune system. Also on
the topic of adverse drug reactions, we are doing some
work on agents such as Cephaclor and the antipsychotic
Clozapine. That's the primary thrust of our research, but
I've also done some work on drug exposure during
pregnancy, such as with Cyclosporine. In addition, I have
done some educa tional research, which was m ostly
related to the evaluation of medical students.
What is the relevance of your research on adverse drug
reactions to HIV and AIDS?

It's important in HN because the most common index
case diagnosis for HIV remains pneumocystis ca rinii
pneumonia, and this also remains the most common
opportunistic infection in HIV in North America and
Western Europe. Sulfa antibiotics remain the drug of
choice, and indeed, until the advent of combina tion
retroviral therapy, it was safe to say that the only drugs
which were known to prolong life in HN patients were
the sulfas. AZT probably did not prolong life, so the only
effective drugs were sulfas. Unfortunately, about 40-50 %
of people who take sulfas and have AIDS develop adverse
drug reactions, which is about 10 times the incidence of
the general population. This is a big problem because of
the increase in mortality and morbidity. Why it occurs has
been the focus of our interest. We have demonstrated that
sulfas can be broken down to reactive metabolites and that
there appears to be a difference in the sensitivity of cells to
these different metabolites. We knew that this occurs in
adults but recently we have also shown that it occurs in
children for the first time in the study of adverse drug
reactions. This will be published in a couple of months, in
the Journal of Pediatrics and Infectious Diseases. So this
phenomenon is important, it's common across the age
spectrum, and now we're trying to figure out why these
HN cells are so sensitive. We want to know what types of
sensitivity occur and how the drug or its presentation can
be changed to make it safer. We are also looking a t the
possible relationship between viral burden and sensitivity
of cells to drugs. We know now that viral burden is not
constant, it's very dynamic, and we are trying to see if
there is any relationship to drug sensitivity.
What are some of the research avenues that you think
seem promising for the future of HIV research? Do you think
tha.t the virus can be brought under control?

Right now the big thrust is combination retroviral
therapy. I'm going to share with you right now that I don't
think it's going to work. I think that it will have orne
success in controlling the disease but if you look at the
success rate in clinical practice, it's not as high as in
clinical trials, which is no surprise. I think that the virus is
persistent, it's cunning and it's simple. It follows a very
simple paradigm: it will mutate its way past any retroviral
drugs. I think that retroviral therapy is promising, I think
that it's important, but I think that it's going to be a
constant struggle . There will also be new ad v erse
reactions to these drugs and new problems tha t will
26

develop, so I think that we are in for a long, tough battle.
A viral vaccine is another possibility, and it might work,
but I think that HN will be with us for a long time due to
the nature of the beast.
EVALUATION OF MEDICAL STUDENTS

Shifting gears now to your involvement with Clerkship
and your research on medical student evaluations, could you
describe what that has been about?

Well, I'm interested in evaluations in the broades t
sense because one of the things that I don't think we do
very well as clinical educators here at Western (and it's not
unique to Western, I don't think anyone does it very well)
is evaluate students . So I think that the evaluation
component of our clinical education is not strong, and I've
been looking at different ways to improve that. I think that
the problem with evaluating students clinically is
knowing what to evaluate, and evaluating things that are
clinically relevant. To be blunt, although people get into
medical school on the basis of marks, there is no evidence
that marks are related to clinical performance. Traditional
evaluations using tests and multiple choice questions
don't evaluate skills and attitudes, so you need a different
way to look at it. There are two possible approaches-one is
that you can be a nihilist, and like many clinical educators
say that there is no way to evaluate this, so they throw up
their arms in despair. I think that we can be more
innovative, and that there must be ways to evaluate those
skills, so we just have to be more clever about it. The
problem with clinical evaluation is that it is a lot of work.
Good clinical evaluations do require a concerted effort
and a certain mindset on the part of the evaluator. But
there are certain problems with that-I think that our
system does not reward good evaluators. People who give
appropriate criticism are not rewarded for it, and it just
results in a lot more work. Therefore, several
unsatisfactory behaviors on the part of the students are
not monitored, especially in relationships with colleagues.
Also, often students are not rewarded for a job well done,
and we work hard in addressing that issue.
ON MED ICAL STUDENTS

I think that the two most important attributes in a
student are honesty and reliability. If you know when to
ask for help, you won' t get into trouble. It's important to
be able to reach a rational diagnosis in a reasonable period
of time, to know how to access information to treat the
problem, and to communicate it effectively. I think that
that is more important than, say, being able to recite the 20
differential diagnoses for asymptomatic hypercalcemia,
for example.
In my mind, the most important characteristics of a
clerk are those which define a competent physician. For
example, in the pediatric rotation, what's important is
being able to talk with a child, talk with the family, and
come up with a differential diagnosis of things that are
common and important.
In terms of things of value, when someone is
functioning clinically, one of the most important things is
getting along with people . Medical students are an
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interesting bunch in that they tend to be self-selected, but
you can't select your patients or the people you work with.
So you have to get along with people from a wide range of
backgrounds and personalities. That's the reason that in
clerkship, if someone has a problem working with clerk A
or clerk B, my response would be that they have to work
through it. Otherwise, it would tend to become divisive.
THE FUTURE OF CLERKSHIP

Do you foresee any changes in the Clerkship portion of
the medical curriculum?

Well, we now have a patient-centered curriculum so
Cle rkship will probabl y mov e towards being more
patient-centered , although i t could be argued that
Clerkship is patient-centered anyway. I think that there
w ill have to be changes in Clerkship due to the changes
occurring in London. Ten years ago, we had 3 adult
hospitals and 1 children's hosp ital with 3000 beds, and
now we'll have 1000 beds only in the city. So we'll have to
rethink about how we do Cle rkship . People won' t be
spending their whole Clerkship in London, that's for sure.
I think we'll also have to think about how Clerkship is
divided. Does the issue of blocks make sense? I think they
probabl y don 't, and that there will have to be some
changes in that area. One thing that has recently changed ,
and that will be a huge advantage for the class of 2001, is
that Phase 3 has been eliminated, which means that
Clerkship will now start at the end of August and end in

September. Right now Clerkship ends in October, then
you do your electives and you only have time to do 2-3
electives before the CaRMs match. Now, there will be
more time for electives, which will be a major advantage.
Perhaps a key to Dr. Rieder's success in combining his
roles as researcher, medical educator, teacher and clinician
lies in his personal philo ophy: "I believe that when I do a
job, I want to do it as be t as I can. Personal responsibility
and pride in a job well done are the things I was brought
up with. I believe in finding the three or four things I like
the most in my work and focusing on them". Dr. Rieder's
rol e model is Frederick the Great, a man whose
'singularity of purpose' he finds appealing. He believes
that at the Faculty of Medicine and Dentistry at Western
"our goal should be excellence .. . to produce the best
undergraduates we possibly can." Clearly, Dr. Rieder is a
man with tremendous energy, who truly enjoys what he
does.
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CHANGING AIDS-RISK BEHAVIOUR:
A Strategy Based On Underlying
Psychological Processes
By Dan Mendonca, MEDS 2000

T

he spread of Human Immunodeficiency irus
(HIV) is a subject which periodically grabs the
public's attention. Recently, for instance, the media
has drawn a disturbing picture of the sky-rocketing
prevalence of HIV in Asian countries. Efforts to pre ent a
worsening HIV pandemic center on modifying risk
behaviours, and education would seem to be the sole
instrument for effecting such change. Unfortunately, the
issue of educating people about their own reproductive
health is a highly contentious one. Most will concede,
however, that at the very least, individuals must be made
aware of how sexually transmitted diseases are spread,
and of how the risk of such infection may be reduced.
During the first decade of the AIDS epidemic, public
health officials advised that to protect against HIV, one
should either abstain from sexual intercourse, use
condoms consistently, or enter into a monogamous
relationship with a trusted partner. As a re ult,
monogamy came to be regarded as a substitute for AIDS
preventive behaviours such as condom use. Monogamy,
however, ceases to be a fail-safe alternative if it refers in
practice to a series of sexually monogamous
relationships. In fact, it is in these types of relationships
that sexual activity is often unprotected, and engaged in
with partners who are unlikely to have been tested for
HIV.
Safety, in a monogamous relationship, demands that
both partners are assured of their own HIV negative
status. This may be because neither has ever engaged in
unprotected sex (or had exposure to other risk factors),
or because both have tested negative for HIV after
abstaining from all risky practices during a "window
period " of two to six months. These criteria d o not
characterize most sexually active individuals, who
typically became sexually active in their teens, and who
are unlikely to have had the same partner since that time.
Relatively few people have been tested for HIV, and this
is especially true for persons in long-term relationships.
Furthermore, HIV testing is not protection against HIV
imported as a result of one partner's non-monogamous
behaviour during the relationship.

ABOUT THE AurHOR
Dan Mendonca is a student in his second year of medical
school at UWO. Prior to entering Medicine, he completed a
Bachelor of Science degree in Biology at the University of

In the case of heterosexual university students and
many other single individuals, much unprotected sexual
intercourse takes place within what individuals perceive
to be close relationships. The initial practice of safer sex
(generally condom use) is eroded with the development of
trust in one's mate. Many switch from using condoms to
using oral contraceptive pills as the relationship becomes
more serious. 1 The emphasis is on contraception rather
than on safer sex.
There has been much research on the promotion of
AIDS-preventive behaviours . Successful interventions
need to involve elicitation research to clarify the specific
needs and sensitivities of the target population. As well,
they should draw upon empirically validated models of
behaviour change. One such research effort, spearheaded
at Western, has resulted in the formulation of an
information-motivation-behavioural skills (1MB) model
for changing AIDS-risk behaviour Y This model
conceptualizes preventive behaviour as being dependent
on an individual's information about AIDS, motivation to
reduce AIDS risk, and behavioural skills for performing
acts related to risk reduction. Currently, the 1MB model is
being used by educators in London-area high schools, and
is the basis for Health Canada's national guidelines on
reproductive health promotion for primar y care
physicians.•.s

INFORMATION
Efforts to assess the AIDS prevention knowledge of an
individual should seek to identify the spontaneous, readyto-use AIDS facts which are utilized in real-life situations.
To get at this type of knowledge , open-ended
questionnaires might be used, as well as focus groups in
which individuals discuss their beliefs about AIDS
prevention.
Researchers have found that heterosexual university
students and members of many other groups invoke
"implicit theories of partner AIDS risk" when determining
whether or not to practice safer sex. That is, an attempt is
made to detect risky partners on the basis of how the
partners dress, how the y act, and where the y are
encountered. To the same end, students may use
inaccurate AIDS prevention heuristics, or cognitive shortcuts in their decision-making. 6•7 (TABLE 1, 2).

Western Ontario.
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TABLEt.
Inaccurate Theories Concerning Partner AIDS Risk
Partner is deemed unlikely to be HIV positive, if...

•

•
•

there is self-serving attributional bias operating e.g .
"Someone to whom I am attracted could not possibly
have an STD."
he I she is dissimilar to one's prototype of an HIVinfected per on.
he I she has a respectable social network
(e.g. from a good neighborhood and family).

TAB LE 2.
Inaccurate AIDS-Prevention Heuristics
"Trusted partners are safe partners."

Once partners begin to trust one another, they decide that
they can trust their partner not to have engaged in
behaviours that could make them HIV positive. Trust is
een, in effect, as a sub titute for condoms or HIV testing.

"Monogamy is safe"

Monogamy is not a substitute for AIDS preventive
behaviour unless both partners are completely certain that
they are HIV negative.

"It's too-late-anyway"

Many people are unaware of the po sibility that a person
can have repeated, unprotected sexual contact wi th an
HIV infected person and not develop HIV.

MOTIVATIO N
Having up-to-date information i no guarantee that an
individual will be motivated to practice AIDS preventive
beha viour. Individuals may possess negative attitudes
concerning condom use (or abstinence), may perceive
condom use (or abstinence) as socially stigmatizing or
ma y feel little personal vulnerability to HIV. To reach
individuals with negative attitudes towards condom use,
one might stress its normativeness in popular culture. To
addre s perceived invulnerability, videotaped scenarios
might be shown in which indi v iduals in trusting
relationships recount their story of having contracted
AIDS through unprotected intercour e.
Persons in monogamous relationships may feel that
addres ing issues of safety could jeopardize the stability of
their relationship . In this instance, individuals might
titrate their perception of risk against how intimate they
are with their partner.
Motivation may also be explored from a population
pers pecti ve. It is possible that in certain societies, for
example, women might succumb to unsafe sexual activity
due to gender based differences in ocial power, economic
dependence on their partners, or normative influences
w hich are opposed to female initiative in exual matter
(TABLE 3).

TABLE3.
Issues Undermining Motivation to Engage in AIDS
Preventive Behaviour
Some discussion topics are seen as potentially harmful
to relationships and are avoided if possib le. Many
believe, for instance, that discussing AIDS prevention
will lead their relationship par t ner to become
suspicious about their past or even current behaviour.
An increasing sense of interdependence in a
relationship often brings about a shift in focus from selfenhancement and elf-protection to relationship
maintenance.
HIV testing may be perceived as a "milestone" in a
relationship, signifying a new level of commitment
w hich a less committed partner may find threatening.
Entertaining the possibility that one's partner
previously engaged in risky and perhaps stigmatizing
behaviour is a prospect individuals are motivated to
avoid
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BEHAVIOURAL SKILLS

CONCLUSION

It is crucial that informed, motivated individuals obtain
the skills necessary for practicing AIDS-prevention. These
skills include acquiring and updating accurate information
about AIDS prevention, harmoniously yet assertively
negotiating AIDS prevention, and exiting situations in
which safer ex cannot be negotiated. One should also be
able to engage in public behaviours, such as condom
purchasing, consulting with physicians and seeking HIV
testing. For many individuals, the ability to avoid drinking
or drug use before sex has also been related to safer sexual
behaviour. Finally, to the extent that condoms are
associated with lower levels of sexual enjoyment,
individuals might be encouraged to eroticize safer sex.
Behavioural skills that are nece sary but lacking should
be taught and then rehearsed so that they are rea dily
translatable into real world preventive action. This could
include observing model enacting AIDS preventive
behaviours, or per onally role playing such behaviour and
receiving feedback. Interventions delivered to couples
rather than individuals offer the opportunity for issues to
be processed within a supportive context. Additional skills
may be relevant for specific groups, for example, those
characterized by ethnicity, sexual orientation, or chemical
use tatus.

For the most part, individuals are free to be sexually
active. Along with ownership over one's own sexuality,
however, comes inherent responsibility. People must take
seriously issues involving reproductive health. This is
especially true in view of the growing prevalence of HIV
infection and other viral STDs. AIDS preventive behaviour
can be a sound and effective solution to this growing
problem. Consistent condom use and HIV testing must be
used for primary and secondary prevention of infection.
It has been shown, for example, that the seroconversion
rate among AIDS patients and their uninfected partners is
very low when condom u e is maintained.
While the spread of sexually transmitted disease is
preventable, it continue to be a major cause of human
suffering and economic loss. Human papillomaviru
infection, for instance, is a lesion which can predispose to
developing cervical cancer. Similarly, the spread of pelvic
inflammatory disease is usually via sexual routes, and can
result in chronic pelvic pain or infertility. It is essential,
therefore, tha t physicians motiva te their patients to
practice prevention.
Educators have found the IMB model for AIDS-risk
behaviour change to be a practical tool for teaching STD
pre ention. The behavioural cience community continue
to evaluate and improve upon such methods, and their
re earch has proven extremely valuable in the global fight
against AIDS.
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Miracles can happen.
But behind every miracle is hard work and determination.
The determination to make our lives a little better,
the hard work necessary to get closer to a cure.
It doesn't happen overnight; it often takes years of
dedicated research. But when that research culminates in
a breakthrough or a new pharmaceutical,
miracles become possible.
Committed to hard work, determination and cnring.
Tile qualities that cnn make miracles happen.
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AIDS
By Romy Saibil, MEDS 2000

28 year old male presents to the emergency room
with a rash, dry cough and a fever. He presented to
his family physician three week earlier with flulike symptoms, dry cough and mild dyspnea, although he
looked well. He was told he had a community-acquired
infection and was prescribed Septra.
Two weeks later, he had lo t his appetite. His cough
and dyspnea were wor e, and he became tachypneaic
upon wa1kin9 for a few minutes. He was referred to the
local hospital s Emergency.
While in the Emergency Department, several test
were ordered. The che t x-ray hawed bilateral perihilar
infiltrates and interstitial disea e pattern. His blood gases
showed hypoxia. His p02 was 50 mmHg and his ~C02
was 28mmHg. His CD4+ count was <200 cells/nun. His
temperature was 38.5°C and his WBC was 1500 cells/mm3 .
He did not know he was HIV positive.

A

Consider the following questions:
1. How doe the CD4 count help in monitoring patients

who are infected with HIV?
2. What do the bilateral perihilar infiltrates and the
interstitial disease pattern on the chest radiograph mo t
likely indicate?
3. What is the pathogenesis of PCP?
4. What is the significance of fever in a person with
advanced HIV iilfection?

ANSWERS TO THE CASE STUDY
1. The stage of HIV di sease can be inferred from
eval uation of clinical parameters and laboratory tes ts.
Examples of clinical parameters include weight lo and
decreasing functional capacity. The CD4 count is an
example of one of the lab tests . CD4+ count is a
quantitative measure of the lymphocytes to which HIV
oinds specifically, and which may become depleted as a
result of HIV infection. Measuring the number of CD4
lymphocytes has until recently been the primary test for
monitoring imm un e function. In addition to
establishing the s tage of HIV infection, it help with
establishing a prognosis, and helps to determine the
appropriateness of initiating antiretroviral therapy and
prophylaxis for opportunistic infections.
2. Pneumocystis carinii pneumonia
3. P. carinii has such low virulence that the initial infection
in an imm un ocompe tent perso n is suppressed b y
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normal host defense mechani sms and causes no
ob ervable damage . In immunocompromised hosts,
PCP is usually a reactivation of a latent infection as a
re ult of childhood exposure. HIV-infected individuals
are at greatest ri k for PCP when the CD4+ T-cell count
is <200 mm3 or <20% of total circulating lymphocytes,
or when they have had a previous episode of PCP.
4. Fever i a very non pecific problem in patients with
advanced HIV infection. The development of a new
fever s hould prompt a careful his tory and physical
examination. There are a number of opportunistic
infec tions that may present as a fever of unknown
origin in a patient with immune deficiency. In addition
to the large spectrum of infections that can produce a
fever, there are a number of noninfectiou processes,
such as malignancies and drug reactions, that should be
considered.
The following section is designed to te t and expand your
knowledge of Acquired Immunodeficiency Syndrome.
How many questions can you an wer correctly?

Scoring: [1J-15l= superior knowledge, [10-12 ] =above
average, [8-91= adequate, l5-7l=fair, [1-4l=sub-par.
1. Which one of the following cancers is
nQ! associated with AIDS?
a) Carcinoma of the cervix
b) Ovarian Cancer
c) Kapo i's Sarcoma
d) B-cell Lymphoma
2. Define Cytomegalovirus (CMV)
a) vi ru s of the genu Cardio irus found in Africa,
South America, and elsewhere.
b) virus which many people carry for a lifetime without
causing any illnes , but which in an individual with
immune deficiency may infect the eyes, lungs, gut
and other organs.
c) an epidemiologic class of viruses that are acquired
by close co ntact (incl uding sexual contact) or
injection and cause persistent infection.
d) an epidemiologic class of viruses that are acquired
b y inhalation of fomites and replicate in the
re piratory tract, causing generalized reaction.
3. The following are all methods for detecting HIV except:
a) Southern Blot
b) ELISA (enzyme-linked immunoabsorbent assay)
c) Western Blot
d) lmmunoblotting
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4. The following are drugs used to interfere with the ability
of HIV to reproduce itself, which have also been shown
to improve the outcome for many people with AIDS,
except:
a) Zidovudine~
b) Retro ·
c)

d)

izoral~

5. The following are drugs used in treatment of
pneumocystis carinii pneumonia, except:
a) Septra~
b) Fansid
c) Pentamidine~
d) Cymevene~
6. Shingles is
a) a rare, self-limited blistering cutaneous disorder, of
unknown origin.
b) a group of acute infections caused by herpes simplex
virus type 1 or type 2.
c) an acute infectious disease believed to represent
activation of latent varicella-zoster virus in those who
have been rendered partially immune after a previous
attack of chicken pox.
d) primary cutaneous herpes simplex acquired by direct
exogenous infection of traumatized skin lesion,
usually associated with localization of lesions to area
of trauma and regional lymphadenopathy.
7. Which of the following is not a type of transmission of
HIV?
a) Venereal transmission
b) Parenteral transmission
c) Respiratory transmission
d) Perinatal transmission
8. Reverse Transcriptase
a) helps integrate cD A into host D A
b) copies viral RNA genome into double-stranded
eDNA
c) reverses the process of AIDS.
d) cleaves the envelope glycoprotein, gp 160, into two
subuntis, gp 140, and gp 120.

c) 8 years
d) 10 years
11. Pnemocystis carinii is due to
a) virus
b) bacteria
c) protozoa
d) fungus

ANSWERS TO THE MULTIPLE CHOICE QUESTIONS
1. Which one of the following cancers is not associated with

AIDS?
b) Ovarian Cancer
2. Cytomegalovirus (CMV)
b) virus which many people carry for a lifetime without
causing any illness, but which in an individual with
immune deficiency may infect the eyes, lungs, gut and
other organs.
3. The following are all methods for detecting HIV except:
a) Southern Blot
4. The following are drugs used to interfere with the ability
of HIV to reproduce itself, and which has been shown to
improve the outcome for many people with AIDS, except:
d ) Nizoral~
5. The following are drugs used in treatment of
Pneumocytstis carinii pneumonia, except:
d) Cymevene~
6. Shingles is
c) an acute infec tious disease believed to represent
activation of latent varicella-zoster virus in those who
have been rendered partially immune after a previous
attack of chicken pox.
7. Which of the following is not a type of transmission of
HIV?
c) Respiratory transmission
8. Reverse Transcriptase
b) copies viral RNA genome into double-stranded
eDNA

9. Adverse drug reactions in HIV positive individuals are
increased by what factor?
a) 2X
b) 5X
c) lOX
d) 20X

9. Adverse drug reactions in HIV positive patients are
increased by how many times?
c) lOX

lO.The average time of onset of AI DS from time of
contraction of HIV virus is
a) 2 years
b) 5 years

11. Pneumocystis carinii is due to
c) protozoa
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lO.The average time of onset of AIDS from tim e of
contraction of HIV is
c) 8 years
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MEDICAL VOCABULARY
By Zakir Esufali, MEDS 1999

This section is designed to test and expand your
knowledge of medical terminology. How many items can
you correctly define?

Scoring:[ 13-15 ]=Superior knowledge, [10-12]=Above
average, [B-9l=Adequate, ls-7l=Fair, [1-sl=Poor
1.

5.

a) Electric-like shocks spreading down the body upon
forward flexion of the head, typically seen in MS.

Hegar's Sign

b) A tingling sensation in the dis tal end of a limb
when percussion is made over the site of a divided
nerve.

a) Softening of the lower uterine segment during
pregnancy.
b) Dark blui h and congested appearance of the
vaginal mucosa during pregnancy.

c) Spasm of the facial muscles elicited by tapping the
facial nerve in the region of the parotid gland.

c) Softening of the cervix and vagina during
pregnancy.
2.

d) The characteristic facial expre sian of Hagar.
Roth's Spots

6.

d) In meningiti , flexion of the hip and the knee upon
flexion of the neck.
McBurney's Operation

7.

a) A radical operation which includes excision of the
vermiform appendix.
b) Radical surgery for the cure of inguinal hernia.
c) Urethroplasty for hypospadias repair.
d) Surgery performed for repair of urinary
incontinence in women.
Apoptosis

a) White or gray oft-edged opacities in the retina
seen in diabetes, hypertensive retinopathy, and
SLE.
b) The appearance of the choroid as a red circular area
urrounded by gray-white retina, as in Tay-Sachs
disea e.

3.

c) Light brown macule
characteristic of
neurofibromatosis and Albright's syndrome.
d) Round or oval white spots sometimes een in the
retina in the cour e of ubacute bacterial
endocarditis.
Apraxia
a) Failure of m uscle coordination.
b) Loss of the ability to carry out familiar or
purposeful movements.

4.

a) Programmed cell death.

8.
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ev us flammeu distribution over the trigeminal
nerve.

b) Ptosis, s trabismus, and loss of light reflex and
accommodation secondary to paralysis of the
oculomotor nerve.
c) Premature aging of an adult, with early graying,
hair loss and cataracts.

a) A seizure which is feigned for the purpose of
attaining a specific goal.
c) An attack resembling an ep ilep tic seizure but
having purely psychological causes.

b) Paralytic drooping of the upper eyelid.
c) Forward displacement or bulging, especially of the
eye.
d ) A condition marked by the presence of small
whitish ulcers, e pecially in the mouth.
Weber's Syndrome
a)

c) Defect or lo s of power of expression by peech,
writing or signs, secondary to an insult to the brain
center.
d) Inability to recognize familiar objects.
Pseudoseizure

b) An absence seizure.

d) An attack re embling an epileptic seizure but which
can always be stopped by physically restraining the
patient.
Chvostek' s Sign

9.

d) A neuropsychiatric disorder due to thiamine
deficiency, most often due to alcohol abuse.
Hypertropia
a) Farsightedness.
b) Strabismus in which there is pronounced d eviation
of the visual axi of one eye toward that of the other
eye.
c) Inflammation of the eyelids.
d) Strabismu s in which there is permanent u pward
deviation of the vi ual axis of one eye.
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10. Meniere's D isease

ANSWERS TO MEDICAL VOCABULARY

a) Deafness, tinnitus, and dizziness in association
with nonsuppurative disease of the labyrinth.
b) Progressive, bilaterally symmetrical perceptive
hearing loss occurring with age.
c) Psychogenic hearing loss occurring in hysterics and
malingerers.
d) Hearing loss due to a defect of the soundconducting apparatus.
11. Tumescence
a) The production of foul-smelling compounds due to
enzymatic decomposition.
b) Any condition marked by the presence of a
neoplasm.
c) Swelling.
d) An accumulation of fluid in a sac, cyst, or bursa.
12. Balint's Sign
a) Partial or complete external opthalmoplegia in
Grave's Disease.
b) Ocular motor apraxia.
c) Sharp pain associated with pinching of the
appendix between the thumb and iliacus in chronic
appendicitis.
d) Fine tremor of the tongue observed in sleeping
sickness.
13. Cheyne-Stokes Respiration
a) Rapid, short breathing, with pauses of se eral
seconds.
b) Breathing with jerky inspiration.
c) Air hunger.
d) Breathing characterized by rhythmic waxing and
waning of respiration depth, with regularly
recurring apneic periods.
14. Kayser-Fleischer Rings
a) Pigmented rings at the outer margin of the cornea,
seen
in
lenticular
degeneration
and
pseudosclerosis.
b) Circular ridges composed of collagen fibers
surrounding the outer margin Descemet's
membrane.
c) White rings seen adjacent to the optic di k in
ophthalmoscopy when the retinal pigment
epithelium and choroid do not extend to the disk.
d) Rings which are visualized the junction of the
conjunctiva and the cornea.
15. Coryza
a) Allergic conjunctivitis.
b) Mucopurulent cough.
c) Acute rhinitis.

.

d) Painful mucous-containing defecation.

1.

Hegar's sign: (a ) Softening of the lower uterine
segment; indicative of pregnancy, appearing
approximately in the sixth weel< of pregnancy [(b)
Chadwick's sign; (c) Goodell's sign].

2.

Roth 's Spo t s : (d) Round or oval white spots
sometimes seen in the course of subacute bacterial
endocarditis [(a) Cotton-wool Spots; (b) Cherry Red
Spots; (c) Cafe au Lait Spots].

3.

Ap ra xi a : (b ) Loss of ability to carry out familiar
purposeful movements in the absence of sensory or
motor impairment, especially inability to use objects
correctly [(a) Ataxia; (c) Aphasia; (d) Visual
agnosia].

4.

Pseudoseizure: (c) An attack resembling an epileptic
seizure but having purely psychological causes,
lacking the electroencephalographic changes of
epilepsy, and sometimes able to be stopped by an act
of will.

5.

Chv os te k's Sign: (c) Spasm of the facial muscles
elicited by tapping the facial nerve in the re~on of the
parotid gland; seen in tetan)' [(a) Lhermitte s Sign; (b)
Tinel's Stgn; (d) Brudzinski s Sign].

6.

M cBurney's Operation: (b ) Radical surgery for the
cure of inguinal hernia [(c) Browne Operation; (d)
Kelly's Operation] .

7.

Apoptosis: (a) Programmed cell death [(b) Ptosis; (c)
Exopthalmos; (d) Aphthosis].

8.

Weber's Syndrome: (b) Paralysis of the oculomotor
nerve on the same side as the lesion, causing ptosis,
strabismus, and loss of
ligh t reflex and
accommodation; also spastic hemiplegia on the side
opposite the lesion with increased reflexes and loss of
superficial reflexes [(a) Sturge-Weber Syndrome; (c)
Werner's Syndrome; (d) Wernicke-Korsakoff
Syndrome].

9.

Hy pe r trop i a : (d) Strabismus in which there is
permanent upward deviation of the visual axis of an
eye [(a) Hyperopia; (b) Esotropia; (c) Blepharitis].

10. M en i e r e ' s Diseas e : (a ) Deafness, tinnitus, and
dizziness in association nonsuppurative disease of the
labrynth [(b) Presbycussis; (c) Psychogenic Hearing
Loss; (d) Conductive Hearing Lossj.
11. Tumescence: (c) The condition of being swollen; a
swelling [(a) Putrescence; (d) Hygroma].
12. Balint's Sign (b ) Ocular motor apraxia [(a) Ballet's
Sign; (c) Bassler's Sign; (d) Castellani-Low Sign]

13. Che y ne-Sto k e s Respiration (d) Breathing
characterized by rh ythmic waxin g and waning of
respiration dep th, with regularly recu rring apneic
periods [(a) l3iot' s respuation; (b) Cogwheel
respiration; (c) Kussmaul's respiration] .
14. Kayser-Fleischer Rings (a) Gray-green to red-gold
pigmented rings at the outer margin of the cornea,
seen in progressive lenticular degeneration and
pseudosclerosis [(b) Scwalbe's rings; (c) Scleral rings;
(d) Conjunctival rings].
15. Coryza (c) Acute rhinitis.
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A REVIEW OF THE
TRANSMISSIBILITY OF THE
HUMAN IMMUNODEFICIENCY V I RUS
By Bijan Motamedi, MEDS 1998
ince the first cases of Acquired Immunodeficiency
Syndrome (AIDS) were initially encountered in 1981,
the disease has spread, and the epidemic is arguably the
biggest medical crisis of our time. Due to the latency period
(8 to 11 years) and significant under-reporting it is very
difficult to accurately estimate the spread of the Human
Immunodeficiency Virus {HIV) epidemic. However, the
World Health Organisation has estima ted that 5 to 10
million people are currently infected with HIV world-wide,
and this number is expected to rise to 15 million by the year
2000. u Despite all the knowledge gained about the
pathogenesis of the disease, and means to inhibit its
progress, relatively few studies have focused on the
transmissibility of the virus and the significance of various
risk factors involved. HIV has been isolated from blood,
seminal fluid, pre-ejaculate, vaginal secretions, and even
urine, cerebrospinal fluid, saliva, tears, and breast milk of
infected individuals. However, due to very small
concentrations in most bodily fluids, three primary routes of
transmission have been identified: sexual contact with an
infected person, significant exposure to infected blood or
blood products (including needles shared among
intravenous drug users), and perinatally from an infectea
mother to her child. The purpose of this paper is to attempt
to answer some basic questions with respect to the
transmissibility of HIV. Pertinent literature has been
reviewed.
I. SEXUAL TRANSMISSION
Risk Factors For Transmission Among Homosexuals
By far the most common route of transmission is
through sexual contact. Among different sexual practices,
homosexual transmission of the virus through penile-anal
intercourse is the most documented and best understood.
This represents over 60% of HIV infections in North
America. The association between AIDS and homosexuals
was noted with the first few hundred documented cases of
AIDS. Even now, in North America, an estimated 30% of
the gay population is HIV+ Y.J Many factors have been
associated with this link. The principal reason for the higher
incidence of AIDS in the male homosexual population is
due to the fact that many cases among this group were
reported early on, and because of its spread due to a high
incidence of multi-partner sexual activity, in a sexually selfcontained group. 1n a study done by Winkelstein et al.
within the male homosexual population in San Francisco,
the men infected with HIV averaped 61 sex partners
compared to 25 for the healthy group.
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Aside from the demograJ?hics of this population, their
sexual practices are also assoaated with an increased risk of
transmission. Male homosexuals engage in a variety of
sexual practices, several of which result in exposure to
blood and semen. Epidemiological studies have established
that among different sexua1 practices, receptive anal
intercourse 1S associated by and large with the highest risk
of HIV acquisition. This can be explained by the high rates
of traumatization of the rectal mucosa. Other practices that
traumatize the rectal mucosa such as doucbing, use of
dildos, and fisting appear to increase further the infection
risk for the receptive partner. Insertive anal sex could also
place a man at IISk for HIV infection, although the insertive
partner would be at lower risk than the receptive partner.
Appropriately, these practices have been labelled as
"unsafe ' sexual practices and are presently practised only
with condoms &y many homosexual men, or have been
abandoned by some. Although clearly safer than anal sex,
several reports have also suggested that unprotected oral
intercourse may also transmit fllV. -1.5.6.7
HETEROSEXUAL TRANSMISSION
Although heterosexual transmission still only accounts
for 9% of AIDS cases reported in the United States, it
comprises the most rapidly growing categoryY World-wide
heterosexual transmission is the predominant mode of
infection. In Africa, where seroprevalence rates of HIV are
highest, acquisition through heterosexual contact accounts
for 80% of ail HIV infections.• World-wide, prostitutes have
been the key "vector" of HIV spread.5 Although the relative
efficiency of transmission continues to be evaluated, both
male-to-female and female-to-male transmission have been
documented.
Information on the heterosexual transmissibility of HIV
and risk factors affecting this transmissibility has been
obtained from studies of sexual partners of individuals
known to be infected, also called "partner studies." The one
consistent finding that emerges from all such studies is that
male-to-female transmission seems to be considerably more
efficient than female-to-male transmission. However,
different authors seem to disagree on the relative
differences. This lack of consistency seemingly arises,
firstly, from the fact that such studies have been very few in
number. The second problem is that due to the need to
control for the many different variables (e.g., frequency of
intercourse, use of condoms, other sexual partners, exact
timing of infection) that come into play m designing a
randomised-control study, it is very difficult to fina a
large sample size, which is necessary to strengthen the
statistical significance of a study.
There are two methods that can be used to quantify
sexual transmissibility through vaginal-penile intercourse.
One way is to look at the number of exposures required
per infection (i.e., the risk of infection per sexual
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intercourse with an infected person). A second method
looks at the percentages of steady sex partners of HIVinfected individuals who have acquired the virus from
their counterpart. This latter method, despite its
weaknesses (frequency of intercourse is not accounted
for), is very valuable, less problematic and can easily be
done on a larger scale. 5
MALE-TO-FEMALE TRANSM ISSION
The predominant mode of documented heterosexual
transmission has been male-to-female transmission.
Retrospective studies of partners of HIV-infected
haemophiliacs and their female sex partners have been
particularly valuable because investigators have been
able to enroll relatively large numbers of sexually active
couples in which the female partners generally had no
other risk factors and were much likelier to have a
monogamous relationship. 5 Published results of these
studies suggest that approximately 10% of the regular
female sex partners of infected haemophiliac men have
themselves become infected with HIV. 8 Other studies
have determined this risk to be as high as 15% or even
30 % among other heterosexual groups (nonhaemophiliacs).2.9·10 The risk of infection through a single
exposure is extremely low. In a study done by Padian et
al., this risk was estimated at less than 0.002 per sexual
encounter. However, this risk is very difficult to calculate
since although some remain uninfected after hundreds of
unprotected sexual contacts, others have become infected
after only a few encounters. 11 •12 It seems that this risk is
different for different populations or geographic
locations. For example, as mentioned before, in Africa
where the HIV epidemic has the highest proportions,
most of the viral spread has occurred through
heterosexual transmissiOn, indicating a seemingly more
efficient transmission than in North America. A
community based cohort study done by Dr. Francis
Plummer on prostitutes from one area in Nairobi
demonstrated that 67% of 124 uninfected prostitutes
seroconverted to HIV-1 over a 30 month follow-up. 13 This
dichotomy between the heterosexual transmission of
HIV in Africa and the West is a major unanswered
question in the epidemiology of HIV-1 transmissibility.
These findings ali imply that other factors come into play
affecting the transmissibility of HIV.
I)

FEMALE-TO-MALE TRANSMISSION
Female-to-male sexual transmission of HIV, like
transmission of other STDs, appears less efficient than
male-to-female transmission. Transmission from infected
women to their male partners has been poorly studied.
Even in regions where HIV is predominantly acquired
through heterosexual contact, few data are available. It is
impossible to confidently put a number on the risk of
such transmissions. A partner study done by Padian et
al. reported only one case of seroconversion among male
partners of 72 monogamous heterosexual couples in
which the female was HIV positive. However, in a
similar study done by the European Study Group on
Heterosexual Transmission of HlV, 19 of 159 (12%) of
male partners became infected. Higher rates of female-tomale transmission in this study compared to the findings
of Padian et al. may reflect a different distribution of
cofactors that promote transmission, unacknowledged
risks among male partners, and random variation in both
studies. Larger studies are needed in order to make more
conclusive deductions. 9·12. 14
II)
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II. H IV T RA N SM ISSION THROUGH BLOOD OR
BLOOD PRODUCfS
Transfusion Recipients
The exact proportion of world-wide HIV infections
through blood transfusions is unknown. In Africa,
transfUsion recipients have been estimated to account for
more than 10% of total HIV infections. In North America,
this fraction is less than 3% (this includes individuals infected
through tissue transplantation from HIV infected donors), of
which 1/3 suffer from haemophilia or another coagulation
disorder. In North America, almost all such infections have
taken place before the initiation of HIV blood-donor
screening programs in 1985. owadays, in addition to the
laboratory screening tests, blood donors have to fill out an
exhaustive questionnaire regarding their lifestyle. This is of
course meant to screen out blood donations from people
with any risk factors for HIV exposure. Currently, with the
additional implementation of HIV-antigen testing, the risk of
acquiring HIV infection through a olood transfusion in
Canada is estimated at 1/600000. Nevertheless, at the present
time, more than ten years after the implementation of HIV
screen programs, the impact of HIV infection through blood
transfusions is still very real, especially in the haemophiliac
population. In 1988, 55% of the haemophiliacs throughout
the United States were HIV positive.2.15·16
Studies suggest that HIV transmission through blood
transfusions is by far the most efficient mode. In one
retrospective study 90% of recipients of HIV positive blood
became infected. Again, this percentage varies depending on
the study, and ranges from 70% to 90%, possibly due to
factors such as the stage of the disease of the donor and the
amount of transfused blood. Fortunately this mode of
transmission is almost eradicated in most parts of the
world.2.15
VICfiMS OF NEEDLE-STICK INJURY
Transmission of HIV through accidental needle-stick
injuries, although very rare, is always a concern among
health care workers, especially medical researchers
working with concentrated virus. A health care worker's
risk of HIV infection is a product of the prevalence of HIV
infection in the patient population, the risk of hazardous
exposure and the probability of HIV transmission through
a single exposure. The amount of blood transmitted
through such injuries is minute. Depending on the study,
the calculated risk of HIV seroconversion from needlestick exposure ranges from 0.29% to 0.50%. Depending on
the hospital and the precautions taken, investigators nave
found the risk of percutaneous injury among U .S.
surgeons to be between 1.2% to 3.0% per operation.
Therefore the risk of HIV infection for a surgeon operating
on an HIV ~ositive {unknown) patient is fhe product of
(1.2 % - 3.0 Yo) and (0.29 % - 0.50%). This results in a
calculated risk ranging from 35 per million to 150 per
million. 16 Although seemingly low, this risk could reach
significant levefs when calculated over a period of a
liFetime (career). Obviously the only way to reduce the
risk is to follow universal blood and body fluid
precautions, dispose of needles and other sharp objects
properly, and follow other prudent infection control
measures.2. 17
HIV Transmission in Intravenous Drug Users
Transmission of virus through in travenous drug
injection is ano ther practice that mvolves exposure to
infected blood. Injection in and of itself is not a risk factor. It
is the sharing of needles and syringes with HIV infected
individuals tnat allows viral transiDlSsion. Sharing needles
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is a common practice among LV. drug u ers world-wide,
largely driven by legal and economic necessity. As of 1992,
I.V: drug users made up 29% of reported cases of AIDS in
the United States. This group i also much more likely than
the general population to be involved in other high risk
behaviour . Therefore, it is very difficult, if not impossible,
to estimate the number of people who have become
infected olely through sharmg needles. Similarly, it is
difficult to calculate the risk of infection through one
exposure to an HIV contaminated needle. Using a complex
mathematical model, in a study done by Kaplan and
Heimer, this risk was estimated at 0.0067 per injection
episodeY The risk of HIV infection among LV. drug users
is dependent on the frequency of needle sharing, the
number of partners with whom needle are sharea, the
probability that the e partners are HIV infected, and even
the manner in which sharing occurs. Among practice
a ociated with a high risk of infection, it is worthwhile to
mention the practice of 'boothing" (wa hing out any drug
left in the syringe with the u er's own bfood while the
yringe needle is still in the vein), and drug use at "shooting
gallerie " (sites where drug are ola and injection
equipment is made available for rental or sharing).3
III. PERI NATAL TRANSMISSIO N
With the rapid spread of infection among women of
reproductive age, perinatal transmission is now a major
consequence of the HIV epidemic. According to the World
Health Organisation, by 1992, more than 1 million HIV
infected inJants were born. Thi mode of transmission is
apparently very efficient. One in four infants born to
eropo itive mothers is infected.u It has been shown that
antiretroviral therapy throushout pregnancy, particularly
during labour and delivery, significantly decreases this risk.
Perinatal HIV transmission can occur both in utero, or at
birth. Identification of maternal fac tors increa ing or
decreasing the likelihood of HIV transmi ion may help to
explain diJferences in transmissions rates. Such factors may
include the mother's stage of HIV infection, her degree of
immunodeficiency, amount of viral antigen, high HIV
replication rate (m vitro), as risk factors, and maternal
antibodies to viral components as potential protective
factors . The mode of delivery itself has also been associated
with an altered risk. Any kind of traumatic delivery, such
as forceps delivery, or even inva ive fetal monitoring, has
been sugge ted as potential risk factors. On the other hand,
orne have suggested caesarean section as a protective
measure a opposed to vaginal delivery that could expose
the fetu to a greater amount of vaginal and cervical
ecretions. Although no hard data is yet available, breast
feeding has also been reported as a post-partum risk factor
for viral transmission.u
IV. RISK FACTORS OR CO-FACTORS INFLUEN O NG
HIV INFECTIO N
Multiple factors probably influence the infectivity of
an HIV infected person, or the susceptibility of an
uninfected person to HIV infection. An understanding of
these factors is potentially important for desi~g public
health interventions that will decrease the mcidence of
transmission. Several of the e factors, such as practice
increasing the risk of trauma to the rectal mucosa in
homosexual men, or to the uterus in pregnant women,
have been di cussed.
Of all potential co-factor , the most investigated one is
the possiole association between HIV and other STDs.
More than a hundred studies have looked at this
interrelationship. It appears that both ulcerative and non-
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ulcerative STDs increase the risk of HIV transmis ion
approximately 3-to 5-fold. 14 Several reasons can be
postulated for this finding. One aspect of the ho t
response to STD that may contribute to BIV transmission
is the recruitment of inflammatory cells, such as Tlymphocytes or macropha~es, where HIV is more
frequently found. Similarly, It has been sugge ted that
these inflammatory cell constitute a more suitable
environment for HIV invasion. Thus, STDs would increase
both the infectivity of the reservoir and the susceptibility
of the recipient. Another mechanism by which some STDs
might facilitate HIV transmission is disruption of
epithelial barriers in the genital tract. The integrity of the
genital mucosa or epithelium appear to be an important
protection against transmission, and is clearly breached in
case of genital ulcer disea es such as chancroid, herpe
and syphilis. Conversely, most studies have found that
HIV induced immunosuppression almost certainly is a
factor in prolonging the natural history and diminishing
the response to therapy of some STD . At a community
level this probable interplay between HIV infection and
other STDs' incidence may well underplay the explosive
growth of the HIV pandemic. in some communi tie .
Other factor postulated to augment HIV infectivity
are both symptomatic di ea e and early infection. Thi
would be intuitive considering the state of high viremia in
either ca e. Similarly, some studies have suggested that
antiretrovial therapy (zidovudine) may reduce infectivity.
Several factors have al o been suggested to increase the
vulnerability of the host. In men, lacl< of circumcision, and
in women, cervical atrophy (such as in post menopausal
women) and use of IUDs have both been postulated. Data
regarding oral contraceptives is very contradic tory.
Whereas some have proposed oral contraceptives as a
protective factor, others have discussed them as a possible
cofactor increasing susceptibility of the host.
It also appears that different strains of the virus could
differ in theu virulence. Moreover, recent discoverie
suggest that innate susceptibility to HIV could differ
between people depending on their genetic make-up .
Plummer has found that among airob1 prostitutes, tho e
with certain HLA types seem to be resistant to the viru
and do not get mfected despite numerous daily
expo ures. 3•13•16
Finally at this point it is appropriate to briefly discuss
the u e of condoms as means of protection. The protective
role of condoms towards HIV transmission might seem
trivial, however, over the years, this role has been much
over-emphasized. Several tudies now suggest that
although condoms do afford protection to the user, the
level of protection i not 100%, and is in fact far from it. A
study done by Waller has uggested that this protection
could even be as low as only one order of magnitude
(x10). 19 Although this finding is extreme, it is important to
accept that condoms do not provide full protection. The
failures have been attributed to concfom breakage,
improper use, potential passage of virus through intact
condoms, and also more ri k taking sexual beh aviour
when condoms are used. 13
V. PRACTICES AND M EANS O F CONTACT NOT
ASSOCIATED WITH HIV TRANSMISSION
As mentioned before, HIV has been isolated from body
fluids other than blood or genital secretions. This finding has
raised questions about the transmissibility of virus through
casual contacts with an infected person. However, viral
detection in these body fluids has been both infrequent and
in very small concentrations. There have been anecaotal case
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reports of people with no obvious risk factors becoming
infected with HIV through what was believed to be "casual"
contacts with an infected person. In each case, a better
investigation uncovered possible risk factors previou ly
unaccounted for, such as accidental exposure to bfood.
Many studies both in the United States and in Europe
have looked at the risk of mv transmission through casual
contacts in settings such as household or boarding school
contacts of persons infected with HIV. In most settings
members had a variety of interactions with the infected
person. These included sharing household items, sharing
bathrooms, or even helping the person eat or bathe. All of
these studies reached the same conclusion: no evidence was
found of anY. mv transmission to persons lacking other risk
factors. Similarly, some studies focused on the possibility of
arthropod transmission of IDV. Again no support was found
for this mode of transmission. u;n
This brief overview highlights the magnitude of the
problem. Undoubtedly, there is much more to be learned
about IDV transmissibility. A better understanding of the
cofactors involved, and the role that each flays in the spread
of the virus, is essential in order to contra the epidemic, and
possibly assist researchers in finding a vaccine.
REFER£ CES
1.

PRACTICE CONCENTRATED IN U.S .
IMMIGRATION LAW SINCE 1969

i.Affrrty WE. NI!W trrnds in HIV/AIDS Epidemiology. Joumal

Apl1eresis,

2. Cohen PT, Sande MA, Volberding, P.A . The AIDS Knowledge Base, Cl10pter 1:
Epidemiology and Transmission, 2nd edition , Little Brown and Co. , University of
Califomia,

Organon Canada Ltd./Ltee
200 Consilium Place, Suite 700
Scarborough, Ontario M I H 3E4
Tel: 1-800-387- 1326 Local: (416) 290-6131
Order : 1-800-465-7114 Fax: (416) 290-6133

of Clinical

1993; 8:174-7.

I!W York, 1994.

3.

Devita VT Jr, Hellman S, Rosenberg SA, AIDS: Etiology Diagnosis Trrolmml and
Prewntion , 90-120, 3rd edition, Lippincott Company, Pl1iladelphia, 1992.

4.

Winke/stein W , Lyman DM, Padian N, et a/. Sexual practices and risk of infection by
HIV: Tl1e San Francisco Mm's Health Study, JAMA 1987; 257:321·5.

5.

Brookmeyer R, Gail MH. AID Epidemiology: A Quantitative Approach, 19-36, Oxford
University Press, New York, 1994.

6.

Holmberg SD, Horsburg CRJ, Ward JW, Jaffe HW. Biological factors in the sexual
transmission ofHIV. J lnfrc Dis. 1989; 160:116-125.

7.

Osmond D, Bacchetti P, Chaisson RE, at a/. Time of exposure and risk of HIV infection
in homosexual partners of men with AIDS. Am I Public Hrolth 1988; 78:944-8.

8.

Geodert J/, Kessler CM, Aledorl LM , et a/. A prospective study of HIV type 1:
Infection and dewlopment of AIDS in subjects with hemophilia. N Eng/ f Med 1989;
321-1141-8.

9.

European Study Group on Heterosexual Transmission of HIV. Comparison offemale to
male and n10/e to female transmission of HIV in 563 stable couples. BMJ 1992; 304809-13.

10. lAZZDrin A , Saracco A, Musicco M , eta/. Man-to-Woman sexual transmission of HIV:
ris k factors rrlated t o sexual behavior, man ' s infectiousness , and woman 's
susceptibility. Arch Intern Med 21991; 151 :2411 -6.
11 . Hearst N , Hullry 58. Prroenting tire Hderosexual Spread
patients the best advice? JAMA 1988; 259:2428-32.

of AIDS: Are we giving our

12. Padia11 NS, Shiboski SC. J=ell P. The iffect of number of exposures 011 tile risk of
llderosexual H/V transmission . / Infect Dis 1990; 161:883-7.
13. Plummer FA , Simonsen JN, Cameron DW, et a/. Cofactors in male-female sexual
transmission ofHIV-1. I Infect Dis 1991 ; 163:233-9.

Manufacturer and Distributor for:

Marvelon® Andriof®
Cotazym® Humegon®
Norcuron® Zemuron®

14. Padian NS, Slliboski SC. Jewell NP. Female-to-male Transmission of HIV, JAMA
1991; 266:1664-7.
15. Corey L, AIDS: Problems and Prospects, 31-50, Stl1 edition, Norton Medical Books,
NroJ York, 1993.
16. Wasserlreit JN. Epidemiological Surgery: lnle"e/ationships between HIV Infection and
Other Sexually Transmitted Diseases. Sexually Trans mitted Diseases 1992; 19:61 72.17. Lin EY, Brunicardi FC. HIV Infection and Surgeons. World f. Surg 1994;
18:753-7.
18. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. /
Acquir Immune Deficien Syndr 1992; 5:1116-8.
19. Weller SC. A meta-analysis of condom effectiveness in reducing sexually trans mitted
H/V. Soc Sci Med 1993; 36:1635-44.
20. Frumkin LR, Leonard JM , Questions and AnSW<'rs On Aids, 1-52, Medical Economics
Books, Oradell, N= Jersey, 1987
.n

38

- - - - - - - - - - - - - - - - - - - - - - - - U. W .O. Medical Journal 67 (1) 1998

Feature

Articles

VIRUSES AND THE IMMUNE
SYSTEM: LESSONS FROM HIV
By Dr. Grant Mcfadden, JPRRI
t has become increasingly apparent that out of the
multitude of different families of viruses that have coevolved wi th their higher order vertebrate hosts,
including Man, only a small minority of these cause any
discernible disease. In fact, the normal course of events for
most viruses that have propagated for long periods of
time within a single host species is for the virus and host
to co-exist with each other in a relatively benign
relationship that frequently involves little or no outright
pathogenesis. As most people know, the retrovirus we
now call Human Immunodeficiency Virus (HIV )
originally evolved in Old World Monkeys, which harbour
many related lentiviruses collectively referred to as Simian
Immunodeficiency Viruses (SIVs).The identity of the
original simian lentivirus strain that entered the human
population to become HIV-1 has not been rigorously
established, but in the case of HIV-2 there is a close
linkage with an endogenous SIV strain from the Sooty
Mangabey monkey . In any case, the best available
information is that HIV strains began infecting, and
adapting to humans in the latter part of this century. In
evolutionary terms, this is very recent indeed. Since most
SIVs in their "native" monkey hosts do not cause any
disease at all, why does the introduction of this apparently
benign primate lentivirus into humans cause such a
catastrophic collapse of the cellular immune system? And
why are our closely related primates, such as
chimpanzees, so apparently resistant to the development
of AIDS when infected with the same HIVs?
To virologists, the observation that normally benign
viruses, which cause only sub-clinical infections in their
native hosts, can suddenly induce severe or even lethal
infections in a non-evolutionary host is not new at all. In
fact, it is probable that most, if not all, viruses that cause
outright disease do so only after infecting new nonadapted hosts. The reasons why a virus might come into
contact with a new host can be as varied as animal
migration, ecological changes brought about by alterations
in environmental conditions, or even chance encounters.
Whatever the reason for the virus finding and infecting a
new host species, the end result is that the virus now has
to survive in the face of a responsive immune system
dedicated to the task of preventing the spread of the new
contagion. Who will win the resulting tug-of-war? The
truth is that the outcome is rarely predictable, but we can
uncover some clues as to the dynamics of the struggle by
studying other related virus/host battles. One of the great
difficulties in dissecting the fundamental mechanisms of
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AIDS pathogenesis is the absence of a good animal model
to mimic the virus / host interplay of HIV in humans. To
that end, our lab has spent many years analyzing one
particular nonhuman virus/host interaction, namely the
infection of rabbits by a pathogenic virus named myxoma
virus. These studies allow us to make some tentative
predictions about the eventual outcome of the global AIDS
pandemic in Man.
Myxoma virus, unlike the relatively smaller RNAcontaining HIV, is a large DNA-containing member of the
poxvirus family. It is closely related to variola virus, the
causative agent for smallpox in Man (before the virus was
eradicated by a global vaccination program in the late
1970s). Like so many viral pathogens, myxoma virus was
discovered only after the virus made an unexpected leap
from its native evolutionary host, the Brazilian jungle
rabbit (or tapeti), to a host that the virus had never
encountered before, the European rabbit. This host species
leap occurred in 1896 when a scientist, Dr. G. Sanarelli,
brought a collection of European lab rabbits from Italy to
his new research station in Uruguay for some unrelated
scientific experiments. Upon arrival in South America, Dr.
Sanarelli's rabbits began to die unexpectedly of a
previously unknown acute lethal syndrome that we now
call myxomatosis. Later, this disease was shown to be
caused by a virus harboured within the native tapeti
popula tion from the rain forest, and was spread by
arthropod vectors, mainly the mosquito. This new virus
was studied extensively in the early part of this century,
and achieved a certain notoriety when it was used, first in
Australia and later in Europe, in an attempt to control the
serious overpopulation of European rabbits which had
taken over large areas of the countryside, devastating
crops and causing widespread ecological damage.
Virologists have extensively studied this deliberate release
of myxoma virus into a susceptible rabbit population, and
our lab in particular has been interested in the molecular
mechanisms by which the virus is able to so effectively
disrupt the normal immune responses of its infected host.
In humans, HIV infection eventually results in AIDS,
but only years or decades following the initial primary
infection. In contrast, myxoma virus in European rabbits
causes lethal immunosupression with brutal rapidity and
kills over 99% of infected hosts within two weeks. Thus,
within the initial phases of the myxomatosis epizootic (the
animal version of an epidemic) in Australia in 1951-52,
there were massive reductions in rabbit numbers, as the
mosqui to-born virus decimated the rabbit populations.
Unexpectedly, however, and within relatively few rabbit
generations (less than 10 years), the original strain of
highly virulent myxoma virus gradually evolved into new
variants of the virus that were dramatically less
pathogenic, and which allowed for the survival of a higher
percentage of infected rabbits. At the same time, the rabbit
populations themselves changed as the selection pressures
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brought on by the extreme lethality of the virus resulted in
the repopulation of the infested areas with rabbits that
were now much more resistant to the dis ease
manifestations of the virus. The end result was a dynamic
series of genetic changes in the virus and the selection of
rabbit hosts more tolerant to the viius, that together has
culminated in a new less-pathogenic v irus / host
relationship which continues to evolve to this very day.
So what predictions can we make for the future of the
ongoing AIDS pandemic, in terms of how HIV is likely to
adapt to the selection pressures exerted by Man? First, it is
unlikely that HIV will quietly disappear from the human
population. In fact, sequencing studies of the human D A
genome reveal the presence of many retrovirus-like
sequences that were acquired during Man's evolutionary
past, and there are reasons to suspect that human
populations have been subjected many times to virusdriven pandemics similar to that observed in the rabbit
populations in Australia . Second, as HIV progressively
replicates and mutates within the human population, the
severity of the AIDS symptoms will likely evolve to a less
virulent disease as the human immune system and the
virus become more adapted to each other. However, just
because the overt symptomology of AIDS will likely
become less severe, there is no reason to suppose that the
transmission of virus itself will abate. Rather, it is
predicted that as the pathogenesis caused by the evolving
strains of HIV diminishes, the percentage of the human
popula tion that is actually infected with the virus will

continue to increase. Finally, how long can we expect to
wait to see this predicted attenuation of the AIDS disease
itself? This calculation is quite difficult because of the high
mutation rate of HIV and the lack of information
concerning the extent of allelic varia tions of relevant
immune loci that might moderate disease progression, but
the time scale will almost assuredly be in the order of
many human generations . In fact, for all practical
purposes, it is difficult to conjure a scenario that actually
eliminates HIV from the human population, at least by the
development of vaccines and therapies alone. Rather, as
advances in the treatment and preven tion of AIDS
continue to provide real hope for at least the eventual
reduction in the absolute numbers of AIDS-associated
mortalities, it is a virtual certainty that the HIV virus itself
will be with us for the foreseeable future.
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EFFECT OF HIV INFECTION
TUBERCULOSIS

ON

By Ian MacDonald, MEDS 2000

INTRODUCTION
Mycobacterium tuberculosis infects one third of the
w orld' s population, resulting in 8 million new cases of
tuberculosis (TB) and 3 million deaths annually. 1 Before the
emergence of HIV, the vast majority of M. tuberculosis
infections were kept in check by the host immune response
and remained latent for the lifetime of the human host.
However, worldwide spread of HIV infection ha s
undermined human defenses against M. tuberculosis and
presents a serious risk factor for the progressi~m of latent M .
tuberculosis infection to active TB. In the Uruted States, for
. decades, there had been a steady decline in the number of
ca es of TB. By 1985 the decline levelled off and by the late
1980 's incide n t TB cases began to increase steadily .
Worldwide, by mid-1995, nearly 6 million persons were
estimated to be coinfected with M. tuberculosis and HIV.6
Tuberculosis has become the most common opportunistic
infection and the leading cause of death in persons infected
w ith HIV worldwide.

PATHO GENESIS
M . tuberculosis is acquired by inhalation of infectious
airborne particles that reach the alveolar air spaces. The
inhaled m ycobacteria survive phagocytosis by alveolar
macrophages and p r od u ce a cell-mediated immune
response . After ingesting m ycobacteria, macropha~e s
present T-lymphocytes wi th processed mycobactenal
antigens. The sensitized lymphocytes then proliferate and
secrete cytokines which are able to recruit aggregates of
macrophages with increased lytic enzyme concentration
and enhanced phagocytic activity. A chronic inflammatory
response develops in which the bacteria are killed by
repeated phagocytosis.

INFLUENCE OF HIV INFECTION ON
PATHOGENESIS
In the normal host, tuberculosis infection usuall y
remains latent, caused by dormant organisms that survive
the immunologic response. Reactivation TB occurs when
latent organisms overcome immunologic control, as is the
case in HIV-induced CD4+ T-lymphocyte depletion. The
risk of reactivation in HIV-infected patients with latent TB
is more than 25-30 times higher than HIV-seronegative
control s. 6 It is also s u gges ted that persons with HIV
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(regardless of CD4+ cell counts) who are newly infected
w ith M . tuberculosis progre s to active tuberculosis at a ra~e
as high as 37% in the first 6 months rather than 2 to 5% m
the first 2 years.5 HIV also confers anergy (diminished
reactivity to specific antigens) upon the infected
indiv iduals, making the interpretation of the tuberculin
skin test (TST) difficult. HIV-related enteropathy in infected
patients may cause malabsorption of drugs, further
complicating the treatment of tuberculosis.
EPIDEMIO LOGY
There are reasons for the increase in the incidence of
tuberculosis aside from the emergence of the AIDS
epidemic, including the deterioration of public health care
facilities and the rise in the number of persons living in
crowded settings. However, HIV has had the most serious
impact on the epidemiology and natural course of TB.
Cross-ma tching of TB and AIDS registries has provided
evidence that the TB epidemic in the United States is, in
large part, a result of HIV-associa ted immunosuppression.
Cross-ma tching the TB and AIDS registries from the 50
state health departments, the District of Columbia, Puerto
Rico, and Guam, has yielded estimates that a minimum of
30% of excess TB cases from 1985 through 1990 can be
attributed to HIV-induced imm u nosuppression. 2 The
largest increases in incidence of TB occurred in
demographic groups and locations in which the prevalence
of HIV is highest, particularly in urban areas.
In addi tion to HIV altering the epidemiology and
natural history of TB, TB appears to influence the course of
HIV infection. Case-control studies have shown that
patients dually infected with HIV and TB had a worse
outcome as measured by the development of opportunistic
infections and death, compared with HIV-infected p atients
a t a similar stage but withou t TB. 8 Bo th groups had a
similar level of immunosuppression as measured by the
absolute CD4+ lymphocyte count. The effect of active
tuberculosis on the HIV-infec ted patient may be the
activation of viral production in cells harboring latent virus,
v ia cytokines from macrophages con taining in gested
m ycobacterial products, and promoting the spread of
infection to unaffected cells. This process can lead to a
greater viral load, a decline in the n u mber of CD4+
lymphocytes, and an increased risk for oppor tunistic
infection and death.
The rise in the number of cases of tuberculosis in the
United States has coincided with an increase in the number
of cases of drug-resistant tuberculosis . Drug resistant
strains can emerge via incomplete compliance with therapy
or an incorrect cour e of treatment, such as exposure to
only one effective drug. When anti-TB drugs are used in
combination, growth of organisms resistant to any single
drug is prevented by other drugs in the combination.
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Primary resistance occurs when patients are infected with
an already resistant strain of tuberculosis; secondary
resistance occurs when resistant mutants of an initially
drug-susceptible infection appear in the setting of p oor
compliance. Initially it was thought that most cases of
resistance were secondary. However, recent studies have
shown that primary resistance accounts for a large number
of drug-resistant cases, particularly among the HIVinfected. Coinfection with HIV and drug-resistant TB may
help explain the drastic rise in the overall incidence of
tuberculosis.
CLINICAL PRESENTATION
The clinical, radiographic, and laboratory features of TB
in HIV-infected persons vary depending on the patient's
degree of immunosuppression. Infection with HIV is
associated w ith increased dissemination of tuberculosis,
increased number and severity of symptoms, and rapid
progression to death unless treatment is begun. General
symptoms of tuberculosis in HIV-seropositive patients
include fever, night sweats, weight loss, anorexia, and chills.
Tuberculosis in HIV-infected patients, as in o ther
populations, is primarily a pulmonary infection. Symptoms
include cough, sputum production, dyspnea, and pos ibly
pleuritic chest pain. However, with advanced HIV infection,
extrapulmonary disease is a prominent feature.
Disseminated disease and lymphadenitis are the m ost
common forms of extrapulmonary TB. It is plausible that
extrapulmonary TB indicates a poorer ou tcome than
tuberculosis alone, as the former appears to be associated
with a greater degree of immunodeficiency as measured by
CD4+ cell counts and the presence of oral candidiasis.
The appearance of chest radiographs from HIV-infected
patients with TB may vary depending on the degree of
immunodeficiency, although they are often atypical. Most
commonly diffuse lobar infiltrates are noted, although focal
consolidation may also be present. Cav itary lesions are
uncommon however, possibly reflecting the overall immune
dysfunction of patients with advanced HIV infection.
Tuberculin skin testing with purified protein derivative
(PPD) may be less useful in HIV infected patients w ith
suspected tuberculosis as the sensitivity is inversely related
to the degree of immunosuppression. These patients may be
anergic due to the decreased delayed-type hypersensitivity
(DTH) response common in those with HIV infection,
resulting from impaired cell-mediated immunity. In these
instances at least two control DTH skin test antigens should
be given concurrently with PPD. Generally, all HIV-infected
persons with 5 mm or greater induration on PPD skin
testing are considered positive and should rece iv e
treatment. 3
DIAGNOSIS
Isolation of M . tuberculosis via sputum cultur e is
required for the definitive diagnosis of TB. Given that
infection may be present at an extrapulmonary site in HIVinfected patients, clinical specimens other than sputum (e.g.,
urine, blood, CSF, pleural fluid, pericardia! fluid, purulent
material, biopsy specimens) should be submitted for culture
when extrapulmonary TB is suspected.3 Newer methods,
such as radiometric and continuous culture, allow a more
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rapid cultivation of m ycobacteria than the traditional
techniques. The combination of newer procedures and a
D A probe specific for an M. tuberculosis ribosomal RNA
sequence can identify M. tuberculosis in 1 to 3 weeks.1 This
may be clinically significant in identifying TB in HIVinfected patients, due to the accelerated course associated
with coinfection. Culture techniques are also important in
obtaining the drug-susceptibility profile of a particular
strain and in following a patient's response to antimicrobial
therapy.
Smears for acid-fast bacilli (AFB) can give an early
indication of mycobacterial infection, although a significant
number of bacilli per ml of specimen are required for a
positive result. There are problems with specificity as the
smear does not distinguish between different types of
mycobacteria, and atypical species may be present in the
immunocomprimised. In general, HIV-infected patients
have had lower rates of sputum smear positivity, at least in
part because of a lower incidence of cavitary disease.
Newer diagnostic techniques promise rapid detection of
M . tuberculosis based on the polymerase chain reaction
(PCR). This technique relies on gene amplification in which
m ycobacterial D A in a clinical sample is extracted,
amplified, and identified. With PCR, diagnoses can be made
within hours and is generally more sensitive and specific
than smear and culture results. This may be important from
the perspective of the HIV-infected patient in whom sputum
smear results are unreliable due to the potential for
extrapulmonary infection.
TREATMENT

Standard antituberculosis drugs are effective for
treating tuberculosis in the HIV-infected patient. Most M .
tuberculosis strains isolated from patients with AIDS are
susceptible to first-line agents. A regimen consisting of
isoniazid, rifampin, and pyrazinamide for two months,
followed by isoniazid and rifampin for 4 months, is
recommended as initial therapy. Resistance to any one of
these drugs requires longer treatment. Published guidelines
by the Center for Disease Control do not recommend longer
treatment regimens for patients with TB who are HIV
infected and treatment should be prolonged only if there is
evidence of a slow response.7
The potential for drug-resistant TB should be
considered in all patients being treated for TB. This is
especially true for multiple-drug resistant tuberculosis
(MDRTB), defined as resistance to two or more drugs.
MDRTB primarily affects HIV-infected patients and is
associated with mortality rates of up to 89%. 7 Most patients
die within 1 to 3 months.5 Patients with MDRTB were also
more likely to have pulmonary and extrapulmonary active
disease simultaneously, although the latter is still prone to
the drug-susceptible regimen, as first-line agents penetrate
most tissues well. The treatment regimen usually depends
on the pattern of susceptibility, but often includes the
aforementioned first-line agents along with second-line
agents known to be effective against a resistant strain. These
include ethionamide, cycloserine, ofloxacin, and
ciprofloxacin.
Directly observed therapy (OOT), in which the patient is
observed taking the medication, is meant to ensure
compliance with the preventive therapy regimen and thus
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reduce the risk of reactivation in the patient. Treatment
noncompliance is also a major cause of secondary resistance
in tuberculosis, thus DOT can help prevent the increased
incidence of resistant TB.
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our nnderstanding of the epidemiology of TB and provided a
more rapid diagnosis and initiation of drug therap y. This
approach, along with the traditional interventions of rapid
identification and ensuring compliance with therapy, will
enable us to control the revival of TB.

PROPHYLAXIS

Chemoprophy laxis is recommended for any HIVseropositive patient who is PPD+ with a greater than 5 mm
induration, and has no evidence of active disease. Preventive
monotherapy with isoniazid can substantially reduce the risk
of reactivation among IDV-infected patients who are infected
with TB. As has been stated, the HIV-infected individual with
latent TB is at extremely high risk for reactivation of active
disease. One study reported a tuberculosis incidence of 7.5
per 100 person-years in HIV-infected individuals receiving
placebo compared with 2.2 per 100 person-years in those
receiving isoniazid.' Options for preventive therapy are
limited when the likely exposure is to MDRTB, although
rifampin has been suggested. Another major concern is the
effect of using prophylactic isoniazid alone in contributing to
the evolution of drug resistance.
CON CLUSION

The mv epidemic has possibly been the most important
factor responsible for the increased rates of TB. With the advent
of increasing drug resistance in strains of M. tuberculosis and the
spread of IDV in regions with the highest rates of tuberculosis,
TB has become the most common opportllllistic infection and
the leading cause of death in persons infected with HIV
worldwide. As the 21" century approaches we are facing the
resurgence of an infectious disease once thought to be
amenable to eradication. Modem techniqu es have enhanced
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CHALLENGES OF HIV DRUG
COMBINATION THERAPY:
Psychosocial and Practical Impact Reviewed
By f. Scott Turton , ACOL

IN THE BEGINNING ...
From the late 1980's to present, advances in HIV
therapy ha ve given us a spectrum of m_edications ~nd
approaches with varying degrees of efficacy. The first
attempt, AZT, showed some promise in delaying the
onset of AIDS but had no real effect in prolonging life.
The virus appeared to develop quick resistance and
research began on alternative medications. Other drugs
(a class of drugs called nucleoside analogues_) w ere
developed demonstrating various levels of effectiveness
(DOl, D4T). Two years ago , a combination of two
nucleoside analogues became the standard therapy and
the combination of AZT / 3TC became widely used. This
combination suppressed viral replication_and incr~a~ed
CD4 counts for a year or more in a vanety ~f clinic~!
trials. For those patients who had used AZT pnor to this
new combination, the virus was able to de ve lop
resistance to both medications and only short term
benefit was achieved. With the recent development of
protease inhibitors (Saquinavir, Ritonavir, Indina~ir), a
new class of medications was now added to the nuxture
and the triple combination became standard therapy.
Triple and quadruple combinations have recently shown
that viral activity can be reduced to undetectable levels
and maintained for one or more years. Finally, another
class of medications, non-nucleoside re erse
transcriptase inhibitors (
RTI's) are being developed
for use in combination therapies.
CHALLENGES O F HIV DR UG C O M BINATI O N
THERAPY
Combination therapies (a.k.a. drug cocktails) provide
both health benefits and practical challenges to people
living with HIV. A review of current literature suggests a
number of obstacles to compliance. One commentator
writes that taking these medications inv olv es a life
change, and stresses that most patients taki~g . the
"cocktail" need to organize their lives around a difficult
and demanding pill taking schedule.
ABOUT THE AUTHOR
Scott Turton completed undergraduate work with the
University of Western Ontario and Graduate s~ies ~
Wilfrid Laurier University with a Masters degree tn ~cral
Work. Scott has worked in the HW/AIDS field for ezght
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Triple and quadruple drug combinations often
involve taking at least twenty pills per d~y ,_ each
medication having differing requirements for hmmg of
doses, and consideration a s to whether or not the
medications need to be taken with food. Saquinavir, for
example, must be taken at eight hour intervals with a small
meal. Indinavir, in contrast, must be taken at least one hour
before and two hours after eating, three times per da y.
Depending on the specific drug, directions may stipulate no
food and lots of water, low fat food, or high fat food. All of
these requirements lead to substantial disruption in normal
routine and would often have an impact on adherence to the
regimen. Obviously, changes in diet and sch~uling of meal
times and snacks (or no snacks) becomes an ISSue. For some,
disruption in sleep patterns may occur if the patient n~s
to wake earlier for a dosing or stay up later than the1r
normal schedule. In regards to dosing schedule, ma~y
studies have demonstrated that it is not the number of pills
taken per dose, but the number of doses _whi_ch ~pacts on
compliance levels. These same studies mdi~ate that
compliance levels drop off with more than twice a day
dosing. 2 At present, the dosing sche~ules for _the drug
cocktail remains three times per day, at eight hour mtervals.
One must also consider the profile of side effects for the
medications as a possible barrier to compliance. Common
effects such as nausea, stomach pain and diarrhea may
exacerbate compliance. One journalist writes of compli~ce
issues and states that we are assuming that these medical
and organizational issues are the main barriers to
compliance when in fact, financial cost and lack of support
may deter one from even commencing this regimen. Drug
costs for protease inhibitors and NNRTI's can well be
prohibitive if one does not have a~cess to governmen~ dru_g
plans or private plans. The working poor are o_ften m ~s
situation with r elatively poor access to hfe savmg
medications.
Recent data suggests that compliance is also dependant
on environmental, psychological, and social fact~rs . In _a
recent study Singh and others found that compliance_Is
influenced by a variety of interdependent psy~hosoCial
variables which "interact in complex ways to influence
overall quality of life and even longevity". In t_hi s
longitudinal analysis examining the psycholog~cal b~Ie~s
associated with compliance, results demonstrate that Within
the study sample, non-compliant patients demonst:ated
"significantly greater psychological ~istress~ emotional
disturbance, depression and poor adaptive copmg assessed
by standard psychological tests".4 In a related study on stress
and stressors, researchers discovered that the average HIV
positive respondent in the study appear~d to have "more
depressive symptoms and more percel\'_ed ..stress ~han
would be expected in the general population . Emotional
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factors such as depression, must then be considered by a
treating physician as a possible challenge in compliance to a
difficult and demanding drug regimen.
WHY IS COM PLIAN CE SUCH AN ISSUE?
Quite simply, if there is any interruption of the drug
regimen , resistance will occur and the therap y will
ev entually become ineffective. When people stop their
medicine a resurgence of the v irus is evident, to some
extent, within one day. The trick here is to stop replication
by suppressing the viral activity. With the extremely high
rates of replication of this virus (approximately 10 billion
new copies per day) any interruption of the pharmaceutical
pressure on replication through repeat cycles of nonadherence or erratic patterns of compliance likely means
that those mutations are going to thrive, and you are going
to end up with a whole population of the virus that is
resistant to the therapies .6 Chris Tsoukas of Montreal
General Hospital emphaticall y states that viral load
reduction which reduces HIV's replication opportunities is
"the only demonstrated way to postpone the development
of viral resistance".
ROLE O F PHYSICIAN S IN PROM OTING
COM PLIAN CE
For the most part, commentators believe that medical
schools have been inadequate in addressing the issue of
recognizing the optimal conditions for compliance to
medical advice. Eracker and colleagues note that "few
medical schools teach their students to recognize the
conditions under which the patient can be expected to
follow advice (much less the methods for communicating
effectively with patients), or the interview skills needed to
assess what the patient knows, believes, or is concerned
about". 7 With the reorganization of lives around a difficult
pill regimen, Mirken believes that physicians must spend
time understanding a patient's life before recommending a
specific regimen? Customizing the treatment to a patient's
lifestyle, attitudes, and beliefs will impact on the patient's
willingness and ability to follow a treatment plan. As
prev iously mentioned, paying attention to emotional
factors such as depression may also enhance compliance
through active treatment of the emotional condition .
Providing referrals for emotional and practical supports (i.e.
access to financial supports or payment programs) are also
appropriate interventions for patients.
PSYCHOSOCIAL TRANSITIONS
It appears that the introduction of these powerful
combination therapies has de-stabilized many people living
with HIV from a psychological and social standpoint. In the
writer's own practice, a number of people now question
their goals and possibilities for long term survival. It is as if,
one client states, the world has been turned on its side and
something new and frightening has been created. At first
thought, logic would dictate that people would rejoice at
new possibilities for a prolonged and healthy life. It appears
that those individuals who have developed clear self
identifications as (a) I am ill with HIV and (b) I will have a
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shortened life because of HIV, are now being asked to
redefine themselves and their world. Derek Scott of the
AIDS Bereavement Project of Ontario defines this as an
existential crisis. Scott describes the formation of Self as
transition between Self-as-uninfected to Self-as-infected.8
The writer would expand on these Self identifications by
stating that we have three identifications happening in this
pro cess. First, the indiv idual would identify Self-asuninfected-and-living. Second, the individual would
identify Self-as-infected-and-dying. With the advent of
combination therapies, the most recent addition would be
Self-as-infected-and-living. Movement from one of these
Self identifications to the next would provoke an existential
crisis. An individual may question his/ her identity, have to
refocus goals and beliefs for the future, and in many cases
redefine relationships and careers. Scott believes that for
p eople who have resigned themselves to what they have
been told is ine v itable, "the hope and uncer tainty
surrounding these therapies can contribute to a feeling of
cri s is, as once again, the Self and identity undergo a
profound shift". 8
CONCLUSIONS
It appears that the introduction of HIV combination
therapies has been a promising medical breakthrou gh, a
practical challenge for compliance and minimizing
resistance, and a p sychosocial challenge for many living
w ith HIV . It becomes evident that simply giving the
medications will not suffice. Complex and interacting
variables such as lifestyle, beliefs, resources, and emotional
health have to be considered when developing a treatment
regimen. A customized approach to treatment is essential
for ensuring efficacy of the drugs.
Educators are now struggling with the possibility of
relaxed safe-sex behaviours due to the misperception that
new drug regimens represent a cure. This is perhaps an area
for further discussion and research as mortali ty rates
decrease (due to the effectiveness of the therapy) and
infection rates increase.
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HIV/AIDS:
Epidemiology, Advances in Therapy, Prevention
By Dr. Janet Gilmour, SJHC

INTRODUCTION

VIRAL LOAD MEASUREMENT

As the HIV pandemic continues well into its second
decade, the global picture continues to be b leak.
According to the UNAIDS there are 8,500 people infected
every day. Greater than 40% of these new infections occur
in women. More than half of these new infections occur in
people between the ages of fifteen and twenty-five years.
One thousand children are infected every day. Of the
children living with HIV I AIDS, 75% of them have a
mother who is also HIV infected. Nineteen percent of the
children have a mother living with AIDS and 6% have had
a mother die of AIDS.1 There is no doubt that the impact
of this disease continues to be devastating. The developing
world has been most hard hit. In parts of Africa, 30-40% of
all adults are HIV infected. In Hurare, Zimbabwe, 40% of
pregnant women were found to be HIV infected. Life
expectancy at birth has decreased by as much as 25% in
severely affected countries. Mortality from AIDS
continues to increase in the developing world.
In the developed world (Canada, United States,
Western Europe and Australia) the rate of new infections
has stabilized, and even decreased in some areas. For the
first time ever the death rate from AIDS in North America
decreased in 1996. Recent developments have led to
improved understanding of the pathogenesis of the
disease. Several new antiretrovira1 medications have been
developed and are now accessible to some people with
HIV. These recent advances have resulted in a sense of
cautious optimism.
A cause for considerable concern however, is a recent
resurgence of infections among Canadian and American
men who have sex with men. Additionally, in Vancouver
and Montreal, HIV is currently spreading with alarming
speed among injection drug users (IDU's). In Ontario, as
well, the situation in lOU's is very unstable. Presently,
heterosexual women comprise the group with the greatest
increase in rate of new HIV infections. At the HIV Care
Programme in London, more than 20% of new referrals
are heterosexual women, with no history of IOU or
prostitution.

New methods have been developed that can
reproducibly measure the amount of HIV-1 RNA in
plasma. Plasma HIV-1 RNA concentration (viral load) is
reported as number of copies per ml serum. Viral load has
been shown to be the best predictor of clinical outcomes
of all markers studied to date. 2 Measurement of viral load
has rapidly been adopted as integral to the management
of HIV infection. Besides providing valuable prognostic
information, change in viral load in response to
antiretroviral therapy ha s proven to be a reliable
prediction of clinical response to antiretroviral treatment. 3•4
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ANTIRETROVIRAL THERAPY
The last two years have seen significant changes in
treatment of HIV infection . Currently there are three
classes of antiretroviral medications available (to a
variable degree) to treat HIV infection: nucleoside
analogue reverse transcriptase inhibitors (NRTI's), such as
Zidovudine, (AZT); non-nucleoside reverse transcriptase
inhibitors (NN RTI 's), and protease inhibitors (PI) .
Combinations of medications (three or more) are used to
provide greater, more durable virologic suppression.
Clinical trials have shown that combinations of two
NRTI's and one PI significantly decrease both morbidity
and mortality. 5
Treatment guidelines now strongly support earlier
more aggressive antiretroviral therapy than ever before. 6
Clinical trials are ongoing, studying the effects of initiating
antiretroviral therapy at the time of acute infection. For
the first time, scientists and clinicians are designing
studies to address the possibility of eradicating the virus.
Just one year after protease inhibitors have become
widely available, many people have already benefited
greatly from their use. Undoubtedly their widespread use
has contributed to the decrease in death rates due to AIDS
that we have seen across orth America . How durable
their effects will be remains to be seen. Even so, despite
the successes that have occurred, much needs to be done
for treatment of HIV-1. Many patients treated with
available medications fail to achieve virologic control.
Others are unable to tolerate the significant side effects
associated with these treatments that, as of yet, do not
offer even the hope of a cure. Most limiting is the fact that
the majority of the people in the world with HIV infection
do not have access at all to any of these medications, by
virtue of their high cost. (Approximately $1,000 per month
for "standard" triple therapy- see Table 1).
PREVENTION
Success has also been achieved in preventing
transmission of HIV -1. Vertical transmission can be
reduced by 67% with use of Zidovudine. The vertical
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transmission rate of 26% can be reduced to approximately
8% with Zidovudine taken from 14 weeks gestation
through labour and deliveries, and administered to the
infant for six weeks following birth. 7 A voidance of breast
feeding where there are good alternatives can reduce HIV
transmission by 15-30%. HIV testing should therefore be
offered to all pregnant women, as part of routine prenatal
screening.
Zidovudine (AZT) has also been proven effective at
reducing HIV infection (seroconversion) following
occupational exposure.8 To be effective post-exposure
prophylaxis (PEP) needs to be initiated as soon as possible
following the exposure, ideally within 1-2 hrs. Many
hospitals have a standard PEP policy accessible through
the emergency department or via occupational health and
safety offices. Whether PEP would be effective following
sex ual exposure has not been determined. The use of
barrier prophylaxis significantly reduces sexual
transmission of HIV, but does not eliminate it. People
whose lifestyle put them at risk for acquiring HIV need to
be provided with information about risk reduction and
harm reduction techniques.
Thus, while the last few years have seen significant
progress in the understanding and treatment of HIV-1
infection, the pandemic is far from controlled. In 1996
alone, 1.5 million people died of AIDS. More than 23
million people have been infected with HIV-1 to date. All
estimates predict that by the year 2000 this number will
exceed 40 million.
Without a cure or vaccine, the most effective strategy
for fighting HIV I AIDS is prevention. Studies done in
several countries have shown that prevention programs
can result in behavioural changes. More effort needs to be
directed toward implementing effective education and
prevention programs worldwide.

A rticles

TABLE 1. MEDICATION EXPENSE

TYPE OF
ANTIRETROVIRAL

MEDICATION

NRTI's

Zidovudine

APPROXIMATE
COST/MONTH

(AZT)

RETROVIR

$325.31

Zalcitabine
(DOC)

Protease Inhibitors
(PI's)

HIVID

193.50

Didanosine
(DOl)
VIDEX

184.80

Larnivudine
(3TC)

315.50

Stavudine
(d4T)
ZERIT

250.00

Saquinvir
(Invirase)

550.79
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Indina vir
(Crixivan)

NNRTI's

$510.00
(wholesale price)

Ritonavir
(Norvir)

$554.00

Nelfinavir
(Viracept)

Study Med.Expanded Access

Delavirdine

Study Med.
- Expanded Access

Nevirapine
(Viramune)

Study Med.
Expanded Access
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GLIMPSE OF THE FACE
IN TANZANIA

OF

AIDS

By Jennifer Hankins and Shane Longman, MEDS 1999
nnocence lives in
a mud hut on the
outskirts
of
Arusha, Tanzania.
The interior is
decorated
with
magazine clippings
of white fashion
models and black
sports stars, taped
to
mildewing
cardboard ,
and
hammered into the
dirt walls by Coke
bottletops pierced
with nails. As a
result
of
his
constant diarrhea
and frequent lung
infections,
Innocence is too
fatigued
and
emaciated to work
Innocence
any longer. When
he and his wife were clinically diagnosed with AIDS a
couple of months ago, she took their four year old
daughter and moved in with another man. Innocence has
not seen either of them since then. His family does not
speak about him any longer, and does not help to support
him. They do not visit him, give him food, or help pay for
rent or medicines. Occasionally, a neighbour will leave
food outside his door.
Richard had two wives . He and one wife died of
AIDS-related illnesses a few months ago, leaving his other
wife, Gladness, to look after her own five children and the
four children born to the deceased wife. Two simple
wooden crosses mark their shallow graves in a nearby
corn field, easily visible from the mud hut that is
Gladness' home now. Gladness' family and friends have
abandoned her. Her two youngest children died recently,
and her four year old is frequently ill. Her oldest son is not
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The making of sugar cane juice for people living with Aids in Arusha

yet of legal age to own land, and Gladness is afraid that
when she dies her children and step-children will be
forced into the streets when neighbours and relatives
divide up her belongings and land.
These are some of the stories told to medical and
nursing students involved in MedOutreach, a student
group from the University of Western Ontario, as they
visit the homes of families coping with the daily realities
of living with AIDS in Arusha, Tanzania. A 1988 census
estimated that there were approximately 1.3 million
people in the Arusha region, with about 130,000 people in
Arusha town itself.1 In the summer of 1997, students in
MedOutreach had the opportunity to work with Sister
Denise Lynch of the Medical Missionaries of Mar y
(MMM), coordinator of the AIDS Prevention Programme
in the Diocese of Arusha. By participating in the MMM
AIDS outreach programs, these students were able to see
for themselves that many people with AIDS in Arusha
suffer in isolation and most die in their homes without
adequate care.
Fortunately, the MMM programs are making inroads.
In the first six months of 1997, team members from the
AIDS Prevention Programme made 2,488 home visits in
Arusha to provide emotional support, food, medicine for
concurrent illnesses, funds for rent, legal aid, and ongoing
education for family and friends .2 Recently, outreach
workers have been bringing sugar-cane, ginger and lime
juice along on their home visits. In addition to providing
AIDS patients with energy, this juice is produced and will
be marketed locally in support of the AIDS Prevention
Programme. 3 Besides home visita tion, the AIDS
Prevention Programme also runs a number of community
education programmes, such as "Behaviour Change", for
young adults in secondary schools. In an informal survey
done in Arusha by the AIDS Prevention Programme,
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about 75% of both boys and girls declared that they had
their first sexual experience between 10 and 12 years of
age, emphasizing the need for early education about HN
transmission. 2 Of special concern for girls in secondary
school is the "sugar-daddy" factor : there are reports of
parents who can no longer afford to pay the fees for
econdary school advising their daughters to "find
someone to pay for them" and giving them condoms to
prevent pregnancy. Unfortunately, young girls in thi
ituation who aspire to a future through higher education
often find themselves at increa ed risk of becoming HN
po itive. 3
While working in more remote areas of Tanzania
students from MedOutreach had the additional
opportunity to learn about the impact AIDS is having in
the e regions of the country. Cultural practices amongst
the Maasai, a proud tribe of nomadic warrior herdsmen,
offer insight into the spread of HN in such locations.• It is
not uncommon for a Maasai elder to have five wives and
25 living children, all living within a single "boma" (a
collection of round mud huts surrounded by a hedge of
dense thorns to guard their cattle and goats from lions and
leopards). When a warrior from a distant boma comes to
visit, it is culturally proper for the village elder to offer the
visiting warrior one of his wives for the night. The
husband welcomes the prospect of a visiting warrior
impregnating his wife since the social status of the elder is
enhanced with each new child that is born. This is one
rea on why the Maasai have been resistant to using
condoms.'
Another tradition potentially increasing the risk of
HIV transmission amongst the Maasai is the practice of
group circumcision of young boys . Circumcision is a
required ritual in which a Maasai boy must participate in
order to become a young adult warrior, or "Moran ".
Traditionally, the ritual i held in the early morning
following a night of celebration and excitement. A group
of up to 20 boys, ranging in age from approximately 12 to
18 (ages are actually unknown to most Maasai ), are
circumcised with the same knife. If a boy flinches or shows
fear, both his family and the boy will lose respect in the
village. The concern with regards to HIV is that by the
time the cohort of boys become circumcised, it is likely
that some of the older boys will have travelled to the
cities, met with sex workers, and may be HIV positive.
Efforts to encourage the use of a separate knife for each
circumcision, or at least to clean the blade between
procedures, have been met with reluctance because, like
many populations, the Maasai are very resistant to make
changes to their traditional practices.'
Perhaps one of the most disturbing reasons for HIV
transmission in the Maasai is a well known "cure" that a
Maasai medicine man advised for a HIV positive man.
The medicine man had explained to the patient that "the
AIDS" in his body could be reduced by half if he were to
have sex with a young virgin girl because half of his virus
would be passed on to her. If he had sex with enough
virgin girls, he would be cured. This "dilution effect" cure
dramatically demonstrates the need for education of the
Maasai people about HN and how it is spread.'
Various epidemiological studies have shown that the
picture of AIDS in Tanzania is serious. As in the rest of
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sub-Saharan Africa, the majority of HIV in Tanzania is
transmitted through heterosexual contact with an infected
person .5•6 Condom use is not widespread; in a recent
western Tanzanian study, 88% of men and 63% of women
had heard of condoms, but only 20% of men and 3% of
women had ever used one. 7 In the Arusha region, HIV
prevalence rates are estimated to be higher in women than
in men, in urban than in rural areas, in urban areas of low
socioeconomic status than tho e of high socioeconomic
status, and in divorced and separated individuals than in
married and cohabitating individuals.8 Factors associated
with higher HN prevalence rates in women in the Arusha
region include having travelled outside of Arusha in
Tanzania and abroad, having multiple sexual partners,
and having sexual intercourse while under the influence
of alcohoP
Epidemiology is nece sary for revealing the context of
HIV and AIDS in Tanzania, but it is the opportunity to
meet with people living with HN and AIDS that gives this
picture its colour and texture . Students with
MedOutreach were privileged to have a glimp e of how
AIDS exists in the Tanzanian setting; the haunted look in
Gladness' eyes is a memory that will not easily be
forgotten. Clearly, any interventions aimed at reducing the
spread of HN in Tanzania will have their greatest effect if
they are able to address the personal experience of living
with this disease.
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GEOGRAPHY OF AIDS

Spatial diffusion and the Canadian Experience
By john Ho, MEDS 2000
INTRO DUCfiO N
In 1981, the Western world was introduced to a new
disease that seemed distant and unimportant to the
general public as it was labeled a "homosexual disease".
However, within just a few years of the first recognized
cases, Acquired Immune Deficiency Syndrome (AIDS) has
gained such a strong foothold that it is now a global
epidemic. It is estimated that since 1981, over 6.8 million
cases of AIDS, and 1 million deaths due to this disease,
have occurred worldwide. 1 Considering that most
Western countries are in the later stages of demographic
transition, the appearance of an infectious disease as a
major cause of deaths is alarming. Already, in 1989 it
became the number one killer of men 25-34 years of age in
Toronto. In that year, it also entered the top four
contributors to potential years of lost life superseding
diabetes, chronic lung disease and kidney disease. 2 The
spread of the disease has followed a complicated path.
Distinct geographical patterns of transmission have
emerged which reflect the behavioural patterns of infected
people and the interaction networks of the population as a
whole. Intricate epidemiologies exist both in and within
different regions of the world. Today, we know a lot about
the disease but not enough to stop it. In an attempt to
better understand this pandemic, the study of this disease
through geographical paradigms has been employed.3

SPATIAL DIFFUSION
Medical geography has many tools available to help
explain the spread of diseases. One of these devices is the
spatial diffusion theory defined as the "process by which
behaviour of characteristics of the landscape change as a
result of what happened elsewhere earlier".• Loosely
translated for the purposes of this topic, it is the spread of
a disease both spatially and temporally from limited
origins. The spread of a disease is dependent on several
factors including the presence of suitable agents to
transmit the disease and appropriate hosts. The nature
and spread of the disease usually reflect the geographical
and temporal patterns of individual contacts. Spatial
diffusion is characterized by a disease origin and changes
in the prevalence rate over time.
There are four main models of spatial diffusion :
Expansion diffusion, Relocation diffusion, Contagious
diffusion and Hierarchical diffusion. Expansion diffusion
is a relatively simple model. It simply describes the
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expansion and diffusion of the disease resulting in more
agents possessing the disease. Relocation diffusion is also
a simple pattern that is characterized by a change in
location of infected agents. Often, relocation diffusion is
characterized by great leaps in movement, potentially
bypassing intervening populations; however, there is no
change in the prevalence of the disease. Contagious
diffusion is a slightly more complex archetype involving
dose contact of individuals. It is often explained in terms
of a wave phenomenon in which there is an epicentre with
high rates of infection, with a gradual decline in
prevalence moving outwards - a distance decay effect. The
last type, Hierarchical diffusion is typified by the spread
of a disease from a large city to smaller cities over time.
This diffusion type is also related to diseases where
spread is closely associated with contact of individual .•.s.6
These diffusion types are not mutually exclusive; often,
disease diffusion processes are a combination of the above
types or may have several types occuring at different
times depending on the state of progression of the disease
cycle.
As with any sort of diffusion, there are situations that
may promote the spread of the disease as well as
situations that may not favour the movement. Situation
that promote the diffusion of disease are known as
diffusion networks. These networks consist of the intricate
system of people, locations and the links that connect
these places -- both physical links and communication
links that allow the movement of people, goods and
diseases . Factors that serve to prevent diffusion of
diseases are known as barriers. There are three
manifestations of barriers: absorbing, reflecting and
permeable barriers. Absorbing barriers tend to stop a
disease from moving at all. Immunization or genetic
immunity often has this effect as the disease as unable to
seed itself into a population. Reflecting barriers tend to
concentrate or deflect diseases towards a certain
unblocked area preventing infection of another locale. For
example, if two towns are separated by a dense forest, a
disease will tend to stay on the side of the forest that it is
on and concentrate its effects there. The final type of
barrier is a permeable type. This barrier serves to dilute
the process of infection or slow down the progression. All
of these barrier types can either be physical barriers or
cultural practices developed over time to prevent spread
of infection. Examples of physical barriers include deserts
or vast expanses of water. The e physical barriers are not
as effective in modern times due to the accessibility of
rapid transport over vast distances. Cultural barriers tend
to be more effective. These include religious and cultural
practices, such as drinking tea in Asia to prevent infection
with cholera as the water must be boiled first. As well,
these barrier types are not mutually exclusive. Often
combinations of the various barriers may exist in an area.
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GLOBAL TRENDS
~orld~ide, ~ere are at least three distinct patterns of
HIV mfechon with a fourth one suggested. Pattern I is
usually the trend seen in Western countries such as the
~~~ed States _and Fr~ce. Here, the predominant group
Imhally afflicted With this infec tion is the male
homosexual/bisexual population spread through
homosexual sexual activity . As well, an almost
simul taneous secondary wave of infection occurs in
intr~venous drug users. Heterosexual infection initially
begms at low levels but increases with time. Women are
largely unaffected with ratios above 10:1 male to female.
~erinatal infections are rare due to the low prevalence of
mfected females, however, the pervasiveness is
increasing.7
Pattern II is typical of sub-Saharan Africa where the
epidemic began in the mid to late 1970's. The disease is
most p~e~alent in the heterosex ual population with
transmissiOn occurring through heterosexual sexual
activity . Generally, the male to female ratio is 1:1.
Consequently, perinatal infections are also a major
problem in these regions.7
The third pattern of infection is characteristic of Asian
count~ies such as Thailand and eastern European
countries where the epidemic began in the mid to late
1980's. C~rently, Pattern ill countries account for a very
s~all £I:action ?f cases. However, future projections show
disturbmgly high levels of infection, greater than those in
other parts of the world. It appears that introduction of
HIV to these areas is usually through contact with people
or blood products from Pattern I and II countries.
~rostitutes ap~ear to be the most heavily infected groups
m these countries. 7
The fourth pattern suggested is derived from
observations of countries like Brazil and Honduras. This
p~ttern_ stresses the importance of bisexuals as the major
dissemmator of the virus spreading the disease from the
homosexual population to the heterosexual population.
However, caution should be taken as the sexual
ori~ntation o~ these individuals is self-reported. These
Latm countnes tend to have a ' macho' attitude and
describing oneself as bisexual is favoured over being
homosexual.'
These patterns are broad and general observations. In
f~ct, some co~tries may have several patterns occurring in
d_Ifferent reg.ons or even within the same metropolitan
aty. As well, the patterns of the disease should be expected
to change as the disease makes its course through the
population of these areas. 8

EPIDEMIOLOGY IN CANADA

According to the World Health Organization, Canada
had 8,232 cases of AIDS reported at the end of June 1993.
Early predictions for the cumulative total of cases were
estimated_at_ll,OOO cases by the end of 1993.9 These reports
and predictions must take into consideration the level of
co~pleten~ss _i ~ reporting and the delay in reporting
w~?' can significantly affect the accuracy of the statistics.
Imhally, the mode of transmission eluded scientists.
However, as the scientists learned more, it became evident
that transmission occurred through contact with infected
bodily fluids, especially blood and semen.

The major methods of transmission include sexual
activity, injection drug use, contact with blood or blood
p~od_ucts and through perinatal routes.9 The prevalence
Within the ?,ay comm~ty was largely due to the "party
atmosphere of the gay lifestyle. The mentality of the gay
population at the time included multiple sexual partners,
unprote~ted sex (as there was no risk of pregnancy), and a
perception that a cure for most sexually transmitted
diseases existed. Initially, all of the cases in Canada were
attributed to gay men. However, as the epidemic spread
through the community, strong educational programs to
erect cultural barriers were initiated. The incidence of new
cases amongst the gay community has stabilized and even
dropped. Current prevalence levels are approximately 1015%.2 However, there are indications of a second smaller
increas: in incidence attributable to young gay m;ues who
are havmg unprotected sex.
Since the first cases reported in 1981, the
eJ?idemiology of HIV I AIDS has changed drastically. The
disease has spread to injection drug users and from there
~o ~he het~rosexual population. It is reported that the
mcidence m 1993 was at 2% with regional variations.
Rec:nt studies have estimated that the prevalence may be
as high as 15-20% in the general population with incidence
rates of 6-7%.2 Other people became infected after
~eceiving tainted blood products, although this sub-group
IS rapidly _d eclining as blood products are now thoroughly
screened m Canada. As women became infected so did
children who were either in utero or breast-f~eding .
Seventy-four percent of pediatric cases in Canada have
been attributed to perinatal transmission as of July 1993.9
Other sub-populations at risk of contracting the disease
are health care workers, although universal precautions
have made the chances of being infected extremely low. 9
In an interesting turn of events, HIV I AIDS is now
prea?ing rapidl y within the heterosexual population,
espeoally among heterosexual young women. It is clear
that heterosexual transmission has become an important
contributor in this disease's progression.
THE NUMBERS GAME IN CANAD A

ot surprisingly, research and literature into
HIV ! AI£?S is very scarce in Canada . The majority of
publicatiOns are from the provincial and federal
governments. However, this information is sufficient to
illuminate patterns and trends in the HIV epidemic here in
Canada. According to statistics from Health Canada
adjusted for reporting delays and under-reporting, as of
September 30, 1995, Canada had a total of 15,926 cases of
AIDS re~orted . -!"s _of December 31, 1995, the provinces
hardest hit by this vuus were Ontario with 40.6% of cases,
Quebec with 31.1 %, British Columbia with 17.1% and
finally Alberta with 6.2% of cases. Together, these four
provinces account for 95% of the cases of AIDS reported in
Canada. 10
. Within these four provinces, epidemiological
differences exist. Ontario, Quebec and Alberta can
attribute approximately 70-78% of AIDS cases to
homosexual activity while British Columbia has a higher
rate at 88%. The other provinces can attribute 66% of
their AIDS cases to homosexual activity. It is interesting
to note that Quebec has a significantly higher rate of
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females infected (6.0% compared to 1.6% in the rest of the
country) and a higher rate of heterosexual infection. This
anomaly has been attributed to the high rate of immigrants
from Africa where the disease is prevalent in the
heterosexual population.2 Regarding infections occuring in
the smaller provinces, there is a greater number of
heterosexuals infected compared to homosexuals. This
variation in demographics can be ascribed to the lack of
large metropolitan cities with large gay populations.
The spread of HIV in Canada largel y follows a
hierarchical diffusion. These results are similar to findings
in Finland and the United States, countries which are in
similar states of maturity. 11 The areas in Canada that
reported the highest number of AIDS cases (78.1%) in 1983
were in the large metropolitan cities of Toronto, Montreal
and Vancouver -- cities with strong international
connections. Only six percent of cases were in medium
sized cities with populations between 50 000 to 750 000
people with the remaining cases (15.6%) in other areas.
However, by the end of 1987, the proportions changed to
63 .1 %, 21.6% and 15.3% respectively. These numbers
indicate the disease originated in urban cores of large cities
and gradually spread to suburbs, smaller cities and rural
areas. This diffusion process is very similar to patterns
seen in other developed countries such as the United States
and Finland.12
THE SMALLER PICTURE: ONTARlO

While global and national patterns are interesting,
they can often overshadow important underlying spatial
variations within smaller regions. 13 This is especially
evident in Canada due to its sheer size and diversity
within each region. According to statistics from Health
Canada, Ontario is the province with the greatest
number of AIDS cases. This is not surprising as Ontario
is the largest province in Canada consisting of
approximately 40 % of the population . Within the
province, it appears as if Toronto was the epicentre. This
is expected as the city serves as a major international,
commercial and transportation hub. As well, the
presence of the country's largest urbanized area contains
the country's largest gay community. Although these
characteristics were unlike the occurrences found in the
United Kingdom, they were similar to those of Helsinki
and the Finnish experience.11 •14•15 Due to the tremendous
variation in demographics within the provi nce,
variations in the spread of the epidemic exist.
Over a five year span from 1988 to 1993, the spread
of AIDS moved rapidly in Ontario. Initially, the areas of
primary infection were in the urbanized areas of Ontario
particularly Windsor, London, Ottawa, Toronto and the
rest of the Golden Horseshoe . 16 Within Metropolitan
Toronto, the cases were concentrated within the Central
Business District, due to the presence of the "gay village".
Parts of northwestern Ontario were still devoid of any
cases of AIDS. However, by the end of 1993, a significant
number of cases appeared in the outlying regions of the
metropolitan areas. The most updated statistics show
that even the northwestern regions of Ontario are not
free of AIDS cases either. 10
It is interesting to note that although the Central
Business District of Metropolitan Toronto still has the
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highest cumulative number of cases, the number of new
cases in this area has actually decreased. In stark
contrast, the outlying regions have seen tremendous
increases not only in cumulative cases, but also in
incidence. This trend appears to be typified by a
hierarchical diffusion superimposed by an expansion
diffusion. As the initial wave spread from downtown
Toronto, it hit other larger cities, appearing to miss
intermediate locales. However, as the disease
progressed, outlying regions began to feel the effects. 17
The possibility also exists that the movement of AIDS to
the more rural parts of Ontario could be due to migration
of people diagnosed with AIDS in cities returning to
their home towns - a relocation diffusion. This pattern
has been documented in North Carolina and helps to
explain the rapid diffusion of the disease. 1
Curiously, the spread of AIDS cases appears to occur
along an east-west axis within Southern Ontario. This is
possibly explained by migration patterns and the social
and family networks in existence in the province similar
to situations in New York City.19 Vehicular traffic along
the 401 highway is the busiest in the country with
Toronto as the centre of the highway system. Everyday,
over 46 000 people travel into the downtown core from
the eastern and western areas of the Golden Horseshoe
by rail alone. 20 It appears as if the disease followed the
network in place to spread to other communities. These
observations would be in agreement with those found in
Uganda where the disease spread along its trucking
routes. 21 ' 22
Other factors, which may help to explain the initial
spread of the disease in Toronto, may include the
behavioural patterns of homosexuals in Toronto. In a
survey, it was reported that gay men who lived in
smaller cities were more likely to live in a relationship
than their counterparts in large metropolitan cities. This
also correlated with the number of people in
monogamous relationships.23 Thus homosexuals in the
urban areas tended to have greater numbers of partners,
thus facilitating the diffusion of the virus.
CO NCLUSIO NS

Geography is a particularly useful tool in medicine,
especially in helping to elucidate the current epidemic
with HIV I AIDS . Geography is able to illustrate the
spatial-temporal variation in patterns of HIV infection
and AIDS Y As well, it can provide direction for
researchers and help predict future trends, thus aiding in
effective deployment of scarce health care resources .
Lastly, it is able to combine various sources of
information from various disciplines and synthesize
more useful information than the parts alone. While the
current epidemic is disturbing and striking a largely
ignorant population, intervention programs can help
stabilize the current infection rate, and perhaps someday
extinguish this disease. It is obvious that cities play key
roles in the dissemination of this disease. However, it is
also obvious that the outlying areas are at the greatest
risk of becoming infected as HIV makes it way through
the population. The general trend of HIV infection and
AIDS cases in Ontario thus appears to be following a
combination of hierarchical, expansion and contagious
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diffusion . The purpose of this paper was to perhap
integrate and synthesize some new ideas in th e
geography of HIV I AIDS. However, only the "tip of the
iceberg" has been observed. There is a tremendou
opportunity for further research . More research in
Canada can onl y help bring a better understanding of
this epidemic, and help parties interested manage the
progression of this disease more suitably.
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P

ublic awareness of the issue of the Human
Immunodeficiency Virus (HIV) in sport grew on
ovember 7, 1991 when Earvin "Magic" Johnson
announced his retirement from professional basketball due to
his HIV positive status. The statement made by a physician,
that a Montreal woman had claimed to have slept with "nearly
50" professional hockey players before she died of AIDS,
reinforced that high risk behavior outside of the sporting
context could bring HIV into the sport arena.• Magic Johnson
was not the first professional athlete known to be HIV
positive. The death of Jerry Smith, a former Tight End with the
Washington Redskins, of AIDS in 1987 didn't capture the
same media attention as Johnson's case. 2 The New England
Journal of Medicine reported a case of a bodybuilder with
AIDS as early as 1984. 3
Awareness of AIDS in the athletic community continues
to grow with the stories of Arthur Ashe, Greg Louganis and
boxer Tommy Morrison who recently returned to the ring.• A
1992 survey of NCAA institutions reported 8 schools known
to have HIV infected athletes and 4 schools with athletes
known to have AIDS, one of whom is still playing. 5
The majority of official statements have concerned three
issues: testing of athletes, the participation of HIV positive
athletes, and the practice of universal precautions b y the
athletic health care team. 5 Several groups have published
guidelines to address these issues. These include the World
Health Organization (WHO), in association with several
sports medicine bodies, in 1989. In 1991, The American
Academy of Pediatrics published guidelines on HIV in the
athletic setting. 6 A comprehensive joint position statement
entitled Human Immunodeficieny Virus (HIV) and Other
Blood- Borne Pathogens in Sports, was published by the
American Medical Society for Sports Medicine and the
American Academy of Sports Medicine in 1995. 7 The
Canadian Academy of Sports Medicine published its first
brochure on this issue entitled AIDS and the Athlete in 1989.
This was replaced by a more current, bilingual document:
HIV and the Athlete: Question and Answers about AIDS in
1992.1.8
The National Basketball Association took the lead among
professional organizations in taking responsibility to make
players aware of HIV after the Magic Johnson issues arose.9
On November 19, 1991, the National Hockey League
encouraged all league officials to provide HIV testing and
counseling but no mandatory testing. The ational Football
League sent letters to all club general managers, presidents
and trainers on December 5, 1991 regarding HIV. This letter
stated, "It is important that we all become better informed
about HIV and AIDS."
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The consensus reached by all of these groups, athletic or
medical, is that there is no need for routine testing for athletes,
no justifiable restrictions due only to HIV infection, and that
appropriate attention to infection control in training facilities is
necessary. 5 Their concern is related more to off-field risk
behavior than to risk during competition.9
Major sports organizations have been supportive of the
HIV positive athlete and in protecting their athletes from
infection. They all stress the need for education regarding offfield risk behaviors as the greatest risk to athletes lies in sexual
practices and parenteral drug use. 7•9 They also advocate the use
of common sense precautions when dealing with bleeding,
such as the use of gloves, not reusing towels and bandaging
wounds. Most sports organizations have permitted unlimited
time-outs to control bleeding?
The NFL's HIV I AIDS policy, in effect since July 6, 1992, is
a good example of what most organizations uphold. The aim
of their policy is to provide the best possible information to all
players and staff. Most of the education is on off-field risk
behaviors. They also advocate no mandatory testing and no
mandatory disclosure of test results. Policy on disclosure can
be complicated as some states require the reporting of positive
test results}0 There is more variance in policies of the CAA
schools where 33 schools have policies on participation of HIV
positive athletes. Fifteen schools ban the activity of these
individuals in some or all sports according to the 1992 survey.'
There are no data for HIV prevalence in any sport group.
Using data related to the NCAA age range (18 - 24) we may
estimate that there are around 216 athletes in the NCAA with
HIV. Actually, intercollegiate athletes may be at a slightly
higher risk compared with non- athletic controls due to an
increased frequency of sexual partners and the decreased use
of contraception in this population.
Nor are there any data assessing the risk of HIV
transmission from athlete to athlete, or from athlete to medical
personnel. There is only one reported case of an athlete
contracting HIV during competition. 11 The authors of the
report claim that a 25-year old Italian soccer player bumped
heads with an HIV positive player during a game in 1989. This
player had tested negative for HIV one year earlier. He denied
any risk behavior and claimed to be in a long-term
monogamous relationship. This case has been dismissed by the
medical and sporting communities as invalid. 9 This case was
based on flimsy evidence and there was doubt as to the
lifestyle of the player. Experts have dismissed the possibility
that sport was responsible for transmission after reviewing all
aspects of the case.2
There has never been a report of HIV transmission from an
athlete to the training staff. It is estimated that for healthcare
workers exposed to HIV there is one case of seroconversion for
every 250 needle stick exposures. This risk increases with
hollow bore needles.
Statistically, we can be certain that there are HIV infected
athletes competing at all levels of sport from high school to
professional. However, the lack of documented cases is
significant considering the known prevalence of HIV.7 The risk
of transmitting the virus, even during contact sport, although
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not zero, is far too small to quantify. It may be useful to
compare the risk of contracting illY to that of contracting
Hepatitis B which is more common and more likely to be
transmitted during sport. As of 1994, there were only 3 reports
of Hepatitis B among NFL players.10 All of these infections were
due to off- field behaviors. The only validated case of Hepatitis
B transmission during sport was between two high school
Sumo wrestlers in Japan in 1982.7
The NFL has actually attempted to quantify the risks of
mv infection during a game. They es timate this risk to be
approximately one infection per 85 million game contacts.• This
is about equal to one infection for every million games. The
NFL is one of the few organizations that does not necessarily
interrupt play due to blood.10 There is an average of 4 to 5
bleeding injuries per game in the NFL Most of these are
abrasions that do not represent measurable risk. inety percent
of the body is covered by NFL equipment and uniforms. This
further reduces the possibility of exchanging blood during a
game.
There was a report in 1984 of a bodybuilder with AIDS.3
This athlete admitted to a 4 year history of sharing needles to
u e anabolic steroids once per week. He discontinued this
practice two years previously when he contracted Hepatitis B.
He denied any other risk factors. This case reinforces that the
major risk to athletes is in off-field behavior. It is estimated that
38% of anabolic steroid users inject the steroids parenterally.•
According to the 1992 survey, 4% of CAA schools have
routine illY testing within an education program.5 Two of
these schools have mandatory testing. Seventy-eight percent of
CAA schools offer no testing through their athletic program.
The CAA guidelines recommend against mandatory testing.
HIV testing for those at risk should be accompanied by pre-and
post-test counseling and an education program. Also, the team
ph ysician should be aware that the patient's right to
confidentiality prevents disclosure of an athlete's test results to
the rest of the team or training staff. Physicians are advised to
counsel the HIV positive athlete about transmission and, if the
athlete participates in a combative sport (i.e. football, wrestling),
they should strongly suggest an alternate sport choice.
At the present time there is no medical or public health
justification for screening of athletes for HIV. The process of
screening is neither effective nor practical? Such testing would
ha ve to be done at least every three months. Also, mass
screening for widespread infections among a low risk group
leads to a high false positive rate. Although some organizations,
such as the evada Boxing Commission, require testing of all
their athletes, this is contrary to the current recommendations.
The best way to deal with this issue is to educate the athletes
and then provide testing and counseling for those at risk on a
voluntary basis.
Uni ve rsal Precautions refers to a group of hygienic
guidelines used in the handling of potentially infectious bodily
fluids in order to prevent or minimize the transmission of
pathogens.5 Universal Precautions hould be followed by all
health care providers. The World Health Organization and
Center for Disease Control recommend that all skin lesions
hould be cleaned immediately and covered, gloves should be
u ed when handling blood, and that participation should
immediately stop if bleeding occurs. The athlete can return to
play once the bleeding has stopped and the wound has been
cleaned and co vered . Most leagues will not permit
participation if blood is on the uniform regardless of the
source.
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The 1992 survey showed that 80% of CAA school '
athletic departments are familiar with Universal Precautions,
62% have education programs for their training staff and only
one quarter of the schools post the Universal Precautions in
their training rooms.
The effect of athletic participation on the mv infected
individual is also a concern. Magic Johnson originally retired
from the NBA because his doctors believed that the stress of
training and competing at the professional level may worsen
the course of his infection. It is now believed that moderate
exercise can cause an increase in immune system function.2
Moderate exercise may cause a decrease in the occurrence of
orne cancers as well as cause an increase in endogenous
opioids that can also protect immune function. Exercise and
athletic participation reduces stress and anxiety. Some believe
that stress and anxiety may open a window of opportunity for
AIDS to develop. Athletic activity probably does not make HIV
infection progress to AIDS. It may in fact delay the onset of
AIDS. Individuals symptomatic with AIDS are usually unable
to continue playing at a high level of intensity.
While the risk of contracting HIV during sport is a
theoretical possibility, the likelihood of this occurring is
extremely small. Therefore, there are no justifiable grounds for
involuntary restriction of an HIV positive athlete. The physician
hould counsel the athlete about the risks of transmitting the
infection and strongly encourage him or her to choose a low
risk sport option In all cases the athlete's right to confidentiality
must be protected. Universal Precautions should be adhered to
by all athletic and medical staff. All sources acknowledge that
recommendations will have to be modified if the available
information changes in such a way as to warrant new
initiatives.
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INFECTIOUS SKIN
MANIFESTATIONS OF HIV
AND AIDS
By oreen Ahmad, MED5 2000
uman Immunodeficiency Virus (HN) can result in
many dermatologic disorders, some of which may
be the presenting sign of the disea e. Many of the
cutaneous disorders that are HN specific, but also some
comm on dermatoses, can present atypically when an
individual is infected with AIDS. Usually, skin conditions
can be broadly divided into those that are of an infectious
nature and those that are non-infectious.
Non-infectious conditions can be further divided into
neoplastic cutaneous lesions and various eruptions such
as psoriasis, seborrheic dermatitis, Reiter's syndrome,
eczema and other dermato es.
Infectious conditions are the major cause of dea th in
patients with AIDS.2 These may also be divided into
several categories. These conditions, and the presentation
of some of the more commonly seen infections, will be
concentrated on in the following discussion.
In an individual who i HN positive, very few T-cells
in the circulation actually harbour HN( about 1 in 1,00010,000); however, a much higher percentage ofT-cells
(about 1 in 10) and other cells in the lymph nodes ar HN
infected. 2 This leads to destruction of CD4+ T -cells,
reduction in their formation, and loss of their normal
functions .2 Therefore, in individuals who are infected with
HN, infections of the skin by agents that would normally
cause only a minimal eruption, will proliferate and thrive
because of the lack of normal numbers of CD4 helper Tlymphocytes.1 The steady drop in the CD4 counts of HN
patients causes multiple interrelated malfunctions of both
the humoral and the cellular branches of the immune
system.3 The infectious skin manifestations that may occur
fall largely under three headings: Bacterial, Viral, and
Fungal and Yeast. Physicians should be aware of specific
eruptions of HN, as well as of the increase in incidence of
some more common dermatologic conditions which may
have an atypical presentation. Recognition of these may
lead not only to a diagnosis but also to more timely
treatment.

H

BACTERIAL INFECfiONS

Staphylococcus Aureus
The most common organism causing cutaneou and
systemic infection is 5. Aureus.• This is attributable (i) to
the fact that the nares can be colonized by the organism
(ii) to subsequent skin infections which are due to lack of

normal immune defenses (iii) to the high frequency of
eczematoid dermatoses, and (iv) the regularity of
indwelling catheters in many of these patients. 1 5. aureus
usually occurs in the form of impetigo, cellulitis or
folliculitis .5 Fortunately, therapy with appropriate
antibiotics is usually curative.1

Syphilis
Syphilis seems to be on the rise in North America .
The lesions usually develop in a similar manner to those
in HN negative persons, but may have an altered course. 1
The presence of ulcerating genital lesions is not only
painful, but also eases the spread of HN after exposure to
an infected partner. 6 Treatment of syphilis ma y be
difficult, and increased doses of drugs may be required.
VIRAL INFECfiO NS

Herpes Simplex
This viral infection occurs in about 20% of AIDS
patients, usually as an ulcer a t the perianal or perioral
mucocutaneous junction.6 It may also present as a
blistering or bullous disease, or resemble impetigo.6 As
defenses become impaired, herpes simplex becomes
chronic. In the past, chronic Herpes simples virus was
used as a marker for suspicion of underlying HN. Most
strains respond well to acyclovir, although resistant
strains that require combination therapy have also been
found. 7

Varicella Zoster
Thi s infec tion is normally more severe and
widespread in HIV infected patients than is herpes
simplex. 6 Cutaneous lesions occur due to a lack of
suppression of latent infection of dorsal root ganglia by
the virus. The virus becomes reactivated by depression of
cell mediated immunity, and this allows the virus to move
along a dermatome and cause an eruption of clustered
vesicles on an erythematous base.1 The possibility of
systemic involvement must also be remembered in
varicella zoster infected patients.8 Treatment is usually
acyclovir, or a combination of acyclovir with foscarnet
and other drugs. 5
FUNGAL AND YEAST INFECfiONS
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Candidiasis
Oral candidasis is an important cutaneous
manifestation of HIV disease , and is often used to
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diagnose AIDS in a person w ith no other cause of
immunodeficiency.1 Mucosal candidiasis occurs in most
HIV infected persons during their illness, and can be
persistent and may cause d ysphagia .7 Commonly it
produces white pseudomembranous plaques on the
mucosa .9 Treatment is instituted when the lesions are
symptomatic, and consists of good hygiene and topicals
such as nystatin or systemic treatment with ketoconazole
or fluconazole.1

DERMATOPHYTOSIS
Infection with dermatophytes occurs in about 20% of
patients with HIV infection. 1 The infection is more severe
than in non-immunosuppressed individuals. Well defined
erythematous lesions with scaling are typical, although
unusual presentations such as tinea faciale have also been
reported . 1 Dermatophytosis is usually treated with
ketoconazole given with a carbonated cola beverage for
acidity. This is the more commonly used treatment since
ketoconazole also eradicates candida. Topicals can also be
used for localized infections.1
Many individuals with HIV will develop cutaneous
manifestations of their disease. Skin changes may be the
first signs to alert a physician to a diagnosis of HIV or
AIDS. Changes in the skin can alert the doctor to further
deterioration in the patient's immunocompetence .
Knowledge of the numerous cutaneous disorders that
exist in individuals with HIV I AIDS are of great
importance in lessening morbidity, and prolonging life .
.;
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UNDERSTANDING THE ROLE OF
CHEMOKINE RECEPTORS IN HIV
INFECTION
By Walter Mak, MEDS 2001

S

hortly after the identification of HIV as the agent
responsible for AIDS, researchers were able to
demonstrate that the T-cell CD4 surface molecule
served as a receptor for HIV. Subsequent work, however,
showed that murine cells transfected with the human CD4
gene were not susceptible to virus entry, thus revealing
that while CD4 was necessary for incorporation of the
virus into host cells, it was not sufficient on its own. • More
recent studies have identified chemokine receptors,
namely fusin and CCRS, as co-receptors for the en elope
glycoprotein (Env) of HIV.•.2.3.•.s
Seminal work by Fiorenza Cocchi and co-workers
gave the first indication that chemokine receptor may be
involved.• Culture supernatants containing an activated
CDB+ T-cell clone were shown to inhibit HIV replication,
as manifested by a decrease in HIV -1 p24 (an HIV
structural protein) production in the supernatant. Cocchi
isolated various proteins secreted by the T-cell clone and
identified them, via direct sequencing of various peptide
fragments derived from the secreted proteins, as the bchemokines RANTES, MIP-1a and MIP-1b, which function
in the body as chemoattractants for the body's leukocytes,
which direct them to sites of infection. Treatment of the
supernatants with antibodies to RA TES, MIP-1 a and
MIP-1b resulted in p24 levels comparable to tho e found
in supernatants devoid of CDB+ lymphocytes, thus
identifying these chemokines as HIV-suppressive factors.
However, it was discovered that certain strains of HIV
were not sensitive to this suppression. In particular, it
was noted that those strains of HIV which preferentially
infected CD4+ macrophages (macrophage-tropic strains)
were susceptible to b-chemokine-mediated suppre sion
whereas other strains of the virus, which preferentially
infected transformed T -cells (T -tropic strains), were
unaffected by these chemokines.• Becau e macrophagetropic and T-tropic strains of HIV were thought to differ
only in the Env portion of the HIV genome/ there was
speculation that the observed HIV-suppressive effects of
the b-chemokines came at the level of viral entry into the
host cell! That is, that b-chemokines interfered with fusion
of the viral glycoprotein envelope with the ho t cell
membrane.
Subsequent studies by Deng et al. showed that this
indeed was the case. They employed a modified strain of
HIV -1, known as a lucile rase reporter virus, in which a
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frameshift mutation had been introduced into the Env
gene. While the modified virus was fully capable of
infecting cells, the mutated Env gene ensured that further
replication of the virus would not be possible, thus
allowing researchers to quantitatively assess HIV-1 entry
into target cells by measuring luciferase activity in the
cells following exposure to HIV. Using this assay system,
Deng et al. demonstrated conclusively that RANTES, MIP1a and MIP-1b inhibited infection of target T-cells by
macrophage-tropic HIV, further implicating chemokine
receptors in the HIV infection process. At this point it
appeared likely that such receptors act as co-receptors for
HIV.t
Several labs employed various methods to identify
possible co-receptor candidates. In one approach, human
embryonic kidney cells were co-transfected with CD4 and
one of several b-chemokine receptors and then challenged
with the HIV-1 based luciferase reporter virus described
earlier! It was discovered that cells transfected with CCRS
became susceptible to infection by macrophage-tropic HIV
strains, which was not the case for cells transfected with
any other chemokine receptor. Furthermore, cells
transfected with only the CCRS gene were resistant to
infection, indicating a co-operative mediation of viral
entry by both CCRS and CD4. A separate study by
Alkhatib et al. utilized cells expressing the lacZ gene of
Escherichia coli. Cells containing the lacZ gene and
expressing the HIV Env gene were mixed with murine
cells co-transfected with CD4 and CCRS. The lacZ gene
was integrated in such a way that fusion of the two cells
would result in the production of b-galactosidase.3 As
predicted, fusion only occurred between Env-expressing
cells and murine cells expressing both CD4 and CCRS.
Similar fusion studies were extended by Dragic and coworkers, who were able to successfully block fusion
between Env-expressing cells and cells containing CD4
and CCRS by adding RANTES, MIP-1a and MIP-1b to the
cell cultures. However, they found that if a certain amount
of time elapsed before the chemokines were added to the
culture, then fusion could not be blocked. This evidence,
they thought, was suggestive of a competitive mechanism
of inhibition of HIV . 2 The latter observation was
presumably due to an overexpression of CCRS, which
then negated the inhibitory effect of the chemokines.
Thus, in the span of a few months, it was proven that
CCRS was the co-receptor for macrophage-tropic HIV.
Meanwhile, parallel studies sought to identify the coreceptor used by T-tropic HIV in gaining entry into host
cells. Fusion experiments were performed where the CD4expressing cells were transfected with a whole cO A
library derived from a human cell line ! Repeated
subfractionation and screening allowed the investigators to
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isolate the co-receptor on a single 1.7 kb cO A insert. This
insert contained an open reading frame encoding a protein
352 amino acids in length. Analysis of the nucleotide
equence revealed that this protein was a member of the
superfamily of G protein-coupled receptors with seven
transmembrane segments, the same family to which all
chemokine receptors belong. Termed 'fusin', this new
protein was found to serve as a co-receptor for T-tropic
HIV in much the same way that CCRS mediated
macrophage-tropic HIV infection. A stromal cell-derived
chemokine was eventually identified as a ligand for this
newly characterized co-receptor, and interestingly enough,
it was also found to have an inhibitory effect on T-tropic
HIV infection of T-cells. 7
A puzzling observation that surfaced amidst all the
work on AIDS in recent years was the observation that
amongst cohorts of individuals with extensive exposure to
HIV, there existed a tiny subset of persons who remained
seronegative for the virus. Shortly after its discovery as an
HIV co-receptor, investigators looked to determine if CCRS
would provide a clue. A team led by Michael Dean was
able to map the CCRS locus to chromosome 3p2I.B Using
complex molecular techniques, the CCRS loci of more than
600 individuals from cohorts of various risk groups for
AIDS were screened for genetic variants of the CCRS gene.
One such variant was detected in 10% of all screened
individuals and was characterized by a 32-base pair
deletion mutation, resulting in a receptor which lacked
three transmembrane segments, including the region
involved in G-protein coupling.8•9 one of the individuals
homozygous for the defective gene showed any obvious
phenotype and all such individuals were seronegative for
HIV despite having been exposed to the virus.8 • 9 •10 o
seropositive individuals were found to be homozygous for
this deletion, suggesting that perhaps a defective CCRS
protein was responsible for conferring immunity to HIV. In
a separate study, Liu and co-workers discovered two
seronegative individuals who were both homozygous for
the 32-base pair deletion and whose white blood cells were
extremely resistant to macrophage-tropic HIV infection,
and sought to investigate this immunity to HIV at the
molecular level. 10 The gene encoding CCRS in these two
individuals was transfected into CD4-expressing cells and
then assessed for ability to either fuse with Env-expressing
cells, or permit infection by the luciferase reporter virus.
The mutated CCRS protein was capable of supporting
neither cell fusion nor infection by HIV. To determine
whether defective CCRS was expressed at the cell surface,
the gene was tagged with hemagglutinin prior to
transfection. Subsequent probing of the transfected cells
with fluorescing anti-hemagglutinin antibodies revealed
that the defective molecule was not e-xpressed at the cell
surface. These findings provided the molecular basis for
immunity of certain individuals to HIV. A point of interest
was the finding that white blood cells from an HIVresistant individual were shown to secrete ten times the
normal amount of b-chemokines. This suggested another
resistance mechanism, whereby an excessive amount of
chemokines inhibits CCRS binding to HIV Env, either by
desensitizing the co-receptor through over-stimulation of
the receptor or by competitive inhibition. More recent
work has disproved the former possibility. Using pertussis
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toxin to arrest chemokine-mediated receptor signalling,
researchers were still able to observe the same degree of
HIV inhibition by the b-chemokines as that observed in
earlier studies. 11
Another point of interest was that while leukocytes
derived from individuals homozygous for the 32-base pair
deletion are known to be highly resistant to macrophagetropic HIV, it had been shown that the same leukocytes
were susceptible to T -tropic HIV infection. 2 This
observation was explained by the theory that macrophagetropic HIV is the dominant form of HIV in asymptomatic
HIV-infected individuals.9 Following initial infection, it is
believed that the macrophage-tropic strain then evolves
into a T-tropic strain of HIV. 12 This presumably correlates
with the gradual loss of CD4+ T-cells and the onset of
AIDS-related symptoms in the individual. Because the
macrophage-tropic HIV cannot undergo replication in
resistant individuals, the switch to a T-tropic strain never
occurs and the individual remains uninfected. Support for
this theory came with the discovery of a dual-tropic strain
of HIV which has a demonstrated ability to use either
CCRS or fusin as a co-receptor. 12 This dual-tropic strain
would take its place in the hypothesis as a transitory strain
of HIV which would appear temporarily during the
evolutionary process. Such speculative insights, however,
await to be firmly proven or disproven.
With convincing evidence that fusin and CCRS served
as co-receptors for HIV in hand, researchers began to work
out the specific details regarding the nature of the HIVchemokine receptor interaction. Using various HIV
chimeric constructs, researchers were able to ascribe
susceptibility to chemokine-mediated inhibition of
infection to the V3 loop domain of gp120. 11 Analogous
studies involving chimeric constructs of the chemokine
receptor itself has allowed investigators to further
characterize the structural determinants of HIV-chemokine
receptor binding. 13 Another area of related interest is the
development of chemokine analogues as possible
candidates for anti-viral therapy. One such analogue is a
derivative of RANTES with a slight modification at the
amino
terminus. 14
This
analogue,
named
aminooxypentane- or AOP-RANTES, has been shown to
lack any chemotactic or leukocyte-activating activities
while retaining a marked HIV-inhibitory effect.
While much of the work in this area of AIDS research
is promising, one must be cautious as well. In recent
months, several groups have claimed to identify other
co-receptors for HIV and SIV, thus confounding the HIV
infection story somewhat.15 The presence of multiple coreceptors, each one ready to do HIV's bidding, would
make the development of an effective anti-viral
compound very difficult indeed. Nonetheless, in light of
the considerable amount of progress made in the
research of HIV co-receptors, there is reason to remain
optimistic. The struggle towards a more complete
understanding of HIV infection has, in the past two or
three years, led us on a rapid and exciting journey of
discovery. Uncovering the secrets of the HIV co-receptor
and further characterization of its role in the entry of HIV
into host cells has already begun, and will continue to
yield valuable insights into the treatment and possible
prevention of HIV infection.
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AIDS

By Harpinder Paul Johar, MEDS 2000

and Marc Raymond, MEDS 98
ince its discovery almost 16 years ago, acq~ired
immunodeficiency syndrome (AIDS) has qUickly
developed into a major public health concer_n
worldwide . It represents the end-stage of a systemtc
infection triggered by Human Immunodeficiency Virus
(HIV). This infection essentially cripples the immune sys_tem
leaving the host prone to the develop?'ent o~ multiple
opportunistic infections and / or mah?nanCles . Such
complications have both shortened the life_ span of AII?S
patients, and also severely affected the quality of what_life
they have left. With the advent of new ~easur~s to fi?ht
AIDS / HIV such as improved prophylaXIs, antiretro~u~l
drugs, and more effective treatment of oppo_rtumshc
infections, the expected life span of AIDS pahe':ts _has
steadily risen. As a result, those AIDS-related complications
which arise relatively late in the progression of AIDS are
beginning to be seen at greater frequ~.ncies. 1 Oc':lla~
manifestations are an example of these late-bloommg
complications experiencing an increase in incidence due to
the extended life expectancy of AIDS patients. Su~ ocular
afflictions of AIDS were first noted by Holland et al. m 1982,
and today it is estimated that over 70% of _ratie~ts with
AIDS will develop some sort of ocular manifestation, and
90% will have ocular disease at autopsy. 2 According to their
respective etiology and course, these complications ~an be
grouped into four main categories: microvascular diseas~,
opportunistic infections, neoplasms, and neuro-oph~almic
manifestations. The purpose of this review is to provtde the
medical student with a brief, systematic overview of such
manifestations and possible treatments. It is through
effective diagnosis and management that vision loss can be
circumvented, thus enhancing the quality of life for patients
suffering from AIDS.

S

MICROVASCULAR DISEASE
Retinal microvasculopathy (RM) is the most common
ocular manifestation of AIDS with between 40 - 60% of
patients affected. 3 The hallmark of this disease process is the
presence of cotton wool spots (CWS) on retinal examination
(HGURE 1). These appear as fluffy white lesions identical to
those seen in hypertension, diabetes, and cytomegalovirus
(CMV) retinitis (see later). They represent nerve fiber layer
infarcts which arise due to focal occlusions of the retinal
capillaries. In addition to cotton wool spots, RM may

FIG URE 1. HIV retinopathy is cha racterized by the presence of multiple
cotton wool spots.

manifest itself as intraretinal hemorrhages, microaneurysms,
and Roth spots (retinal hemorrhages with a white center) . .
The etiology of RM remains unknown. Some .theones
put forward to explain this phenomenon mclu~e
microvascular occlusion due to either immunoglobm
deposition or hyperviscosity. Alternatively, se~ond~ry
swelling and microvascular obstruction due to HIV infection
of endothelial cells may also be to blame.
It is important as clinicians to be able to distinguish
between the cotton wool spots seen with RM and those seen
with CMV retinitis. The main difference is that unlike CMV
retinitis, the cotton wool spots due to microvasculopathy are
not due to a direct infection of the retina. Therefore, RM
cotton wool spots cause little alteration in vision and resolve
spontaneously over a course of six to eight weeks ~thout
treatment. CMV retinitis , on the other hand , 1s best
characterized as a progressive lesion which, if left untreated,
invariably and very quickly causes blindness. The poss~b~ty
of such differing results, stemming from the same rmtial
symptom, conveys the importance in following up any
AIDS patients presenting with cotton wool spots.
OPPORTUNISTIC INFECTIONS
Many organisms are able to take advantage of the
immunocompromised state of AIDS patients and t~en
manifest themselves in ocular lesions. They may be vual,
bacterial, parasitic, or fungal.
VIRAL INFECTION
Herpes zoster ophthalmicus
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Herpes zoster ophthalmicus (HZO) is aD A virus that
elicits a characteristic vesicular rash in the region of the
ophthalmic division of the trigeminal nerve. Swollen
eyelids, conjunctivitis, and keratitis (inflammation of the
cornea) may also be associated with this disease. Although
HZO is not considered an AIDS defining illness, it may be
the initial sign of a HIV infection and any individual under
the age of 50 who presents with HZO should be suspected
of harboring HIV .4 Treatment usually involves oral
acyclovir, a synthetic purine nucleoside with selective
activity against herpes virus infections.
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Cytomegalovirus
Cytomegalovirus (CMV) is another example of a virus
capable of producing ocular lesions in AIDS patients. The
lesion is commonly retinitis and is the most common
intraocular infection associated with AIDS.2 With more than
25% of AIDS patients succumbing to blindness due to CMV
retinitis, it is also the leading cause of blindness within this
sub-population. 5 CMV retinitis also tends to be a rather late
manifestation of AIDS and hence survival after initial
diagnosis is only 8-12 months. 6
As mentioned earlier, the initial lesions of CMV retinitis
appear as cotton wool spots on ophthalmoscopic exam. The
difference between these CWS and those seen with retinal
microvasculopathy is that these spread rapidly over a 1-2
week period to produce a retina characterized by white
fluffy retinal necrosis with hemorrhages and vasculitis
(FIGURE 2). These diseased portions of the retina have
distinct borders which abruptly meet areas of normal retina.
This m<\Y lead to retinal detachment further complicating
the clinical picture for the patient.
Cmrently approved medications for CMV retinitis are
gancydovir and / or foscarnet. Since neither of these agents
are able to eliminate the virus, treatment must be continued
for the lifetime of the patient. Gancyclovir is a guanine
analogue which inhibits viral D A replication and
forscarnet is a pyrophosphate analogue which inhibits CMV
DNA polymerase. For maximum effectiveness, these drugs
should be given at a high induction dose for 2-3 w eeks,
followed by a lower maintenance dose which is kept unless
the retinitis flares up again.
Molluscum contagiosum
Molluscum contagiosum is caused by a D A po virus
and commonly presents as raised eyelid lesion with
umbilicated centers. It may also be associated with a
chronic, low grade conjunctivitis. Treatment option involve
excision, curettage, or cryotherapy. Given the
immunocompromised state of AIDS patients, molluscum
contagiosum tends to behave very aggressively leaving
larger and more numerous lesions than usually seen in the
endemic population.

BACTERIAL INFECTION
Syphilis
Syphilis is a chronic infectious disease caused by the
bacterium Treponema pallidum. If left untreated, syphilis
will gradually progress through primary, secondary, and
tertiary s tages of pathology, each of which may have
ophthalmic manifestations. Primary syphilis may display
chancre of the eyelids and conjunctiva. Secondary syphilis
can exhibit a wide varie ty of complications including
conjunctivitis, scleritis, interstitial keratitis, anterior
uveitis, and papillitis (inflammation of the optic papilla).
The third stage of this condition may display cranial nerve
palsies, ptosis, optic atrophy, and for neurosyphili , the
Argyll Robertson pupil (pupil reacts to accommodation
but not light).
A recent resurgence of syphilis in AIDS patients has
been noted 7, and like other infectious agents, syphilis
follows a more aggressive course in AIDS patients. High
dose IV penicillin G has been found to be effective in the
treatment of both syphilis and neurosyphilis. 7
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FIGURE 2. Typical feahlres of CMV retinitis. The retinitis is characterized by
a discrete, fluffy, white retinal necrosis, with retinal hemorrhages and
vasculitis. There is a sharp, distinct border betweer1 the diseased and normal
retina.

PARASITIC INFECTION
Ocular Toxoplasmosis
Toxoplasma gondii is a protozoan that commonly
infects mammals and birds throughout the world. T.
gondii infection in humans is usually asymptomatic, but in
cases where the patient is in an immuno-compromised
state such as AIDS, infection can be exceedingly
progressive and fatal if left untreated. Ocular
complications of such an infection include vitritis where
the vitreous humor appears hazy. Retinal lesions may also
be present and appear as white infiltrates which become
pigmented scar when the initial inflammation subsides.
T. gondii may also adversely affect the choroid.
Definitive diagnosis of toxoplasmosis in AIDS patients
essentially relies on histological s tudies, isolating the
parasite, and/or isolating T. gondii D A from lesion sites.
Drugs available to treat ocular toxoplasmosis are
pyrimethamine, sulphadizine, and clindamycin.

Fungal Infection
Fungal complications are very common in AIDS, but
ocular involvement is relatively rare. Candida albicans
commonly infects the gastrointestina l tract of
immunocompromised patients and may also afflict the eye.
The typical Candida lesion consists of a fluffy white-yellow
superficial retinal infiltrate. This may lead to the
development of an overlying vitreous haze and ultimately
vi triti s. Treatment involves systemic therapy with
amphotericin B.

NEOPLASMS
Kaposi's Sarcoma
Kaposi's sarcoma is a disease characterized by multiple
vascular skin malignancies. It may present as a multifocal
lesion with manifestations within the ocular adnexae
(eyelids and orbit); or anterior segment (conjunctiva, cornea,
iris) of the eye in addition to visceral invol ement. Within
the adnexae, flat or slightly-raised purple papules may be
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FIGURE 3. Kaposi's sarcoma of the conjunctiva resembles a subconjunctival
hemorrhage.

visible on the eyelid. The orbit may also be involved, giving
rise to proptosis (forward displacement of the eye) and
double vision.
The effect of Kaposi's sarcoma on the anterior segment
of the eye is usually limited to either the palpebral or bulbar
conjunctiva. This commonly presents as a reddish plaque
localized in the conjunctiva of the lower fornix (FIGURE 3)
and may be misdiagnosed as a subconjunctival hemorrhage
or a hemangioma.
Treatment of Kaposi's sarcoma involves excision of the
lesion, use of chemotherapeutic agents such as vinca
alkaloids, daunorubicin, and bleomycin, or radiation. If the
Kaposi's sarcoma is multifocal, systemic chemotherapy may
then be the only viable option.
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of the initiating factor of the ocular alterations as well as
symptomatic relief.
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INDICATIONS AND CUNICAL USES
TREATMENT
ZfTlfROMAX (azithromycin dihydnote) is indicated for lreatment ol mild to moderate infections
caused by susceptible str.lins ol the designated microorganisms in the following diseases and specifoc
conditions. As recommended dosages, dur.~tions ol therapy, and applicable patient populations vary
among these infections, see DOSAGE AND ADMINISTRATION for specific dosing recommendations.
ADULTS
Upper Respiratory Tract
Pharyngitis and tonsilfotis caused by Stnptococcus ~ (group A 6-hemolytic streptococo) occuring
in individuals who cannot use firn-line therapy.
NOTE: Penicillin is the usual drug ol choice in the lreatment ol S. ~ pharyngitis, including the
prophylaxis ol meumatic lever. ZfTlfROMAX is often effective in the en>dication ol susceptible str.lins
ol slreptococci from the oropharynx. However, data establishing the ellicacy of ZITHROMAX in the
subsequent prevention of meumatic fever are not available at presenL
lower Respiratory Tract
Acute bacterial exacerbations ol chronic ol>structNe pu1monaty diseases caused by lloemoptM ~
MorrluJio cotorrholis. or Strq>tococcus pneurriOfliOe. Community-.Kquired pneumonia caused by
S. ~. H. inllumzoe. Mycupjosmo pneutTIOflitN or Chlamydia~ in patients for whom
oral therapy is appropriate.
Skin and Skin Structure
Uncomplicated skin and skin structure infections caused by Stap/Jyjococcus oureus, S. ~ or

Strq>tococcus ~Genitourin..-y Tract
Urethritis and cervicitis due to Neisseria goncxrt>o«Je or Chlamydia trochomotis. Genital ulcer disease in
men due to Hoemophilus ducreyi (chancroid). Due to the small number ol women included in clinical
trials, the effocacy of azithromycin in the lreatment of chancroid in women has not been established.
Patients should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at
the time ol diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should
be initiated if infection is confirmed.
Appropriate culture and susceptibility tests should be initiated before treatment to determine the
causative organism and its susceptibility to azithromycin. Therapy with ZfTlfROMAX may be initiated
before results of these tests are known; O<OCe the results become available, antibiotic lreatment should
be adjusted accordingly.
PREVENTION OF DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX (MAQ DISEASE
ZITHROMAX, uken at a dose of 1200 mg weekly, alone or in combination with rifabutin at its
approved dose, is indicated for the prevention ol disseminated Myroboctmum <Mum complex (MAQ
disease in penons with advanced HIV infections.
TREATMENT
CHILDREN (see DOSAGE AND ADMINISTRATION; Use In Children, PRECAUTIONS section)
Acute otitis media caused by H. intiJenzoe (JHactamase positive and negative Str.liru), M. rotorrl>olis or
S. ~- (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION section.)
Pharyngitis and tonsillitis caused by S. ~ (group A ~hemolytic streptococci) occuring in
individuals who cannot use firn-line therapy. (For specifoc dosage recommendation, see DOSAGE
AND ADMINISTRATION section.)
NOTE: Penicillin is the usual drug of choice in the lreatment ol S. ~ pharyngitis, including the
prophylaxis of rheumatic fever. ZfTlfROMAX is often effective in the eradication of susceptible str.lins
ol streptococci from the oropharynx. However, dau establishing the elfocacy of ZJTMROMAX in the
subsequent prevention of meumatic fever are not available at presenL
~ pneunonia caused by H. ~ S. pt1tiii10tliot. M. pna.moniot or C pna.moniot.
(For specifiC dosage recommendation, see DOSAGE AND ADMINISTRATION section.)
Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for
outpatient oral therapy because ol moderate to severe illness.
Safety and e!fec!M!ness for pneumonia due to H. inlluenzoe and S. ~ we-e not documented
bacteriologically in the pediatric clinical trial due to diffoculty in obuining specimens. Use ol
azithrornycin for these two microorganisms is supported, however, by evidence from adequate and
weli<ontroUed studies in adults.
CONTRAINDICATIONS
ZITHROMAX (azithromycin dihydrate) is contr.lindicated in patients with known hypersensitivity to
azithromycin, erythromycin, or other macrolide antibacterial agents.
WARNINGS
Ra re serious allergic reactions, including angioedema and anaphylaxis (with r.1re reports of fatalities)
have been A!pOrted i-l patients on Zl1liROMAX (azillwomydn clihydratr) lherapy (see CONTRAINOICATIONS
section). Allergic reactions may occur during and soon after lreatment with ZITHROMAX. Despite
initially succ...tul symptomatic treatment ol the allergic symptoms, when symptomatic therapy was
discontinued, the allergic symptoms recurred soon thereafter in some patients without further
azithromycin exposure. These patients required prolonged periods ol observation and symptomatic
treatmenL ~ an allergic reaction occurs, the drug should be discontinued and appropriate therapy
should be instituted. Physicians should be aware that reappear.~nce ol the allergic symptoms may
occur when symptomatic therapy is discontinued.
In the treatment of pneumonia, azithromycin has only been shown to be safe and effective in the
lreatment of community-.Kquired pneumonia due to C pMUmonioe, H. inlluenzoe, M. pnet.manioe, or
S. pneumonioe in patients appropriate for oral therapy. Azithromycin should not be used in patients
with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe
~lness or risk factors such as arry ol the following: patients with cystic fibrosis, patients with noscocomialy
acquired infections, patients with known or suspecled bacteremia, patients requiring hospitaliution,
elderly or debilitated patients, or patient> with signifiGint underlying health problems that may comprornise
their ability to respond to their illness (including im munodefociency or functional asplenia).
P>eudomemlnnous colitis has been reported with nearly an antibacterial agents including ZJTMROMAX

and may r.~nge in severity from mid to life-threatening. Therefore, it is imporunt to consider this
diagnosis in patients who present with diarrhea subsequent to the administr.ltion of antibacterial
agents. Treatment with antibacterial agents alters the normal flora ol the colon and may permit
overgrowth of clostridia. Studies indicate that a toxin produced by Oostrid"tUm diffidk is a primary
cause ol "antibiotic-<WO<iated colitis". After the diagnosis of pseudomembranous colitis has been
esublished, therapeutic measures should be initiated. Mild cases ol pseudomembranous colitis usually
respond to discontinuation ol the drug alone. In moderate to severe cases, consideration should be
given to management with fluids and electrolytes, protein supplementation, and treatment with an
antibacterial drug dinically effective against OoSIIidium diff/Cile.
In lhe absence d data on lhe metaboism and pharmacokinetic i-l patients with lysosomal ipid storage diseases
(e.g.. Tay-Sadls <isease, ~ disease) lhe used ZJTHROMAX in these patients ~ not ltcO I I I tel ded.
PRECAUTIONS
General;

Siroce liver is the major route of elimination lor ZfTlfROMAX (azithromycin dihydrate), the use of
ZfTlfROMAX should be underuken with caution in patients with signifocant hepatic disease.
No dose adjustment is needed in patients with mild renal impairment (creatinine clear.~nce > -40 ml/min),
but there are no data regar<ftng ZfTlfROMAX usage in patients with more severe renal impairmenL
Thus caution should be exercised before prescribing ZfTlfROMAX in these patients.
The following adverse events have been reported with macrolide products: ventricular arrllythmias,
including ventricular tachycardia and tor><J<kl rk poinres. in individuals with prolonged QT intervals.
Although these adverse events have not been reported in clinical trials with azithromycin, one AIDS
patient dosed at 750 mg to 1g daily experienced prolonged QT interval and tor><J<kl rk pointes.
Use In Pnegnancy:
Animal studies have demonstrated that azithromycin crosses the placenu. Safety ol ZITHROMAX
for use in human pregnancy has not been esublished.
Use In Nursing Mothers:
There are no data on secretion in breast milk. Safety of ZrTHROMAX for use in human lactation has
not been established.
Use In Children:
Acute Otitis Meda or Cornrn.nity-Acqed Pnelrnonia: Safety and efficacy ol ZJTHROMAX in lhe treatment
ol children with acute otitis media or corntnLnity-«quired pneumonia (dosage regimen: 10 mg/kg on day
1 followed by S mg/kg on days 2-5) under 6 months ol age have not been established.
Pharyngitis and tonsilitis: Safety and ellicacy d ZJTMROMAX in the treatment d children with phatyngitis
and tonsilitis (dosage regimen: 12 mg/kg on days 1-S) under 2 years ol age have not been established.
Slides evaluating the use ol repeated counes ol thenopy have not been conducted. Safety dab with
the use ol ZJTHROMAX at doses higher than proposed and lor dlnlions longer than reooo101oetlded
are lmited to a smal numl>er ol irnrnurwxomprom c:hlldren who I.Olderwent chronic: treatment.

In animal studies, treatment w;th azithromycin is associated with accumulation in various tissues,
including the extr.t<ranial neur.~l ganglia ~ . e. , retina and sympathetic nervous system). Tissue
accumulation is both dose and time dependent. and is associated microscopicaly with the development
of phospholipidosis ~ntr.l-iysosomal drug phospholipid complexes). The only evideroce in animals
that azithromycin is associated with alterations of intracellular phospholipid meubolism has been the
documentation of small increases in phospholipid content after prolonged lreatment (6 months) or
exaggerated doses. Phospholipidosis has been observed at total cumulative doses only 2 multiples of
the clinical dose. One month alter withdr.~wal of treatment the cO<OCentr.ltion of azithromycin and
the presence of phospholipidosis in tissue, including the retina, is at or near predose levels.

No data C!Xist in humans in regard to the extent of accumulation, duration ol exposure, metabc:>'ism
or excretory mechanisms of azithromycin in neural tissue such as the retina and the cochtea.
Rare cases ol hearing loss have been reported (see ADVERSE REACTIONS section).
No data are available on the metabolism and pharrnacolunetics of azithromycin in children with
lysosomal lipid storage diseases (see WARNINGS section).
Prevention of Disseminated Mycobacterium Allium Complex (MAQ Disease:
Safety and ellicacy ol ZfTlfROMAX lor the pr.--.tion ol MAC in children have not been .,...blished.
Umited safety data are available for 24 children 5 months to 14 years of age (mean 4.6 years) who
received ZfTlfROMAX lor lreatment ol opportunistic infections. The mean duration ol ther.lpy was
186.7 days (""'90 13-710 days) at doses ol < S to 20 mg/kg/day. Adverse events were similar to those
observed in the adult population. . . - d whidl involved lhe gastrointestinal tocL Whie none ol these
children prematlRiy discontinued treatment due to a side tlfe<L one child discontr.Jed due 10 a laboratory
abnormality (eosinophilia). Based on available pediatric pharrnacokinetic data, a dose ol 20 mg/kg in
children would provicle drug exposure similar to the 1200 mg adult dose but with a higher Cmax.
Use In Elderly:
The pharmacokinetics in elderly volunteen (age 65 to 85) were similar to those in younger volunteers
(age 18 10 -40) lor the 5-day therapeutic regimen. Dosage adjustment does not appear to be necessary lor
elderly patients with normal renal and hepatic ILnction receilling treatment with this dosage regimen.
Drug lnteroctlons
Antacids
Aluminum and magnesium containing anucids (Maalox") reduce the peak serum levels but not the
extent ol azithromycin absorption. These drugs should not be taken simuluneously.
Cimetidine
Administr.ltion ol cimetidine (800 mg) two hours prior to ZfTlfROMAX had no effect on
azithromycin absorption.
Theophylline
CO<OCurrent use of macrolicles and theophylline has been associated with increases in the serum
cO<OCentr.ltions of theop/lytline. ZITHROMAX did not affect the phannacokinetics of theop/lytline
administered either as a single intr.lvenous infusion or multiple oral doses at a recommended dose of
300 mg every 12 hours. There is one post-rnarlteting report of supraventricular tachycardia associated
with an elevated theophylline serum level that developed soon alter initiation of lreatment with
ZITHROMAX. Until further data are available, prudent medical practice d ictates careful monitoring
of plasma theop/lytline levels in patients receiving ZITHROMAX and theophylline cO<OComitantly.
Warfarin
ZITHROMAX did not affect the prothrombin time response to a single dose of warfarin.
However, prudent medical practice dictates careful monitoring of prothrombin time in all patients
lreated with ZITHROMAX and warfarin cO<OComiuntly. CO<OCurrent use ol macrolicles and warfarin
in clinical practice has been associated with increased anticoagulant effects.
Zidovudine

Single 1g doses and multiple 1200 mg or 600 mg doses d ZITHROMAX did not affect the plasma
pharmacokinetics or urinary excretion ol zidovudine or its glucuronide metabolite. However,
administr.ltion of ZfTlfROMAX increased the cO<OCentrations of phosphorylated zidovudine in
peripheral blood mononuclear cells.
Didanosine

Daily doses ol 1200 mg ZITHROMAX had no effect on the phannacokinetics of didanosine.
Rifabutin
Co-adm inistr.ltion of ZITHROMAX and rilabutin did not affect the serum cO<OCentr.ltions ol
either drug .

- - - - - -- - --

- - -- - - - - -

Carbamazepine

In a pharmacokinetic interaction study in healthy volunteer<, no significant effect was observed on
the plasma levets of carbamazepine or its active metabolite in patients ~Kefving concomitant
ZITHROMAX.
Concomitant Therapy
The following drug interactions have not been reported in dinical trials with ZITHROMAX and
no specifoc drug interaction studies have been perlormed to evaluate potential drug-drug
interactions. Nonetheless, they have been observed with macrolide products, and there have been
rare spontaneously reported cases with ZITHROMAX and some of these drugs, in postmarl<eting
experience. Until further data are developed regarding drug interactions, when ZITHROMAX and
these drugs are used concomitantly, careful monitoring of patients ~ advised both during and for
a short period following therapy:
Digoxin : Elevation of digoxin levels.
Disopyramide: Increase in pharmacological effects.
Ergotamine o r d ihydroergotamine: Acute ergot toxicity characterized by severe peripheral
vasospasm and dysesthesia .
Triazolam: Decreases in the dearance of triazolam and increases in the pharmacologic effect
of triazolam.
Drugs me tabolized by the cytochrome P450 system: Elevations of serum cyclosporine,
hexobarbital, c~pride. and phenytoin levels.
Antihistamines: Prolongation of QT intervals, palpitations or cardia< armythmias with
concomitant administration of astemizole or terfenadine.
No data are available on the concomitant dinical use of ZITHROMAX and gentamicin or other
amphiphilic drugs which have been reported to alter intracellular lipid metabolism.
ADVER5E REACTIONS
TREATMENT
The majority of side effects observed in controlled d inical trials involving patients (adults and
children) treated with ZITHROMAX (azithromyd n d ihydrate) were of a mild and transient nature.
Approximately 0.7% of both adult patients (n=3812) and children (n=2878) who had multi~ doses
of ZJTH ROMAX discontinued therapy because of drug related side effects. Most of the side effects
leading to discontinuation were related to the gastrointestinal tract. e.g., nausea, vomiting. diarrhea.
or abdominal pain. Potentially sMous side effects induding angioedema and cholestatic jaundice
occured in less than 1% of patients.
Clinkal:
Sing le 1-gra m dose regimen (adults):
In adult patients (n=904), side effects that occurred on the single one-gram dosing regimen of
ZITHROMAX with a frequency greater than 1% included diarmea (6 .1% ), nausea (4.9%),
abdominal pain (4.9%), vomiting (1.7%), vaginitis (1.3%), loose stools (1.2%), and dyspepsia (1.1%).
Single 2-gram dose regimen (adults):
Overall, the most common side effects in patients receiving a single 2-gram dose of ZITHROMAX
were related to the gastrointestinal system. Side effects that occurred in patients in this study with
a frequency of 1% or greater included nausea (18.2%), diarrtlea/loose stools (13.8%), vomiting (6.7%),
abdominal pain (6.7%), vaginitis (2.2%), dyspepsia (1.1 %), and dizziness (1.3%). The majority of
these complaints were mild in nature.
The following adverse experieroces have been reported in patients under conditions (e.g ., open trials,
mari<eting experience) where a causal relationship is uncertain or in patients treated with signifocantly
higher than the recommended doses for prolonged periods:
Alle rgic arthralgia, edema, anaphylaxis (with rare reports of fatalities), serum sickness, urticaria,

vasculitis;
Card iovascular: cardiac arrythmias (including ventricular tachycardia), palpitations;
Gastrointestinal: anorexia, constipation, dehydration, dyspepsia, flatulence, pancreatitis,
pseudomembranous colitis;
Ge neral: asthenia, paresthesia, muscle pain;
Genitourinary: interstitial nephritis, acute renal failure, nephrotic syndrome;
~r/ 8 ili a ry: abnormal liver function including drug-induced hepatitis and choliestatic jaundice,
hepatic necrosis;
Nervous System: dizziness, headache, seizure, somnolence;
Skin / Appendages: serious skin reactions including erythema multiforme, exfoliative dermatitis,
Stevens-johnson syndrome, toxic epidermal necrolysis;
Specia l Se nses: hearing disturbances including hearing loss, deafness and/or tinnitus, vertigo,
reports of taste disturbance.
PREVENTION OF MYCOBACTERIUM AVIUM COMPLEX (MAC) DISEASE:
Chronic therapy with ZITHROMAX 1200 mg weekly regimen: The nature of side effects seen with
the 1200 mg weeldy dosing regimen for the prevention of Mycobocterium ovium complex infection
in severely immunocompromised HIV-infected patients were similar to those seen with short-term
dosing regimens.

lncideroce' (%) of Treatment Related' Advene Events~ in HIV-Infected Patients
Receiving Prophylaxis for Disseminated MAC
Study 155
Placebo

Mean D.Jration "'Therapy(~)
Discontinuation of Therapy (%)

AUTONOMIC NERVOUS SYSTtM
Mouth Dly
CENTRAL NERVOUS SYSTEM
Diz2iness

Headache
GASTl!OINTESTlNAI.
DiafThea
loo5e Stools
Abdominal Pain
Dyspepsia
FlallJience
Nausea
\OOliting

GENERAl
F...,
Fatigue
Malaise
MUSCULOSK£l..ETAI.

Arthralgia
PSYOiiATRIC
Anorexia

(n=91)
303.8
2.3

Study 174

Azittv"omyOO Azittv"omyOO
1200mg
1200mg
weekly
weekly
(n=233)
(n=89)
402.9
31S
8.2
13.S

Rifabutin
300mg
daily
(n=236)
296.1
15.9

Azittv"omyOO
& Rlabutin

2.7

(n=224)
344.4

22.7

0

0

0

3.0

0
0

1.1
0

3.9
3.0

1.7
5.5

0.4
4.5

15.4
6.6
6.6
1.1
4.4
11
1.1

52 .8
19.1
27
9
9
32.6
6.7

50.2
12.9
32.2
4.7
10.7
27.0
9.0

19.1
3.0
12.3
1.7
5.1
16.5
3.8

50.9
9.4
31.7
1.8
5.8
28.1
5.8

1.1
0
0

0
2.2
1.1

2.1
3.9
0.4

4.2
2.1
0

4.9
3.1
2.2

0

0

3.0

4.2

7.1

1.1

0

2.1

2.1

3.1

I

SKIN & APPENDAGES
Pruritus
Rash
Skin Discoloration

3.3
3.2
0

0
3.4
0

3.9
8.1
0

3.4
9.4
2 .1

7.6
11.1

Tnnitus

4 .4

Hearing Decreased
Taste Pl!rverlion

2.2
0

3.4
1.1
0

0 .9
0 .9
1.3

1.3
0 .4

0.9
0
1.3

2.2

SPECIAL SENSES
2.S

Side effects related to the gastrointestinal tract were seen more frequently in patients receiving
azithromycin than in those receiving placebo or rifabutin. In one of the studies, 86% of diarmeal
episodes were mild to moderate in nature with d iscontinuation of therapy for this reason occurring
in only 9/ 233 (3.8%) of patients.
PREVENTION OF MYCOBACTERIUM AVIUM COMPLEX (MAC) DISEASE:
In these immuncocompromised patients with advanced HIV infection, it was sometimes necessary to
assess laborato<y abnormalities developing on study with additional criteria ~ baseline values were
outside the normal range.
~intt Disseminated MAC

I Laborato<y Values
Study 174

Study 155
Criteria'
Nt.mber at SuiJjecU'

(n=88)

Hemoglobin < 0.8xUN'

31%
19%
48%
16%
6%

Platelet C0<rt < 0.75 x UN
WBCCO<rt < 0.75 X UN
NeutropiWs < 0.5 X UN
< SfYJ/mm'
AST (SGOl)

> 2.0 X lJLN I>

AI.T (SGPT)

>200 U/1.
>2.0 X ULN
> 2SO U/1.

Placebo

28%
10%
24%
2%

Azittv"omyOO Azittv"omyOO
1200mg
1200mg
weekly
weekly
(n=208)
(n=89)
30%
16%
49%

28%
13%
39%
8%
34%
6%

19%
11%
60%
23%
5%
33%
8%
31%
8%

Rifabutin
300mg
daily
(n=205)

Azittv"omyOO
& Rlabutin

26%
10%
53%
20%
6%
18%
3%
15%
2%

21%
16%
60%
29%
8%
30%
6%
27%
6%

(n=199)
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LaboratOty test is at le.st 98ftft of the toQI number of sub;Kts

In a phase I drug interaction study perlormed in normal volunteers, 1 of 6 subjects given the combination of azithromycin and rifabutin, 1 of 7 given riiabutin alone and 0 of 6 given azithromycin
alone developed a dinically significant neutropenia(< 500 cells/mm').
OVERDOSAGE
Symptoms:
There are no data on overdosage.
Treatment;
Gastric lavage and general supportive measures are indicated.
Up to 15 grams cumulative dose of ZITHROMAX (azithromydn dihydrate) over 10 days has been
administered in clinkal trials without apparent adverse effect.
DOSAGE AND ADMINISTRATION
TREATMENT
Adults:
CAPSUUS: ZJTHROMAX (azithromydn dihydrate) Capsules should be given as a single daily dose
at least 1 hour before or 2 hou" after a meal.
TABLETS: ZITHROMAX Tablets can be taken with or without food.
SINGU DOSE 1 g PACKET: ZITHROMAX powder for oral suspension as Single Dose 1 g Packet can
be taken with or without food after reconstitution.
Mixing Directions:
Directions for administration of the powder for oral suspension as a Single Dose Packet ( 1 g):
The entire contents of the Packet should be mixed thoroughly with 60 ml (two ounces) of water.
Drink the entire contents immediately, add an additional 60 mL (two ounces) of water, mix. and
drink to assure com~te consumption of dosage.
Fot- skin and skin structure infections, upper and lower retpirato<y tract infections: The
recommended dose of ZITH ROMAX for the treatment of individuals 16 yea" of age and older ~
500 mg as a single dose on the first day followed by 2SO mg once daily on days 2 through S for
a total dose of 1.5 grams.
Ge n itourinary: The recommended dose of ZITHROMAX for the treatment of genital uker disease
due to Hoemophilus ducreyi (chancroid) and non-goncococcal urethritis and cervicitis d ue to
C trochomotis is: a single 1 gram (1000 mg) oral dose of ZJTH ROMAX. This dose can be
administered as four 250 mg capsules, four 250 mg tablets, or as one Single Dose Packet (1 g).
The recommended dose of ZITHROMAX for the treatment of urethritis and cervicitis due to
Ntisserio gonorrl>oeoe is: a single 2 gram (2000 mg) dose of ZITHROMAX. This dose can be administered as eight 250 mg capsules, eight 250 mg tablets, or as two Single Dose Packets (1 g each).
For prevention of disseminated Mycoboctnium avium complex (MAC) disease:
TA8L£TS: ZITHROMAX tablets may be taken without regard to food. The recommended dose of
ZJTHROMAX for the prevention of d~inated Mycobocterium ovium complex (MAC) disease ~
1200 mg (two 600 mg tablets) taken once weeldy. This dose of ZITHROMAX may be continued
with the approved dosage regimen of rifabutin .
In patients with mild to moderate hepatic impa irmen~ there is no evidence of a marked change in
serum pharma<:okinetict of ZITHROMAX compared to those with normal hepatic function. in these
patients urinary recovery of azithromydn appea<l to increase. Heroce no dose adjustment is
recommended for patients with mild to moderate hepatic impairmenL Nonetheless, since the liver
is the principal route of elimination for azithromydn, the use of ZITHROMAX should be undertaken
with caution in patients with significant hepatic disease.
TREATMENT
Children:
POWDER FOR ORAL SUSPENSION: ZITHROMAX Powder for Oral Suspension should be g iven as a
single daily dose at least 1 hour before or 2 hou" after a meal.
Mixing Directions:
ZITHROMAX Powder for Oral Suspension:
Tap bottle to loosen powder. Acid the directed volume of water. Shake well before each use.
Oversized bottle provides shake space. Keep tightly closed. The table below indicates the volume of
water to be used for reconstitution:

Amount of water
to be~

Nominal volume alter
reconstitution (azithromycin content)

Azithromycin concentration

after reconstitution

9 ml (300 mg

~)

9 ml (600 mg

~)

IS ml (300 mg ~)
15 ml (600mg~)

100 mg/5 ml
200 mg/5 ml

12 ml (900 mg

~)

22.5 ml (900 mg bottle)

200mg/S ml

-Otitis Mecio 0< ~Pneumonia:
The 11!000. I ... ded dose of ZITHIIOMAX oral !U!flOJlSion for the treatment of children with acub! otitis me<ia
0< cornnunity--acq pneunona is 10 mg/1<g as a single dose on the first day (not to exceed 500 mg/day)
lolowe:l by 5 mg/llg on days 2 tlvough 5 (not to exceed 250 mg/day). for a tc1a1 dose of 30 mg/llg of
ZITHROMAX (see chart below).
PEDIATRIC DOSAGE GUIDEUNES FOR ACUT£ OTTTlS MEDIA
OR COMMUNITY-ACQUIRED PNEUMONIA
(Age 6 months and a~)
Based on Body Weight
ACUT£ OTTTlS MEDIA OR COMMUNITY-ACQUIRED PNEUMONIA
Dosing Calculated on 10 mg/l<g on Day 1 dose, followed by 5 mg/1<g on Days 2 to 5.
100 mg/ 5 ml
Suspension

Weight

Kg

lbs

5

11

10

22
44
66
88

20
30
40

Day 1

200 mg/5 ml
Suspension

Days 2-5

Day 1

Total ml

per
Treatment
Course

Days 2-5

2.5 ml ( 1/, Up) 1.25 ml ('/• tsp)
5 ml(1 t.p)
2.5 ml ( 1/ 2 Up)

rt,

5 ml (1 tsp)
2.5 ml
Up)
7.5 ml (1'/2 tsp) 3.75 ml (11. Up)
10 ml (2 tsp)
5 ml (1 tsp)

7.5 ml
15ml
15 ml
22.5 ml
30ml

Pluoryngltb and Tonsillitis:
The recommended dose for children with phal)'ngitis and tonsillitis is 12 mg/kg once a day (not to
exceed 500 mg/clay) for 5 days for a total dose of 60 mg/kg of ZITMROMAX (see chart below).
PEDIATRIC DOSAGE GUIDEUNES FOR PHARYNCffiS AND TONSIWTlS
(Age 2 years and ~)
Based on Body Weight
PHARYNGffiS AND TONSILliTIS
Dosing Calculated on 12 mg/1<g once daily Days 1 to 5.
Weight

200 mg/ 5 ml Suspension

Kg

lbs

8
17

18
37
55
73

25
33
40

88

Total ml per
Treatment Course

Days 1-5
2.5 ml
5 ml
7.5 ml
10 ml
12.5 ml

( 1/, t.p)
(1 t.p)
(1 1/ 2 tsp)
(2 tsp)
(2 1/, t.p)

12.5 ml
25 ml
37.5 ml
SOml
62.5 mL

AVAILABlUTY OF DOSAGE FORMS
CAPSULES: ZITHROMAX (azithromycin dlhydn~te) Capsules each contain azithromycin dihydrate
equivalent to 250 mg of azithromycin. The red, No. 0 hard gelatin capsules imprinted with " Piizer"
and "ZZTHROMAX" in black ink, are packaged in white plastic (high density Polyethylene) bottles of
30 and 100 or in a single treatment package (Z-PAK) of 6 blister packaged capsules per box.
TABLETS 250 mg: Each pink, film<oated, modified capsular-shaped ZITMROMAX table~ engraved
"pfizer" on the upper face, and scored on the lower face, contains azithromycin dihydrate equivalent
to 250 mg of azithromycin . The tablets are packaged in white plastic (high density pofyothylene)
bottles of 30 and 100 or in a single treatment package (Z-PAK) of 6 blister packaged tablets per box.
600 mg: Tablets, engraved on front with " Piizer", are white, modified capsular-shaped film<oated
tablets containing azithromycin dihydrate equivalent to 600 mg azithromycin. These are packaged
in HOPE bottles of 30 and 100 tablets.
POWDER FOR ORAL SUSPENSION: ZITHROMAX Powder for Oral Suspension, alter reconstitution,
contains a cherTy flavoured suspension. Each ~ (high density Polyethylene) provides
azithromycin dihydrate equivalent to: 300 mg per 15 ml (1 00 mg/ 5 ml); 600 mg per
15 ml (200 mg/ 5 ml); 900 mg per 22.5 ml (200 mg/5 ml). Dropper is inclucled in the package.
SINGLE DOSE 1 g PACKET: ZITMROMAX powder for oral suspension as a Single Dose 1 g Packet
contains azithromycin dihydrate equivalent to 1000 mg of azithromycin in a sealed, laminated
aluminum foil and Polyethylene pouch.
Product Monograph available upon request.

t Product licensed from Pliva
lithrornax is a Scfiedule F drug.
Relerenc:es: LR. T.l.
1. Zithrornax• Product Monograph, PfiZer Canada Inc., November 7, 1997.
2. Drew RH and CaDis HA Azithromycin-Spectrum of Activity, Pharmacokinetics, and Clinical
Applications. Pharmacotherapy 1992;12(3):161-73.
3. Dartt D. Muttlcenter evaluation of azithromycin and celador in acute lower respiratory tract
infections. Am) Med 1991;91(SuppBA):31S-35S.
4 . "Supplemental new drug submission lor Zithrorna><" (azithromycin dihydrate) Antibiotic
Treatment of Community-Acquired Pneumonia Due to Mycoplasma Pneumonioe or CHomydia
Pneumonioe". Data on fde. Plizer Canada Inc.
5. Hopkins S. Ctinical toleration and safety of azithromycin. Am) Med 1991;91(Suppl A):405-4SS.
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Antihypertensive Agent
Symptomotic Treatment ol Benign PIOslatic Hyperplasia (BI'H)
IIIOICATlOIIS AIIO CliiiCAI. USE ~ Treatment ol rid to moderate esseOOal hypertension, in a general treatment
program in association witfl a thiazide diuretic and/or other ~ agents, as needed lor proper patient response.
Doxazosin may be tried as a sole therapy in patients lor whom treatment witfl other agents C3M ~ effects or is
inappropriate. ...., Pr1111tic ~ (II'H): Treatment ol symptoms ol beniJn prostati: hypelplasia (BI'H). Onstt ol
e11ect is rapid, witfl irnproolanent in peak !low and symptoms seen within 1·2 weas, and mainlained owr tile me study
dilation (up to 4 years). tt may be used in hypertensiYe or normotensive BI'H patients. A number ol clinical conditions can
mimic symptomatic BP!i (i.e. stricture ol ure ra, stricture ol bladde! neck, urinary bladder stones, neurogenic bladder
dyslunction secondary to diabetes. Partinsoo's ~- etc.). These conditions should tllerelore be ruled out belore
dolQzosin therapy IS iritiated.
COIITRAIIOICATlOIIS: Patients witfl a known saasitiYity to dol<3lOsin or qtinazotines.
WARMIIIGS: S,...,. 1101 "Fin! Dose" Etloct: Doxazosin can cause rnarUd hypotension, especially postural hypotensiorl
and syncape in association will tile fiB! dose or tnt lew doses ol therapy. Asililar effect can ocxur ~ therapy is reils1ated
-.g interruption lor mar! thon a lew doses. Pustural effects are most
to occ..- betMen 2-6 hours aftes dose. In
controlled studies ol dol<3lOsin tile incidence ol syncopal episodes was 0.7, . Initial dose ol 1 ~ resulted in a 4,
incidence ol :MlSiural side effects witfl no cases ol syncope. In c:ontroled trials ol normotensive BI'H patien1s, tile occurrence
ol syncape witfl dolQzosin was 0.2'l.. In c:ontroled trials in hypertensiYe BI'H patients receim;j doxa2osin, tile incidence ot
syncape was O.S'l.. The itelilmd ol syncopal episodes or l!liiZSSive hypotension can be rninirri1!d b¥ limiting tile initial dose
ol dol<3lOsin to t mg, b¥ increasing tile dosa9e slowly and b¥ iltrodur:ing .,., odditior1al ~ drugs ido tile
patient's revimerl with cautiorl (see DOSAGE AND ADMINISTRATION). Advise patients ol tile possibility ol syriCOflil and
orthostatic symptoms and to a'IOid drMr1Q or hmrdous tasks lor 24 hours a er Initial dose ol dolQzosin, aftes tile dose is
increased and after interruptioo ol therapy when treatment is resooled. Ciution patients to a'IOid sibAtions where injury crud
resutl sh<Ul syncape occ..-. ff syncape ocrm. place patient in tile SIJI)ine positin ff lllis measure is inadequate, .oorne
expansion with intravenous fluids or vasopressor therapy may be used. A transient hypotensive response is not a
contraindication to lurther doses ol doJWOSin. ~:Rarely (probably <0.1%), af!lhat·antagmists such as dolQzosin
have been associated witfl priapism. This COI1Iiion can lead to permanent impotence il not piOfTll1lly treated. Advise patients
ol tile seriousness ol tile c:onditiorl.
PRECAIITMIIS: Geoertl: Doxazosin therapy does not modify tile nallnllistory ol benign prostati: hypelplasia (BI'H). tt does
not retard or stop tile progression ol BI'H, nor does ~ ~ urine !low sufficiently to significatCiy reduce residual urine
volume. However. SIQflilir:ant reduction ol meaA residual volume has been shown in patients witfl baseline residual volumes
> 50 IlL The patient may axmue to be at risk ol dMioping lli1ary retention and other BI'H complications duritQ dol<3lOsin
therapy. Loot·T... Sallly 1101 e.acy: The 1oog-1erm sa1<ty and efficacy [Le. , 4 years) has not yet been estabished in t11e
treatment ol benign prostati: hyperplasia. Prlllltic c-. ewnoma o1 tile prostate and BI'H cause many o1 tile same
symptoms. These two diseases lrequently ooexist. Tlterelore, patients thouQht to have BI'H should be wmined prior to
starlnJ dolQzosin therapy to out tile presence ol cartinorna ol lhe prostate. DoJWOSin sh<Ul not be used in patients
witfl PSA > 10 r¢11. ooless prostate cancer has been ruled out. Or1llesUiic ..,...._ While syncape is tile most severe
orthostatic effed ol doxazosin (see WARNINGS), other symptoms of lowered bklod pressure like diz2iness, ightheadedness
or wettigo can ocxur. They were commoo in clinical trials, occurrinO in 1111 to m ot al patients treated and causing therapy
discontinualion in about ~ - In platebcH:ontrollerl titration trials tile lrequency ot orthostatic enects in patients givel1 amg or
mar! was1 0'1., oompared to 5%at 1--4 mo. and 3'lo in tile placebo-treated group.
In placebo c:ontroled trials in BI'H, tile incidence ol orthostatic hypotension witfl dol<3lOsin was s 1%. With main1el1ance
doses ol up to a mg/day in normotensive BI'H patients, tile mean decrease; in sitting and standi1g bklod pressure were smal:
512 rnmHg with dol<3lOsin vs 1/1 rnmHg with placebo. Patients with occupations in wllich such Mnts represent pcUntial
problems should be treated with partiaJtor cau1ion. Advise patients ol tile need to le down when symptoms at lowered bklod
pressure occur and to be carelul wllen arising lrom a lying position. II dizzioess. · htfleadedness or palpiUtions are
bothersome, they should be reporled to tile physician. and dose adjustment considered. Patients should also be told that
drowsitess or somnolence can occur witfl doxa2osin, requiring cautiorl in people who most drive or operate heavy machinery.
ff llypotensaoo ocars, place tile patient 11 recumbent position and institute supportive measures as necessary. Plliells ,.;a
' -'" l.iftf FwtiGI: No intormatiorl is Miable regarding use o1 dol<3lOsin it patients with impaired iver lunctiorl or in
patients taking drugs known to ailed hepatic metabolism. Doxazosin is extensively rne13bolized and excreted b¥ tile iver. Use
in patients witfl impaired iver looctior1 is not recorM1ef1ded. PatiHis will -,aiM lleul flodilo: Use in patients witfl
impaired renallunctiort requi'es carelul monitoring. Clinical studies indicab! that tile cispositi1n ol dolQzosin in pa · witfl
renalinsufticiencyassrnilartothatinpatientswitflnormatrenalhn:tion.'-iiCal-oltfledrugwitflclwoni:
dosing may occur. Less than 10'1. ol tile dose ol doxazosin is exaeled in urine as unchanged drug and metaboliles.
Caocomi!Jot Cooolitioos: Ooxazosin should not be presaibed to patients witfl symptomatic BP!i who have tile lollowing
c:oncomitant conditions: Chronic lli1ary retention. high residual urine (OYer 200 ml). peak urine !low ol 5 mlJs« or less.
history ol prior prostabt Sllgery, clvonic fibriiJS or granulomatiiJS prostati:is, urelhril stricture, listory ol pelvic irradiation.
presence ot prostati: calcui, presence ottarge rnedi¥11obe ot prostate, presera ol calaJi in lli1ary bladder, recent listory ot
epidJdymitis, gross hematuria. presence ol neurogenic bladder dyslunction (diabetes metfitus, partinsonism, uninhibited
bladder, etc.). hydroneplvosis, presence ol cartinorna ol tile prostab!. Patients witfl recent history ol myocardial
llllardion, transient isdlernic at!acls, or c:erebrovascdar ar:Odent wiU1in tile past 6 II1Dr1IIIS. 1'1...-r. There are no studies
11 pregnant women. Doxazosin use not recornmeOOed in pregnant women triess lhe po4erltial benefit OIJIWeigl1s tile potential
nst< to mother and letus. Doxazosin aosses tile placental barrier. Studies in pregrgnt rabl1its and rats at daiy oral doses ot 1111
to 40 and 20 mg/'<g respectively re'lealed no Mlence o1
e11ect. A dosage regimen o1 82 ~day in tile rabbit
was associated witfl reduced leta! suMval, an increase in embryo mortality and increase; in 1eta1 and ptacenta1 Wl!ights. 1n
~tal rat studies. postnatal dMiopment, at maternal dol<3lOsin doses ol 40 or 50 ~day. was delayed as
evidenced IJy slower body weight gain and sightly later appearance ol anatomicalleatures and rellexes. UcbliM: Studies in
lac1ating rats indicate that doJWOSin accumuta es in rat breast milk. h is ooknown w!lether lllis drug is exaeled in human
mil Exertise cautiorl when administering doxazosin to a rmilg mother. In general, nuBitg sh<Ul be interrupted. Clilftt:
Use ot dol<3lOsin is not reomnended since saldy and ellicacy have not been estabished. Ellllly: Use cautiously in elderly
patJen1S due to possOiity ot postural hypotension. An age-<elated trend towards increased incidences ot postural hypotension
and postural diuiness was seen in elderly hyperlensive patients treated witfl this drug. l'lr;,tllnl E*tu: Auid retention
resulting il ftiglrt gain may OCCUI duri1g dol<3lOsin therapy. In platebcH:ontrol rnonotherapy trials, patients I!Ctiving
dol<3lOsin gained a mean ol 0.6 kg oompared to a mean toss ol 0.1 kg lor placello-treate patients o.eratl incidence ot body
weight gain rl!10fled as a side ellect in c:ontroled trials was 0.8"4. U.U,.Io.lcolo""* Anat;sis ol hematologic data
lrorn patients receiving doxazosin in c:ontroled trials showed that mean white bklod eel (WBC) (N~74) and mean neutrophil
cooots (PI-..419) were decreased IJy 2.4% and 1.0'1. respedNely, oompared 1o placebo. Adata base Stald1 ol2.400 patients
r!'lealed 4 cases in wllich drug-fetated neutropenia crud not be n*d out. Two had a single tow value oo tile 1as1 day ot
treatment Two had sta11te. 1101111fOOressive neutrophi caunts it tile 11m'mm' oooe owr periods o120 and 40 weas. No
patients became symptomatic as a result ol tile tow WBC or netJ!Jophil cooots. In BI'H patients tile incidence ot clinicaly
signilicant WBC abnormalities was 0.4% with doxuosin. Car•IIC Tuicity 11 Ali•als: See Product Monograph.
~ - .............. ,...... .. ftttifity: See Product Monograph. Dnlllllnclila: DoJWOSin is highly
(98'l.) to plasma protein. In iilro daU in human plasma indicate 1hal dol<3lOsin mesytate has no elled oo protei~
binding ol digoxin, warlarin. phenytoin or indomethacin. Dowosin has been administered to patients taking thiazide
diuretics, beta-adrenergic blocking agents and non-steroidal anti-inflammatory drugs wi1l1 no unexpected interactions
reported. An additive hypotensive ellect was obserwd when dol<3lOsin was co-admiistered with thiazide diuretics and betiadrenergic btoctinl) agents. There is lin1i1ed experience with CARDURA in axnllination with /a inlliitors or cakium cMtnel
~*mrs. Oigoxirr Serum digoxin c:oncentrations were not alleded b¥ treatment will doxazosin. Cimtli16lt: In a randomized,
open-label, aoss-over study in 22 male subjects, tile single co-administration of 1 mg doxazosin wi1l1 400 mg b.i.d.
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c:imebdine resutled in a 10'1. increase il mean AUC ot dol<3lOsin (p • 0.006), and a siglrt but not statisticaly siglificant
increase in IID1 C.... and mean hall-ire ol doxazosin. The ellect ollur1!1er i1dnWiistratiJn ot cimetidine has not been studied.
AIIVBIS( RfACTIOIIS: ~ Doxazosin has been administered 1o approxinately 4,1XXJ patients in clinical trials ol
w!tonl1 ,679 patients were in controlled trials. The most serious ~ reaction occurring in controlled trials was syncape
ocxurring in O.l'K. ol patients and resulting in a discontinuation rae ol 0.2'l.. The most lrequent adverse reactions in
c:ontro11er1 ctinical trials were: headache (16.5%), latiguelmalaise (14.8'A.), diz2iness (14.6'11.), postural diz2iness (8.7'K.) and
edena (6.6'11.). Oisc:ontinuatio ol dol<3lOsin due to ~ reactions occurred in 7'K. ol patien1s, The lolowing ~
reactinns occurred witfl an incidence ol ~ 0.5% it tile c:ontro11er1 ctinical trials program (n:1,679): ~ ~
(3.6%); vertigo (3.0'1.); taclrjcaldia (1.6'11.); postlnl hypotension (O.!lr.); arrhythmia (0.8%); syncape (O.l'K.). Skin and
Ajtpendages:rash (1.7'K.); pnritus (0.8"4). Uusrubs........ rnyalgia (1.3'/o~ .unlgia (0.8"4~ Nenous ~em: somnolence
(4.9r.); sexual dyslll1ction (3.5%); dry mouth (14%); anxiety/nervousness (2.3'/o); insorMa (2.2'l.); paresthesia (1.7'K.~
depfession/apat!ly (1.6%); increased sweating (1.4%); hypoesthesia (1 .6%); ag~tion (O.l'K.); Hushing (O.l'K.); tremor
(0.6%); paroriria (0.5%). Spel:ial Stnses: visiorVaa:orMtotion abnormality (2.4%); conjurlctM1is/! pain (1.2'l.); tinnitus
(0.8"4). Gastrointts/NI: nausea (3.9r.); diarrhea (2.9r.); dyspepsia (2.1%); abdominal pain (1.6%); ftatulence (1.4%);
~ (1.3'/o); vomiting (O.l'K.). ~lory: dyspnea (3.9r.); rf1initis (3.0'1.); epistaxis (0.8"4); sinasitis (0.6'11.);
brondtospasm/bfonc:Mis (0.5%). Urinaly: micturition lrequency (1.~) ; polyuria (1.0'1.); urinary incontinence (0.8'A.);
UINy disorder (O.l'K.). Genmi/Jody: d1est pain (2.7'K.); asther1ia (2.7'K.); muscle cramps (1.7'K.); pain (1.3'/o); lace edena
(0.8"4); weight increase (0.8'A.); general edena (0.5%). HetnaiD/ogy: decrease; in platelets (l!lr.), wlite bklod eel (2.4%~
hernatocri (1.6'11.), 11emogto11in (1.4%), neutrophiiiXIII1! (1.0'1.) (see PRECAUT10NS). The -.g adverse reactinns were
reported in at least 2 but < 0.5% ol1 ,679 patients who received dolQzosin in tile controlled trial program: ~
System: angina pecloris, peripheral ischemia. hypotension; NtrVOus System: paresis. twilching, migraine, amnesia,
movement disorders, emotional lability, abnormallhinking, depersonamtil1. palor, hypertonia, ataxia; Met1bofc thirst, gout.
hypc*aternia; Her7Yiopoieti;: lympltadenopatl, purpura; ~ 5)5ttm: breast pain; Skin Disorrlets: alopecia, dry
skin, eczema; Spel:ial Stmcs: taste perversion, pllot011hobia. abnormal lacrimation; Gasrrointtstinal ~em: increased
appetite, anorexia, lecal incon1inence; lrespintory S)'Siern: c:oughing, pharyngitis; Genml Body System: hot !lushes, bact
pain, infection, leverl!igors, muscle weal:ness. In II1COI1Iroled trials or post-marteling experience tile lolowing occ..-red with
an incidence ol <0.5%: myocardial inlarttion, c:erebrovasa& aa:ident, c:onlusion, in1pand c:oncentration, palor, parosmia,
en:he. tinnitus. renal cala*Js, inlluenza-ib ~ priapism and jMdice. No c:iicaly relevant adverse effects were
noted on serum potassium or glucose, uric acid. bklod urea nitrogen or aeatinine. Doxazosin has been associated witfl
decrease; in WBC IXIII1t (see PRECAUTlONS). lsotaled case ot elevated iver transaminases have occurred. ...., Prlllltic
"""'lasia: Doxazosin has been ad · · ered once daily to 665 both hypertensive and normotensive BI'H patients in
c:ontroled trials. The most serious~ reaction 1hal occ..-red was syncape (0.5%). The 110stlrequent ~reactions
in c:ontroled trials ~m: diz2iness (15.6%). headache (9.8'A.) and latigue (8"4). Disc:on · uation rate ol doxalosin due to
~ reactions: !lr.. The lollowing ~ reactions occurred witfl an incidence ol ~ 0.5% in tile controlled BP!i trials
(n:665 dowosin patients): Catdiovascular. dilliness (15.6%); edema (2.7'K.); hypotension (1 .7'K.); palpitation (1.2'l.);
lad1ycardia (0.9'1.); angina (0.6'11.); syncape (0.5%); posturalllypoter1sion (0.3'/o). Skin and Aj1pendages: increased M3ling
(1.1%); pnritus (0.5%); rash (0.5%). Uusrubs........ onyalgia (0.6'11.). CSnl and f'etiplr9 Nenous System: headache
(9.8"4); paresthesia (0.6'11.). Autonomic: dry moullh (1.4%); Hushing (0.6%). Special Senses: abnonnat vision (1 .4%);
~ (0.5%); tinnitus (0.5%). Psychiatric: somnotenco (3.0'1.); insomnia (1.2'l.); anxiety (1.1%); decrease libido
(0.8"4); depression (0.6%); nervousness (O.S%). ~diarrhea (2.3'/o); alldorninal pain (2.3'/o); dyspepsia (1.8'l.);
nausea (1.5%); 11atu1ence (0.8"4). Rtspi'atory:tlyspnea (2.6'11.); respiratory disorder (1 . 1 %~ rf1initis (0.8"4); epistaxis (0.6,).
~ Disoniets: impotence (1 .1%). Neoplasm: cartinorna (0.5%~ Urinary: urinary tract inledion (1.2'l.); t1ys00a
(0.5%). Genml: latigue (8"4); pain(~); bact pain (1.8"4); c11est pain (1.2'l.); asther1ia (0.8"4); inHuenzHke symptoms
(0.8"4); vir3l inlection (0.6'11.); lever (0.5,); weight increase (0.5%); malaise (0.5%). Additional~ reactinns have been
reported, but are. in general, not cistinguishallt 1rorn symptoms 111a1 may have occ..-red in lhe absence dol<3lOsin exposare.
The lollowing ~ reactions were reported IJy < 0.5% ol 665 patients who received dol<3lOsin in c:ontroled or open,
short· or long-term dinical studies: Cardiovascular S)'Siem: myocardial inlarttion, bradycardia, sudden death; Autonomic
Nerlous System: palor; MeJa1Joi:: hyperglyr2mia, goul ~ ~ l/eprotlrM;1Ne Systern: prostatic
disorder. ejaculation lailure. epididym~; Skin Disorders: dry skin, gen~al pruritus, urticaria, maculopapular rash,
erythematous rash. aggravated psoriasis, eczema; Ctnlnl Netvous Systern: hypoesff1esia, hyperlonia, leg cramps, c:onlusion,
speech disorder, ataxia; Psychiatric: abnormal thin ·ng, depersonalization. paroniria, emotionallab~ity, impaired
c:onc:entration amnesia; Sptda/ Stnses: earache. tas1e perversion, eye pain, visual field deled. cataract; Gastmintminai
~tm: melena. constipation, vomiting, gingivitis, increased appetite; Rtspintory Systtrn: coughing, brondlospasm,
brorlditis, upper respmory tract inledion, sinusitis, pneumonia; Urinaly System: urinary retention, micturition disorder,
abnormal urine. renal pain, urinary incontinence, cystilis; Musculoskelela/ System: arthrtis. tendon disorder, arthralgia,
hernia; Genml Body S)'Siem: rigors, hot !lushes, allergy, sepsis, lungal inledion; Plafdel /JietdD; and CkJIIiJg Oison1tr.
llema1wia. sul1aract1noid hemorrtlage. Da1a lrorn lonitfam (1111 to 50 months), open BI'H studies (11:>450) indicale a higher
rate ol diz2iness 11 !fU1!jer hyperlensive (27'K.) and normotensive (22'11.) patients, impotence in !fU1!jer hypertensiYe (8"4)
patien1s, and discontinualion rates in patients due to adverse Mills (16.7',(,) ~ed to daU 1rorn short·1erm plactboc:on1roled BI'H studies (n:665). See Product Monograph lor oomple1e Adverse Reaction inlormafion.
SYIPTOIIS AND TREAYIOO OF OVERDOSAGE: No data available regarding overdosa9e with doxazosin in humans. ff
adnWistration ot CARDURA leads to hypotension. supp<rt ot tile c:ardiovasaar system is ollist importance. Restoration ot
bklod pressure and normaization ollleart rate may be atCOfl1l1ished IJy ~ tile patient in tile supine positin ff lllis
measure is inadequale, shod< should list be treated witfi.OOme expanders. ff necessary, vasopressors should be used. Renal
lunctiorl should be monitored and supported as needed. As CARDURA is liri1ly protein boon!. dialysis may not be ot benell
DOSAGE AIIO ~ Dosage most be indMduail!d. The absorption ol CARDURA (dolQzosin mesytate) is not
alleded b¥ lood. W11en dolQzosin is being added to tile existing antihypertensiv therapy, rnoritor tile patient tafelully tor tile
ocamnce ol hypotension. ff a diuretic or other ~ agent is being added to dol<3lOsin regimen, dolQzosin dose
reduction and retlrallon with carelut monitoring may be necessary, H dol<3lOsin adrmstration is discontinued lor several
days or longer, therapy siWd be reinsitu1ed using tile iritial dosing regimen. Hyperllaiol-1-11 .. OI1CI Daily: The iri1ial
dose ot dol<3lOsin in hypertensiYe patients is 1 mg givel1 once dUy and 1tus dose sh<Ul not be exaeded. This starting dose
is in ended to minimize postural hypotensive effects. The maximum bklod pressure reduction normaly occurs beMerl
2·6 hours after a dose. The dose may be slowly increased to achieve tile desired bklod pressure response. Usual dose range:
1-8 mg once daiy. Maximum recoiM1ended daily dose: 16 mg once daiy. Doses greater than 4 mg increase tile lietillood ot
l!liiZSSive postural elfects inciJding syncape, postural dizzinesslver1i and postural hypotension. N.. titrated dose ol16 mg
once daiy, tile lrequency ol postural eHects is about 1~ oompared to 3'lo lor placebo. ...., Prlllltic ,.,..,._ H .. Dice Dally: The initial dosa9e ol dolQzosin is 1 mg givel1 once daiy. Depending oo individual patient's urotlynamics
and BI'H symptomatology. dosa9e may t11en be increased to 2 mg and lhereaftes to 4 mg and 8 mg once daiy, tile maxiloom
recorMlended dose. ReatrMtended titration interv;t 1- 2 weas. Blood pressure siWd be evaluated routitely. Doxazosin
sh<Ul be discontinued I tile drug has been increased to maxiloom 1oler.lled dose and irnpovement in lli1ary 1towmetry is
less thon 25% or ~ doJWOSin side eHects are more bothersome than BI'H symptoms or ~ tile patient develops a urinary
c:ontplication secondary to BI'H wllite on dol<3lOsin tllerapy.
Ani!Mitily: Wllile 1abtets containing dol<3lOsin mesytate equivalent to 1, 2 or 4 mg ol doxazosin. Supplied in opaque plastic
,,.,ctensilypotyetl1ytene)botttesol100tablets.
ful Product Monograph available on request
Rfffilf1ICES: 1. CARDURA-1:-2:
Monograph, Astra Pharma Inc. 2. Lepor H e1 al. Doxazosin lor benign
prostatic hyperplasia: l0119'term ellicacy and safely in hypertensiw and normotensiw patients. J Uro/1997;157:525530. 3. Fulton 8 et al. Doxazosin. An update ot its ctinical pharmacology and t11erapeWc apptications in hypertension
and benign prostatic hyperptasia. Drugs 1995;49(2);295-320.
.,.Pliler Products Inc., used under license.
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reactions reported during ther1py were of mild-to-moderate severity.
~
In tho 1115 hypoftllnsive patients treated with NORVASC in ~ ckica1 trials, advorsa o11acts - • reported in
~ d patients and required disconlirwtion d therapy duo ID side o11acts in 1~ of patioru. The . - common
advorsa reactions in conroled clinical triols were: odarna 18.ft). and headache IB.l'JIL The folowing advorsa reactions
- e reported with an incidonc:e of 2.45% in the controled clinical triols program ln;805~
~
' or. edema IB.ft), palpitations 12-0l!.). tochycanfial0.7~). postural dizziness 111.5~1- stio _.

---.--

~ pruritusi0-~1- --: musclecramps lll5~L c:...l _. ...,......

s.,_ hladachola.J'Jil. dizziness IJ.Ol!o). parestha>ialll5~1- - - s,_ flushing 13.1 ~1.

oncreased swutJng IO.ft), dry mouth 1 0.7~1- l'sydoialric: somnoloncol1.4~). G.D o' ot111iuf: nauseal2.4 ~ ).
: n al pain 11 . 1 ~). dyspepsiaiO.&l'). constipation 10.5~). ~: fatiguel4. 1~). pain 10.5~).

NORVASC
lamlodipine besylate)
Tablets 2.5, 5 and 10 mg
Antihypertensive-Anlianginal Agent

In the controled clinical triols in !ll9 angn patients treated with NORVASC, adverse effects were reported in
30.5~ d patients oro! requO"ed disconlinuation of therapy duo to side effects in 0.61' d patients. The .-common
adverse reactions reported in controled clinical triols were: edema l9.ft) and headache (7n1.
The following advone reactions occurred at an incidence of ~5~ in the controled clinical triols program ln.!IJ9t.
~-- edema 19.9~1. palpitations 12-0l!.l. postural dizziness ID.&~). stio _. ~ rash ILOl!o).
pruntus lOA). muscle cramps ll.Ol!o). c-al_. .......... ..._
hudache
11n1. dizziness IU~L paresthesial1.11111. hypoesthesiaiO-"'L- - ! , -flushing 11~ 1.
l'lydOalric: somnolence I!~). insormiaiD-9~). nervousness IO.~L -. nauseal4~).
abdominal pain 1:1.211). dyspepsi al1.4~ ). diarrheall.l ~ ). ftatulencel1.1111), constipotion IO.ft). flnpi.-y
5 , - dyspnea IL 1 ~1- Spocial
abnormal vision 11~ 1. timitus lo.&~). c.or.l: fatigue 1 4.8~).
pain 11.11111. astheniaiLOl!o).
NORVASC has been evaluated IO< safety in about 11.000 patients with hypartension and angina.
The following events occurred in < 1 ~ but >0.1 ~ of patients in comparative clinical trials I double-blind
comparative vs ptacebo or active agents: n = 2.615) or under conditions of open trials or marketing experience
where 1 causal relationship is unceroin.
~ arrhythmia !including ventricular tochycardia and atrial fibrifation). bradycardia. hypotension,
peripharal ischamia, syncope. bchycardia. postural dizziness, postural hypotension. c:-.1 _. ...,......
hypoasthesia, tremor, vertigo. ..__......,._ anorexia. constipation, dysphagia. vomiting.
gingiv~ hyperplasia• ...._,.. asthenia', back pain, hot flushes, malaise, rigors. weight gaWL ~I
arthralgia, arthrosis, myalgia. PsydlliMric: sexual dysfunction tmale' and female). insomnia, nervousness, depression. abnormal dreams. anxiety, depersonalization.~
epistaxis. stio _.
~ prurilus', rash erythematous, rash moculopapula, erythema multiforme. Spociol conjooctivitis,
diplopia, eye pain, tinnitus. Uriooory s, _ micturition frequency, micturition disorder. nocturia. ~ s,.-: dry mouth, increased sweating . . . _ic .... -: thirst~ purpura.
These events occurred less than 1% in placebo-controlled trials. but the incidence of these side effects wa s
between 1 ~ and ~ in al multiple dose studies.
The following events occurred in sf]. 1ft of patients: cardiac failure. skin discoloration, urticaria. skin dryness.
Stevens-Johnson syndrome, alopecia, twitching, ataxia, hypertonia, migraine, apathy, 1rrmesia, gastritis,
pancreatitis, increased appetite, coughing, rhinitis, parosmia, taste perversion, and xerophthalmia.
Isolated cases of angioedema have been reported. Angioedema may be accompanied by breathing difficutty. In
postmarteting experience, jaundice and hepatic enzyme elevations (mostly consistent with cholestasisl in some
c,ases severe enough to require hospitalization have been reponed in association with use of amlodipine.
SYWTliiiS A111D T1IEAT1IIIEJfT Of 0VE11110SAGE

ACT10II AIIO CUMCAL PIIAIIMACOlliGY
NORVASC (amtodipine besylate) is a calcium ton influx inhibitor (calcium entry blocker or calcium ion antagonist).
AmkKJipine is a member of the dihydropyridine class of ctlcium antagonisu.
~TlONS AIIO CUMCAL USE

s, -

~
NORVASC lamlodipine besytate) is indicated in the treatment of mild-to-moderate essential hypertension.
NORVASC should normalty be used in those patients in whom treatment with diuretics or beta· blockers was found
ineffective or has been associated with unacceptable adverse effects. NORVASC can be tried as tn initial agent in
those patients in whom the use of diuretics and/or beU·bkK:kers is contraindicated or in patients with medical
conditions in which these drugs frequently causa serious advorn affects. Combination of NORVASC with a
diuretic, 1 beta-blocking agent. or an angiotensin converting enzyme inhibitor has been found to be compatible and
showed additive antihypertensive effect

s.-:

Clneic- Alotiu
NORVASC is indicated for the management of chronic stable angina (effort-associated angina) in patients who
remain symptomatic despite adequate doses of beta -blockers and/or organic nitrates or who cannot tolerate those

-

agents. NORVASC may be tried in combinotion with bet> -blockors in chrorMc stable angina in patients with normal
ventricular function. When such concomitant therapy is introduced, care must be taken to monitor blood pressure
closety since hypotension can occur from the combined effects of the drugs.

s,.._

COIITIMIDICATlONS
NORVASC lamlodipine besytato) is contraindicated in patients with hyparsonsitivity to the drug 0< othtf
dihydropyridines and in patients with severe hypotension Uess than !I) mmHg systolic).
WAIIIIINGS
Alltiu Ml4/w ~ . . , _
Rarety, patients, particularty those with severe obstructive coronary artery disease. have developed documented
increased frequency, duration and/or severity of angina or acute myourdial infarction on starting calcium channel
of dosage
blocker then~py or at lthe
Oolllew_
_ time_
_, increase. The mechanism of this effect has not been elucidated.

lee,.-
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NORVASC should be used with caution in a presence of fLXed left ventricular outflow obstruction

Iaortic stenosis).

s.,.....

There are no adequate studies in patieru with liver dysfunction and dosage recommendations have noc: been
established. In a smd number of patients with mitd-to-moderate hepatic impairment given single dose of 5 mg,
amJodipine hatf-life has been prolonged. NORVASC should, therefore, be administered with caution in these
patients and careful moritoring should be performed. A lower starting dose may be required I sea DOSAGE AIIO

Overdosage can cause excessive peripheral vasodilation with marked and probabty prolonged hypotension and
possibly a reflex tachycardia. In humans, experience with overdosage of NORVASC lamlodipine besytate) is limited.
When amlocfipine was ingested It doses of 105-250 mg some patients remained normotensive with or without
gastric lavage while another patient experienced hypotension I!IIW50 mmHg) which normalized following plasma
expansion. A patient who tool< 70 mg of amlodipine with benzodiazepine developed shock which was refractory
to treatment and died. In a 19 month-old child who ingested 30 mg of amlodipine I about 2 mg/kg) there was no
evidence of hypotension but tachycardia (180 bpml was observed. Ipecac was administered 3.5 hrs after ingestion
and on subsequent observation (ovemightl no sequelae were noted.

- T l l *).
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NORVASC gives no protection against the dangers of abrupt beto -blocker withdrawal and such withdrawal should
be done by the gradual reduction of the dose of beta -blocker.

PIIECAUTIOIIS
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Although generally calcium chaMel blockers should only be used with caution in patients with haart fa· ro. it has
been observed that NORVASC had no overaa deleterious effect on survival and cardiovascular morbidity in both
shorHerm and long -term clinical trials in these patients. While a significant proportion of the patients ;, these
studies had a history of ischemic heart disease, angina or hypertension, the studies were not designed to
evaluate the treatment of angina or hypertension in patients with concomitant heart failure.

Ciiniclly significant hypotension due to overdosage requires active cardiovascular suppon inctuding frequent
monitoring of cardiac and respiratory function, elevation of extremities. and attention to circulating fluid volume
and urine output A vasoconstrictor (such as norepinephrine I may be helpful in restoring vascular tone and
blood pressure, provided that thoro is no contraindicotion to its usa. As NORVASC is highly protein bound,
hemodiatysis is not likely to be of benefit Intravenous calcium gluconate may be beneficial in reversing the
effects of calcium channel blockade. Clearance of amlodipino is prolonged in elderly patients and in patients
with impaired liver function. Since amfodipine absorption is slow, gastric lavage may be worthwhile in some cases.
DOSAGE AIIO ADMINISTIIATIOIII
Dosage should be individualized depending on patien( s tolerance and responsiveness. For both hypertension
and angina, the recommended initial dose of NORVASC lamlodipine besytate) is 5 mg once daily. H necessary,
dose can be increased after 1·2 weeks to a muimum dose of 10 mg once deify.
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NORVASC lamlodipine besyloto ) moy occasionolly precipitate symptomatic hypotension. Careful monitoring of
blood pressure is recommended, especialty to patients with a history of cerebrovascular insufficiency, and those
taking medications known to tower blood pressure.

Mid-to-moderate peripheral edema was the most common adverse event in the clinical trials tsee ADVEJISE
IIEACTIOIIS). The incidence of peripheral edema was dose-<lependent and ranged in frequency from 3.0 to 10n
in 5 to 10 mg dose range. Care should be taken to differentiate this peripheral edema from the effects of increasing
left ventricula r dysfunction.
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NORVASC is available as white octagonal toblets containing amlodipine besylate equivalent to 2.5, 5 and 10 mg
amlodipine per to blat. The respective to blot strengths are debossed on one tablet face as ·NRV 2.5·. · NRV 5·
and "'NRV 10" with "'Pfizer" on the opposite face. The 5 mg tablet is scored. Supplied in white plastic (high density
polyethylene) bottles of 100 to blots IO< each strength. Also tho 5 mg and 10 mg are supplied in bottles of 250 tablets.

The recommended initial dose in patients over 65 years of age or patients with impaired renal function is 5 mg
once daily. H required, increasing in the dose should be done gradually and with caution lsoo PIIECAUTIOIIIS).
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Although amlodipine was not teratogenic in the rat and rabbit some dihydropyridine compounds have been found
to be teratogenic in animals. In rats. amlodipino has been shown to prolong both the gestation period and the
duration of labor. There is no clinical experience with NORVASC in pregnant women. NORVASC should be used
during pregnancy onty if the potential benefit outweighs the potential risk to the mother and fetus.

Oosage requirements have not been established in patients with impaired hepatic looction. When NORVASC is
used in these patients. the dosage should be carefully and gradually adjusted depending on patient s tolerance
and response. A lower starting dose of 2.5 mg once daily should be considered lsee WAIIIIIIIIGS).
DOSAGE~

tt is not known whether amlodipine is excreted in human mitk.. Since amlodipine safety in newborns has not been
established, NORVASC should not be given to nursing mothers.
.... io CloiWretl
The usa of NORVASC is no< reconvnandad in chldren since salety and efficacy have no< been established in that pop<Ution.

STOIIAGE

In elderly patients 1265 years! ctearance of amtodipine is decreased with a resulting increase in AUC.In clinical
trials the incidence of adveru reactions in elderly patients was approximately 6~ higher then that of younger
population l d!i year>). Adverse reactions include edema. muscle cramps and dizziness. NORVASC should be used
cautiously in elderly patients. Oosage adjustment is advisablelsee DOSAGE AIIO AIIIIIIIISTIIATION).
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through inhibition of the cytochrome P450 system. grapefruit juice can increase plasma
levels and augment pharmacodynamic affects of some dilydropyridino calcium chamel blockers. Following oral
adrninistmion of 10 mg amlodipine to 20 malo volunteers, pharmacokinetics of amlodipino were similar when
amlodipine was administered with and without grapefruit juice.
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As with II drugs, care should be exercised when treating patients with rrultiple medications Oilydropyridino calcium
channel blocker> undergo biotransformation by the cytochrome P450 system, mainly via CYP 3A4 isoenzyme.
Coadministration of amlodipine with other drugs which folow the same route of biotransformation may result in
a~ered bioava~abitity of amlodipine or these drugs. Oosages of sim~arly motobolized drugs, particularly those of
low therapeutic ratio, and especiatty in patients with renal and/or hepatic Nnpairment. may require adjustment
when starting or stopping concomitantly administered amlodipine to maintain optimum therapeutic blood levels.
Orugs known to be inlubitors of the cytochrome P450 system include: azofo antilungals, cimetidine, cyclosporino,
erythromycin. quinidine, terfenadine, warfarin.
Orugs known to be inducers of the cytochrome P450 system include: phanobarbital, phenytoin, rifampin.
Orugs known to be biotnonslormed via P450 include: benzodiazepinas, flecainide, imipramine, propafenone, theophylline.
Amlodipine has a low Irate of first-pass) hepatic clearance and consequent high bioavailobility, and thus, may be
expocted ID have a low potential IO< clinically relevant effects associated with elevation of amlodipine pi sma
levels when used concomitantly with drugs that compete for 0< inhibit tho cytochrome P450 system.
Cioooli4ieo, _ . . _ Cydooporioo. Oifoxia: Pharmacoltinetic interaction studies with amlodipine in haalthy
volunteers have indicated:
• cdid not alter the pharmacoltinetics of amlodipine.
• amlodipino did not change - --induced prothrombin response time.
• amlodipine doos not significantly alter the pharmacotinotics of cycleoporiL
• amlodipine did not change serum . . - levels or lliflxill renal clearance.
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Concomitant administr1tion of Maalo (magnesium hydroxide and aluminum hydroxide) had no effect on the disposition of a single 5 mg dose of amlodipina in 24 subjects.
- - . . . : When beta-adrenergic receptor blocking drugs oro adninistered concomitantly with NORVASC.
patients should be carefuly monitored since blood pressure lowering effect of beta -blocker> may bo augmented by
amfodipine's reduction in peripheral vascular resistance.
AIIYEJIS( IIEACTlOIIS
NORVASC lamlodipina besylate) has been administered to 1,714 patients 1805 hypartensive and !ll9 angina
patients) in controled clinical trials lvs placebo alone ar<l with active comparative agents). Most advono

Store at 1!;-JO"C. Protect from light.
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And in this morning's rush to get away from it all, he forgot his therapy at home .
He just became one of the 62% of Canadian hypertensives who regularly miss, forget or delay taking their
medication (n=301 ). 7
Of course, patients should be advised to take orvasc* every 24 hours. But even a full 24 hours after a missed
dose, long-acting 1· 3565 orvasc * maintains blood levels which can deliver blood pressure reduction.J6. 38·4 1.-H ·65
With proven tolerability and, at 1.9%, an extremely low discontinuation rate .1
Once-a-day orvasc *. Because the best things in life usually arrive in their own good time .

Allows extra time for human nature.
Norvasc• 15 tndlcated tn the treatment of m1ld-to-moderate essential hypenens10n when dmretlcs or beta-blockers are unsUitable. The most common adverse reactions
mclude edema (8 9%) and headache (8.3%)' For dosage adjustments m the elderly and hepauc 1mpa1red. consult the product monograph

and into the next day.

half-life permits once-daily dosing
be taken in the morning or the
of relief with patient-assessed
observed within 1-2 weeks!

tained over

